

Scientific Programme

Tuesday, 20 October 2015

Other
08:30 - 17:55

Room Madrid

Novel Viral and Cellular Targets Against HIV (extra registration required due to a limited seat availability)

EACS Satellite Symposium Convened by HIVinnov, HIT HIDDEN HIV and Thinpad, 3 European Consortia Supported by the European Union's Seventh Framework Programme for Research and Technological Development

Chairs:

Richard Benarous, France
Monsef Benkirane, France
Maurizio Botta, Italy

Welcome Manuel Battegay, Switzerland	08:30 - 08:45
The Current Landscape of EU-Funded Research on HIV/AIDS and Future Prospects within Horizon 2020 Alessandra Martini (European Commission)	08:45 - 09:00
Session 1: Novel Viral Targets and New Classes of Drugs Against HIV Chair: Alessia Zamborlini (France)	
NCIs Are Multimodal Inhibitors Affecting Viral Production Gilles Mirambeau, Spain	09:00 - 09:25
Structural Basis for Retroviral Integration Into Nucleosomes Peter Cherepanov, United Kingdom	09:25 - 09:50
Killing Two Birds With One Stone: The Mode of Action of Allosteric Inhibitors of IN Richard Benarous, France	09:50 - 10:15
Design and Synthesis of Non-Covalent NC Inhibitors Targeting the Hydrophobic Pocket Maurizio Botta, Italy	10:15 - 10:30
Role of Phenotypic Investigation in the Evaluation of HIV-1 Drug Susceptibility Francesco Saladini, Italy	10:30 - 10:45
Coffee Break	10:45 - 11:05
Session 2: New Cellular Targets and the Development of Novel Strategies Against HIV Chair: Maurizio Botta (Italy)	
In Vitro and In Vivo Modelling of HIV Latency and Persistence Monsef Benkirane, France	11:05 - 11:30
Modification of Restriction Factors by SUMO Proteins: Implications for Retroviral Replication Alessia Zamborlini, France	11:30 - 11:45

Scientific Programme

A Novel LEDGF/p75-Associated Complex Controls HIV-1 Latency Stéphane Emiliani, France	11:45 - 12:00
Modulation of NF-κB Activity by Humans and Simian Immunodeficiency Viruses Frank Kirchhoff, Germany	12:00 - 12:25
HIV Cell-to-Cell Transmission, Innate and Adaptive Countermeasures Olivier Schwartz, France	12:25 - 13:00
Lunch Break	13:00 - 14:15
Session 3: New Assays and Screenings to Develop New Drugs Against HIV Chair: Moncef Benkirane (France)	
A Selective Cell-Based Screening to Identify New Antiretroviral Targets Ariberto Fassati, United Kingdom	14:15 - 14:40
Molecular and Cellular Assays to Identify and Characterize Molecules Targeting the HIV-1 Nucleocapsid Protein Yves Mely, France	14:40 - 15:05
Transcriptome Approaches for Single Cell and Latency Population Analyses Angela Ciuffi, Switzerland	15:05 - 15:30
Humanized Immune System Mice for Testing of New Antiretrovirals Ben Berkhout, Netherlands	15:30 - 15:55
Coffee Break	15:55 - 16:10
Session 4: Development of New Drugs Against HIV Chair: Angela Ciuffi (Switzerland)	
Discovery of New Peptides Interacting with HIV Infections Wolf-Georg Forssmann, Germany	16:10 - 16:35
Synergies Between Industry and Academia in the Search for New Therapies for HIV Steven Harper, Italy Davide de Forni, Italy	16:35 - 17:00
Additional Novel Targets	17:00 - 17:45
Conclusion José M. Gatell, Spain Alessandra Martini (European Commission)	17:45 - 17:55

Scientific Programme

Other
09:00 - 18:00

Room Warsaw

STEPS - A Community Initiative to Design the Pathway to a Long-Term Remission of HIV Infection

(extra registration required)

Chairs:

Tamás Bereczky, Hungary
Giulio Maria Corbelli, Italy

Welcome and Introduction Brian West, United Kingdom	09:00 - 09:15
The Research for a Cure in Europe: A Framework Roberto Speck, Switzerland	09:15 - 09:35
Discussion	09:35 - 10:00
The EpiStem Consortium and the Stem-Cell Transplant Strategy Javier Martínez-Picado, Spain	10:00 - 10:20
Discussion	10:20 - 10:45
Coffee Break	10:45 - 11:00
The CHERUB Initiative and the Strategy Addressing the Reservoir John Frater, United Kingdom	11:00 - 11:20
Discussion	11:20 - 11:45
Global and European Efforts Towards an HIV Cure Anna-Laura Ross, United Kingdom	11:45 - 12:05
Discussion	12:05 - 12:30
Lunch Break	12:30 - 14:00
Cure Research in Denmark and the Latency Reversing Agents Lars Østergaard, Denmark	14:00 - 14:20
Discussion	14:20 - 14:45
Cure Research in France and the Role of Primary Infection Christine Rouzioux, France	14:45 - 15:05
Discussion	15:05 - 15:30
Coffee Break	15:30 - 15:45
Transatlantic Collaborations and the Broadly Neutralizing Antibodies Strategy Gerd Fätkenheuer, Germany	15:45 - 16:05
Discussion	16:05 - 16:30
Activities from the Community: AVAC, pxROAR, CUREiculum and More Kevin Fisher, United States	16:30 - 17:00

15th European AIDS Conference
October 21 - 24, 2015
Barcelona, Spain

Scientific Programme

How Can We Improve Community Involvement in Cure Research in Europe? Damian Kelly, United Kingdom Brian West, United Kingdom	17:00 - 17:30
Wrap Up and Conclusions Brian West, United Kingdom	17:30 - 18:00

Scientific Programme

Wednesday, 21 October 2015

Course/Workshop
09:45 - 17:00

Room Belgrade

EACS Pre-Educational Course

Chairs:

Tristan Barber, United Kingdom
Laura Waters, United Kingdom
Mike Youle, United Kingdom

Introduction Mike Youle, United Kingdom	09:45 - 09:55
Women Living with HIV	
Clinical Case Nilani Uthayakumar, United Kingdom	09:55 - 10:20
Overview Mel Rosenvinge, United Kingdom	10:20 - 10:45
Questions Panel	10:45 - 10:55
CHEMS	
Clinical Case Daniela Rojas Castro, France	10:55 - 11:20
Overview Cristiana Oprea, Romania	11:20 - 11:45
Questions Panel	11:45 - 11:55
Coffee Break	11:55 - 12:10
Hepatitis and HIV	
Clinical Case Matthias Zaccarin, Denmark	12:10 - 12:35
Overview Karine Lacombe, France	12:35 - 13:00
Questions Panel	13:00 - 13:10
Lunch Break	13:10 - 13:40
Toxicities in HIV	
Clinical Case Joanna Sawicz, Poland	13:40 - 14:05

Scientific Programme

Overview Andrea Calcagno, Italy	14:05 - 14:30
Questions Panel	14:30 - 14:40
Sexually Transmitted Infections	
Clinical Case Šime Zekan, Croatia	14:40 - 15:05
Overview Katie Conway, United Kingdom	15:05 - 15:30
Questions Panel	15:30 - 15:40
Coffee Break	15:40 - 16:00
Opportunistic Infections	
Clinical Case Henry Kibble, United Kingdom	16:00 - 16:25
Overview Cristina Mussini, Italy	16:25 - 16:50
Questions Panel	16:50 - 17:00

Industry Sponsored Session
13:30 - 15:00

Room Cologne

Industry Sponsored Session

(For more details, please visit the http://www.eacs-conference2015.com/index.php?article_id=47>EACS Conference website)

Course/Workshop
13:30 - 17:00

Room Madrid

WAVE Workshop - Women Against Viruses in Europe - Promoting the Welfare of HIV-positive Women in Europe

Chairs:

Fiona Mulcahy, Ireland
Anna Maria Geretti, United Kingdom

Welcome and Introduction Fiona Mulcahy, Ireland	13:30 - 13:40
---	---------------

Session 1 - Chairs: Karoline Aebi-Popp (Switzerland); Jane Anderson (United Kingdom)

Scientific Programme

Plenary 1: Gender, Socio-Economic Factors, and HIV Treatment Outcomes Determinants of treatment outcomes in HIV-positive women, with a focus on socio-economic factors Fiona Lampe, United Kingdom	13:40 - 14:00
Plenary 2: Strengthening the PMTCT Programme to Minimise Vertical Transmission of HIV and HBV in Cameroon Researching HIV outcomes where resources are constrained Judith Ndongo Torimiro, Cameroon	14:00 - 14:20
Case Study 1: Factors Associated with Mother-to-Child Transmission of HIV-1 in Romania: Is Postnatal HIV Infection Still a Risk?! Covering issues related to HIV transmission, pregnancy and breastfeeding, and care issues pertinent to Eastern Europe - emphasis on lessons to be learned/how things could have been done better Cristiana Oprea, Romania	14:20 - 14:35
Q&A: Improving Outcomes Fiona Lampe, United Kingdom Judith Ndongo Torimiro, Cameroon Cristiana Oprea, Romania	14:35 - 14:50
Coffee Break & Networking - Art Exhibition by Adrienne Seed (United Kingdom)	14:50 - 15:20
Session 2 - Chairs: Annette Haberl (Germany); Margaret Johnson (United Kingdom)	
Plenary 3: How Does Contraceptive Use Increase the Risk of HIV Acquisition? Emerging issues in contraception (including but not limited to drug interactions and address depo-provera and HIV transmission issues) Giovanni Di Perri, Italy	15:20 - 15:40
Case Study 2: Tackling Challenges in Long-Term Treatment Care issues relevant to older women Teresa Branco, Portugal	15:40 - 16:00
Q&A Giovanni Di Perri, Italy Teresa Branco, Portugal	16:00 - 16:10
Session 3 - Chairs: Elisabeth Crafer (United Kingdom); Antonella d'Arminio Monforte (Italy)	
Plenary 4: HPV-related Cancers and Their Prevention in HIV-positive Women Focus on new data on cervical cancers, anal cancer and other HIV-related cancers, and vaccination-related issues Déborah Konopnicki, Belgium	16:10 - 16:30
Case Study 3: Missed Opportunities Covering the patient's experience of how "things could have gone better" in terms of care received Ophelia Haanyama, Sweden	16:30 - 16:45
Q&A Déborah Konopnicki, Belgium Ophelia Haanyama, Sweden	16:45 - 16:55

Scientific Programme

The Next Steps 16:55 - 17:00
Fiona Mulcahy, Ireland

Other 13:45 - 15:00 Room 211

17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV

(The workshop is an affiliated event of the 15th European AIDS Conference. EACS attendees are welcomed between 13:45 - 15:00 free of charge - based on seat availability in the room. Entire Workshop attendance from October 20 to October 22 requires extra registration.)

Changes in Bone Turnover Markers with HIV Seroconversion and Antiretroviral Therapy Initiation 13:45 - 14:00
Laurence Slama, France

Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIV-positive and HIVnegative subjects 14:00 - 14:15
Elena Alvarez, Ireland

Role of Antiretroviral Therapy on Bone Mass and Bone Texture 14:15 - 14:30
Esteban Martinez, Spain

Decreased Bone Mass in Perinatally HIV-infected School-aged South African Children on Antiretrovirals 14:30 - 14:45
Michael T Yin, United States

Bone Changes in Young Men Ages 18-22 Enrolled in a Pre-Exposure Prophylaxis (PrEP) Safety and Demonstration Study Using Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) 14:45 - 15:00
Kathleen Mulligan, United States

Industry Sponsored Session 15:30 - 17:00 Room Cologne

Industry Sponsored Session

(For more details, please visit the http://www.eacs-conference2015.com/index.php?article_id=47>EACS Conference website)

Ceremony 17:30 - 19:30 Room Barcelona

Opening Ceremony

Chairs:
Manuel Battegay, Switzerland
José M. Gatell, Spain

15th European AIDS Conference
October 21 - 24, 2015
Barcelona, Spain

Scientific Programme

Welcome

Manuel Battegay, Switzerland
José M. Gatell, Spain

Address

Maribel Pasarín, Spain
Jordi Casabona i Barbarà, Spain

HIV and Hepatitis - Europe Back on the Agenda

Tamás Bereczky, Hungary

Global Epidemiology in Action

Matthias Egger, Switzerland

90-90-90 by 2020 in Europe

Michel Kazatchkine, France

The EACS Awards

Nathan Clumeck, Belgium

Ceremony
19:30 - 20:30

Exhibition Area

Welcome Reception

Scientific Programme

Thursday, 22 October 2015

Meet the Expert
07:45 - 08:45

Room Madrid

Meet the Expert, - Vaccination for HIV-infected Patients

Vaccination for HIV-infected Patients

Arkaitz Imaz, Spain
Carolynne Schwarze-Zander, Germany

07:45 - 08:45

Meet the Expert
07:45 - 08:45

Room Dublin

Meet the Expert, - ART in HIV Advanced Disease

ART in HIV Advanced Disease

Félix Gutiérrez, Spain
Valérie Martinez, France

07:45 - 08:45

Meet the Expert
07:45 - 08:45

Room Warsaw

Meet the Expert, - HIV-HCV Drug-Drug Interactions

HIV-HCV Drug-Drug Interactions

David Back, United Kingdom
Catia Marzolini, Switzerland

07:45 - 08:45

Meet the Expert
07:45 - 08:45

Room Athens

Meet the Expert, - Management of Opportunistic Infections

Management of Opportunistic Infections

Hansjakob Furrer, Switzerland
José Miró, Spain

07:45 - 08:45

Scientific Programme

Plenary Session
09:00 - 09:30

Room Barcelona

PL1, Antiviral Therapy - Thinking Ahead: Implications of the DAD and START Studies - Joint Plenary with the 17th International Workshop on Co-morbidities & Adverse Drug Reactions in HIV

Chairs:

José Alcami, Spain
Caroline Sabin, United Kingdom

Antiviral Therapy - Thinking Ahead: Implications of the DAD and START Studies - Joint Plenary with the 17th International Workshop on Co-morbidities & Adverse Drug Reactions in HIV 09:00 - 09:30
Jens D. Lundgren, Denmark

Plenary Session
09:30 - 10:00

Room Barcelona

PL2, Insights from HIV Pathogenesis

Chairs:

José Alcami, Spain
Caroline Sabin, United Kingdom

Insights from HIV Pathogenesis 09:30 - 10:00
Marcus Altfeld, Germany

Parallel Session
10:30 - 12:30

Room Barcelona

PS1, Co-morbidities I - Joint Session with the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV

Chairs:

Esteban Martínez, Spain
Stefan Mauss, Germany

ML1	The Interplay of Atherosclerosis and Inflammation Turner Overton, United States	10:30 - 10:45
PS1/1	Lung Function Decline in HIV: Effects of Immediate versus Deferred ART Treatment on Lung Function Decline in a Multi-site, International, Randomized Controlled Trial Ken Kunisaki, United States	10:45 - 11:00
PS1/2	Increased Prevalence of Hypertension in HIV-infected Patients, Most with Suppressed Viraemia on Combination Antiretroviral Therapy, is Associated with Changes in Body Composition Rosan van Zoest, Netherlands	11:00 - 11:15
ADRLH-51	HIV-infected Patients Exert Higher Residual Platelet Reactivity on DAPT Compared to Controls after Acute Coronary Syndrome Franck Boccara, France	11:15 - 11:30

Scientific Programme

ML2	Geriatrics for HIV Physicians Matteo Cesari, France	11:30 - 11:45
PS1/3	Frailty Predicts All-cause Mortality, Hospital Admission and Falls in HIV-infected and Uninfected Middle-aged Individuals Katherine Kooij, Netherlands	11:45 - 12:00
ADRLH-62	Effects of Immediate Versus Deferred Initiation of Antiretroviral Therapy on Bone Mineral Density: A Substudy of the INSIGHT Strategic Timing of Antiretroviral Therapy (START) Study Jennifer Hoy, Australia	12:00 - 12:15
ML3	Summary on Co-morbidities and Adverse Drug Reactions Workshop Judy Currier, United States	12:15 - 12:30

Parallel Session
10:30 - 12:30

Room Cologne

PS2, TB in HIV-infected Patients in Europe - Together We Are Stronger: An EACS-ESCMID-ECDC-WHO Joint Session

Chairs:

Antonella d'Arminio Monforte, Italy
José Miró, Spain

ML1	Epidemiology of TB in HIV-infected Patients in Europe Marieke J. van der Werf, Sweden	10:30 - 10:45
PS2/1	HIV Viral Load as an Independent Risk Factor for Tuberculosis: the COHERE Collaboration Hansjakob Furrer, Switzerland	10:45 - 11:00
ML2	Outcome of TB in HIV-infected Patients in Eastern Europe Daria Podlekareva, Denmark	11:00 - 11:15
PS2/2	One-year Mortality of HIV-patients Treated for Susceptible Tuberculosis (TB) is Higher in Eastern Europe Than in Western and Southern Europe and Latin America Daria Podlekareva, Denmark	11:15 - 11:30
ML3	Challenges Preventing TB in HIV-infected Patients (Including the Concept ART as TB Prevention) Alberto Matteelli, Italy	11:30 - 11:45
PS2/3	Short-course Isoniazid and Pyrazinamide Compared with 6-month Isoniazid for Tuberculosis Prevention in HIV-infected Adults: The Russian Randomized Clinical Trial Zinaida Zagdyn, Russian Federation	11:45 - 12:00
ML4	Pitfalls in TB Management in HIV-infected Patients: IRIS and MDR/XDR-TB Anton Pozniak, United Kingdom	12:00 - 12:15
PS2/4	Target Generic Prices for Novel Treatments for Drug-resistant Tuberculosis Dzintars Gotham, United Kingdom	12:15 - 12:30

Scientific Programme

Parallel Session
10:30 - 12:30

Room Brussels

PS3, Cost Effectiveness, Prevention and Epidemiology

Chairs:

Fiona Lyons, Ireland
Yazdan Yazdanpanah, France

ML1	HIV Molecular Epidemiology Dimitrios Paraskevis, Greece	10:30 - 10:45
ML2	The Community Perspective About Costs, Cost Efficacy and Generics Giulio Maria Corbelli, Italy	10:45 - 11:00
PS3/1	A New Method to Estimate the First Step in the HIV Care Continuum Ard van Sighem, Netherlands	11:00 - 11:15
PS3/2	Cost-effectiveness of Single-tablet Regimens versus Generic Based Multi-tablet Regimens for First-line Antiretroviral Therapy in France Jorge Félix, Portugal	11:15 - 11:30
PS3/3	Cost-Effectiveness of Treating HIV-1 with Single - versus Multi-tablet Antiretroviral Regimens in Germany Björn Vandewalle, Portugal	11:30 - 11:45
PS3/4	The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk Behaviours among People Who Inject Drugs: A Systematic Review and Meta-analysis Gail Gilchrist, United Kingdom	11:45 - 12:00
PS3/5	HIV Acquisition among Migrants Living in Europe: Results from aMASE - Advancing Migrant Access to Health Services in Europe Debora Alvarez-del Arco, Spain	12:00 - 12:15
PS3/6	HIV-related Stigma in Primary Care in the UK: Findings from HIV StigmaIndexUK-2015 Survey Claire Ferraro, United Kingdom	12:15 - 12:30

Special Session
12:00 - 14:00

Exhibition Area

Poster Session

PE1/2	Characterization of the Near Full Length Genetic Constellation of a Unique HIV 1 A1/C Recombinant Strain in South Africa Andrew Musyoki, South Africa
PE1/3	APOBEC3 Host Factors Modulate Viral Production and Infectivity of HIV-2 Susana Bandarra, Portugal
PE1/4	Does the Presence of a Mutation at Position V179 Impact on Clinical Outcome in Patients Taking Antiretroviral Medication? Jasper Vink, United Kingdom

Scientific Programme

- PE1/5 **Performance of Genotypic Algorithms for Predicting Tropism for HIV-1 CRF02_AG Subtype**
Cathia Soulié, France
- PE1/6 **HIV-1 Subtype B Transmission Networks in Poland Indicate Frequent Clustering and Interregional Spread of Infection among Men-Having-Sex-with-Men**
Milosz Parczewski, Poland
- PE1/7 **HIV-1 Diversity and Transmitted Drug Resistance Mutations among Heterosexuals with HIV-1 in Bulgaria**
Ivailo Alexiev, Bulgaria
- PE1/8 **Clinical, Virological and Phylogenetic Characterization of a Multiresistant HIV-1 Strain Outbreak in Naïve Patients in Southern Spain**
Isabel Viciano, Spain
- PE1/9 **Tumor Suppressor p53 Protein Removes the Ribonucleotides Incorporated by HIV-1 RT into DNA**
Mary Bakhanashvili, Israel
- PE1/10 **Dolutegravir based Regimens (DBRs) Viral Load Decay at Week 4 Could Predict Sustained Viral Suppression at Week 96**
Romina Quercia, United Kingdom
- PE1/11 **Viruses Causing Breakthrough Infections in Women Assigned to Tenofovir Gel in the CAPRISA 004 Microbicide Trial Did Not Demonstrate a Higher Replication Capacity**
Philippe Selhorst, South Africa
- PE1/12 **Cellular Proviral HIV DNA in Patients on Stable Combination Antiretroviral Therapy: Correlation with Immunovirological Parameters and Antiretroviral Regimens**
Isabella Bon, Italy
- PE1/13 **Evidence that an Amino Acid Substitution in the HIV-2 Env Protein Lead to a Lack of Tetherin Antagonism**
François Dufrasne, Belgium
- PE1/14 **Characterization of HIV-1C gp120 in Recently and Chronically Infected Individuals in Botswana**
Terence Mohammed, Botswana
- PE1/15 **Comparison of the Analytical Performance of the Cepheid Xpert HIV-1 Viral Load Real-time PCR with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0 Assay**
Brice Dubouil, France
- PE1/16 **Validation of the Xpert VIH-1 Viral Load Real-time PCR (GeneXpert®, Cepheid) for Organ Transplantations**
Aleksandra Maleska, France
- PE1/17 **HIV-1 Genetic Diversity and Divergency and its Correlation with Disease Progression among Recently Infected Individuals Using Next Generation Sequencing**
Ana Rachel Leda, Brazil
- PE2/1 **Responses of NK Cell Subsets to Anti-HIV Antibody Mediated Activation**
Irene Lisovsky, Canada

Scientific Programme

- PE2/2 **Influence of HLA Glycosylation on the Binding of HLA-B*57:01 to KIR3DL1**
Wilhelm Salzberger, Germany
- PE2/3 **Optimization of KIR2DS1 Reporter Cell Assay to Identify HIV-peptide Specific Binding of HLA-C*06:02**
Anais Chapel, Germany
- PE2/4 **Analysis of Cross-recognition of HIV-1-Nef-Specific CTL to Human FAT3 Protein**
Thomas Harrer, Germany
- PE2/5 **Identification of HLA-C Restricted, HIV-1-Specific CTL Epitopes by Peptide Induced Upregulation of HLA-C Expression**
Thomas Harrer, Germany
- PE2/7 **NK Cells Expressing Self-Inhibitory KIR2DL Receptors Display Reduced Ability to Inhibit HIV-1 Replication in vitro**
Korner Christian, United States
- PE3/1 **Plasma L-carnitine and L-lysine Concentrations in HIV-infected Patients at Clinical Stages of the Disease**
Evgeny Butorov, Russian Federation
- PE3/2 **Plasmatic Cytokine Levels in Rapid and Slow Progressors HIV-1 Infected**
Rúbia de Medeiros, Brazil
- PE3/3 **Evaluation of Some of Oxidative and Inflammatory Stress Biomarkers in People Living with HIV/AIDS before and after the Initial Antiretroviral Therapy**
- PE3/5 **Changes in Peripheral T-cell Homeostasis, Gut Inflammation, Intestinal Permeability and Fecal Microbiota in the First Year of Combination Antiretroviral Therapy (cART)**
Camilla Tincati, Italy
- PE3/6 **Peripheral Blood Pre-erythroidal Cells in HIV-1 Infection**
Maciej Stanislaw Tarkowski, Italy
- PE3/7 **Frequently Low Serum Immunoglobuline M Levels on Long-term Suppressive ART - A Possible Indicator of a Functional B-cell Defect Demasked by ART**
Hans-Jürgen Stellbrink, Germany
- PE3/9 **HIV gp120 Enhances CXCR4/SDF-1 Mediated MSC Migration through Activation of ERK and FAK Pathways**
Nicholas Chew, Singapore
- PE3/10 **The Role of miRNA-33 in HIV-mediated Impairment of Cholesterol Efflux in THP-1 Cells**
Mireia Arnedo, Spain
- PE3/11 **Long-Term Immune Recovery in HIV-infected Patients with Candida esophagitis is Impaired Despite Combination Antiretroviral Therapy**
Nina Khanna, Switzerland
- PE4/1 **Analysis of Gut Microbiota Diversity in Chronic AIDS Patients Living in China Using the QIIME Pipeline**
Yang Sun, China

Scientific Programme

- PE4/2 **The Impact of HLAB*5701 on Viral Replication among Patients Infected with HIV-1 B and Non-B Subtypes - Interplay between Host and HIV Genetics**
Małgorzata Dawidek, Poland
- PE4/3 **Circulating MicroRNA Modulations in HIV-1 Patients under Long-term ARV Treatment**
Marjorie Monleau, France
- PE5/1 **Definition of HIV-1 CTL Epitopes Designed from Archived Virus and Exhibiting Affinity to HLA Groove: The Provir Vaccine Strategy**
Herve Fleury, France
- PE5/2 **Kinetic of Total HIV-Dna during Interferon Based Anti-HCV Therapies in Coinfected Patients**
Giancarlo Orofino, Italy
- PE5/3 **Development of Community-led Education about Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns**
Karamoko Tounkara, Mali
- PE5/4 **Inhibitory Role of CD16+ Inflammatory Monocytes on Vaccine-induced Antibody Responses**
Anne Nolting, Germany
- PE5/5 **Impact of Economic Crisis on Immunization of HIV-1 Population in Greece**
Olga Tsachouridou, Greece
- PE6/1 **Novel and Effective Vaginal Microbicide Delivery System Using Nanoparticle Entrapped Microbicides**
Mahesh Sherkar, India
- PE6/2 **Second-generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity Toward Non-B Subtype HIV-1 Viruses**
Ira Dicker, United States
- PE6/3 **Targeted Cleavage of the HIV-1 Proviral Genome Using AAV Vector-mediated CRISPR**
Manuela Nickl, Germany
- PE6/4 **AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro**
Stefan Proniuk, United States
- PE7/1 **Patient Reported Outcomes (PRO) over 48 Weeks in a Randomized, Open-label Trial of Patients with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF)**
David Budd, United States
- PE7/2 **Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy versus Darunavir/Ritonavir with Two Nucleoside Analogues: The PROTEA Trial**
Pierre-Marie Girard, France
- PE7/3 **Does Two-drug Therapy Show Equivalent Efficacy to Standard Three-drug Combinations? Meta-Analysis of 14 Randomised Trials in 3323 Patients**
Pierre-Marie Girard, France

Scientific Programme

- PE7/4 **Safety and Antiviral Effect of Elpida (VM1500), a Novel NNRTI (+Truvada) in Treatment-naïve HIV-1 Infected Patients**
Alexey Kravtchenko, Russian Federation
- PE7/5 **HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-experienced Subjects: Week 48 Safety Analysis**
Bonaventura Clotet, Spain
- PE7/6 **Dual Treatment with Atazanavir/r+3TC vs. Triple Treatment with Atazanavir/r+2 Nucleos(t)ides in Virologically Stable Patients with HIV-1 (SALT Study): 96-week Results from a Randomised, Open Label, Non-inferiority Trial**
Jose Perez-Molina, Spain
- PE7/7 **A Switch to Once Daily Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed HIV-infected Rwandans is Non-inferior to Continued Nevirapine-based Antiretroviral Therapy**
Sean Collins, United States
- PE7/8 **A NRTI Sparing Two-drugs Maintenance cART is Effective and is Well Tolerated (PROBE Study)**
Franco Maggiolo, Italy
- PE7/9 **Comparative Effectiveness of Tenofovir in Treatment-naïve HIV-infected Patients: Systematic Review and Meta-analysis**
Heiner Bucher, Switzerland
- PE7/10 **Atazanavir plus Cobicistat (ATV+c) versus Atazanavir plus Ritonavir (ATV+r), Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-blind, Active-controlled Trial**
Graeme Moyle, United Kingdom
- PE7/11 **Lipid Profile and Inflammatory Markers of Lipoproteins in Virologically Suppressed Patients with Triple Therapy Switching to Lopinavir/R Plus Lamivudine**
Maria Saumoy, Spain
- PE7/12 **The MONOD-ANRS-12206 Trial: Efavirenz May Simplify a Successful Lopinavir-based Therapy Initiated before the Age of 2 in HIV-infected Children from West-Africa**
Carole Seguin-Devaux, Luxembourg
- PE7/13 **Improved Safety and Efficacy of TAF vs. TDF Single-tablet Regimen in HIV-1 Treatment-naïve Women through Week 48**
Chloe Orkin, United Kingdom
- PE7/14 **Switch to Maraviroc (MVC) + Darunavir/Ritonavir (DRV/r) in Virologically Suppressed Patients with R5-Tropic Virus is Associated with an Excess of Virological Failures: 48 Weeks Results of the GUSTA Study**
Barbara Rossetti, Italy
- PE8/1 **High Efavirenz Serum Concentrations in TB/HIV Co-infected Ugandan Adults Receiving Rifampicin-Based Anti-TB Therapy**
Amrei von Braun, Uganda
- PE8/2 **Comparison of Serum Levels of Vitamin A in HIV Positive and HIV Negative Adults in Yenagoa Nigeria**
Okechukwu Anene, Nigeria

Scientific Programme

- PE8/3 **The Efficacy of Second-line Antiretroviral Therapy for AIDS in China: A Retrospective Study**
Qingxia Zhao, China
- PE8/4 **Association between Estimated Cumulative Viraemia and CD4/CD8 Ratio in HIV Patients on Long Term Antiretroviral Therapy**
Kenny CW Chan, China
- PE8/5 **Long Term Virologic Superiority of Emtricitabine over Lamivudine when Used in Fixed Dose Combination with Tenofovir/Efavirenz Among Patients with Low Baseline CD4 Counts in Resource Limited Settings (RLS)**
Ameet Dravid, India
- PE8/6 **Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive Individuals?**
Caroline Sabin, United Kingdom
- PE8/7 **Toll-like Receptor 4 Polymorphism Influence on the Antiretroviral Therapy Effectiveness in HIV-Positive Patients**
Tetiana Kyrychenko, Ukraine
- PE8/8 **Cost Effectiveness of Antiretroviral Therapy in HIV-infected Patients in Kazakhstan**
Rafail Kipshakbayev, Kazakhstan
- PE8/9 **Role of the Decentralization of ART Services in Expansion of Access for HIV-positive IDUs to Treatment**
Nataliya Nizova, Ukraine
- PE8/10 **Real World Experience with Raltegravir and Etravirine as Dual Agent Treatment of HIV**
Dillon Benson, United States
- PE8/11 **Darunavir-Containing Antiretroviral Regimens in Pregnancy: Findings from the Antiretroviral Pregnancy Registry**
William Short, United States
- PE8/12 **Prevalence and Risk Factors Associated with Adherence to Antiretroviral Therapy in HIV-infected Adults in a Tertiary Care Hospital In Mexico**
Juan Domínguez, Mexico
- PE8/13 **Once versus Twice Daily ARV Regimens: Virological and Immunological Outcomes at 48 Weeks**
Guillermo Vilorio, Argentina
- PE8/14 **Factors Associated with Unstructured Antiretroviral Therapy Interruption during the First Year of Treatment**
Mariana Kundro, Argentina
- PE8/15 **Durability of First Antiretrovirals Treatment between 2012-2013 in HIV-patients. Has it Improved with New Drugs?**
Javier De La Torre Lima, Spain
- PE8/16 **Analysis of Toxicity as a Cause of Change of the First Current Antiretroviral Treatments in HIV Patients**
Javier De La Torre Lima, Spain

Scientific Programme

- PE8/17 **48 Week Data of Atripla®, Eviplera® (EPA) or Stribild® in Routine Clinical Use: Efficiency and Safety of Single Tablet Regimens (STRs) in HIV-infected Patients Included in the German STRike Cohort**
Stefan Esser, Germany
- PE8/18 **The Determinants of HIV+ Social Costs: An Empirical Survey in the Italian Setting**
Mariangela Errico, Italy
- PE8/19 **Non-nucleosid Reverse Transcriptase Inhibitor (NNRTI) + Integrase Inhibitor (INI): A Well-tolerated Combination for HIV Maintenance Treatment, a Combination Hypothesized to Have Few or No Long Term Side Effects**
Oswald Moling, Italy
- PE8/20 **Dual Therapy with Lopinavir/r and Raltegravir (LPV/r+RAL) in Treatment-experienced HIV-infected Patients: Data from the German Multicenter PROTEKT Cohort**
Johannes Huelsenbeck, Germany
- PE8/21 **Efficacy of Darunavir/Ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)**
Andrea Antinori, Italy
- PE8/22 **Determinants of Virological Failure in a Large French Cohort in 2014**
Gwenael Le Moal, France
- PE8/23 **Durability of Darunavir/ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)**
Paola Meraviglia, Italy
- PE8/24 **The Position of Rilpivirine in Antiretroviral Therapy: Early Evaluation of its Use in the Swiss HIV Cohort Study**
Delphine Sculier, Switzerland
- PE8/25 **Although Aging HIV-infected Patients Are Burdened with Higher Rates of Co-morbidities and Co-medications, their Response to Raltegravir-based ART is Similar to that of Younger Subjects: An Analysis of a German Real Life Cohort**
Stefan Mauss, Germany
- PE8/26 **Effectiveness and Safety of Fixed Dose ABC/3TC plus Rilpivirine in a Multicenter Cohort of HIV-infected Patients. SIMRIKI Study, GESIDA-8314**
Jesús Troya, Spain
- PE8/27 **Persistency of Single Tablet Regimens (STRs) in Daily Clinical Routine - a Comparison between FTC/TDF-based STRs for Treatment of HIV-infected Patients: Data from the German STRike Cohort**
Eva Wolf, Germany
- PE8/28 **Metabolic Syndrome, Cardiovascular Risk and Renal Impairment in HIV-infected Patients Initiating Antiretroviral Therapy in Portugal**
Ana Lebre, Portugal
- PE8/29 **Potential Cost Savings Associated with Switches from 1st & 2nd-line ART Regimens to Less Expensive Regime; Bichat-Claude Bernard University Hospital Clinic, Paris, France 2014 (ANRS-GOTA)**
Emmanuelle Papot, France

Scientific Programme

- PE8/30 **Durability and Predictive Factors of Discontinuation of Tenofovir-containing Antiretroviral Therapy Regimens in a Cohort of HIV-positive Patients**
Marco Franzetti, Italy
- PE8/31 **Clinical Data and Patient-Reported Outcomes (PRO) in HIV-infected Adults Switching to RPV/FTC/TDF, due to a Previous Intolerance to cART. Interim Analysis of the PRO-STR Study**
Daniel Podzamczar, Spain
- PE8/32 **Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (STRIBILD®) in Patients Treated during Primary HIV Infection Compared to Recent HIV Infection**
Silvia Nozza, Italy
- PE8/33 **Long-term Virological Outcomes of ART-experienced Patients Receiving Raltegravir in a Large European Cohort Study**
Anna Schultze, United Kingdom
- PE8/34 **Maraviroc plus Protease Inhibitor as a Switching Regimen in Clinical Practice**
Marianna Menozzi, Italy
- PE8/35 **Early Start of Antiretroviral Therapy during Primary HIV Infection is Associated with Faster Virological Suppression**
Marco Ripa, Italy
- PE8/36 **Experience of Dolutegravir (DTG) in HIV Infected Treatment Naïve Patients from a Tertiary Care University Hospital in Ireland**
John Lambert, Ireland
- PE8/37 **Simplification for Dolutegravir as a Mono- or Bitherapy Maintains High Proportion of Viral Suppression Even in Highly-experienced HIV-1-infected Patients**
Laurent Hocqueloux, France
- PE8/38 **Switch to Single Tablet Regimen (STR) in Virologically Suppressed Patients: A Comparison between Co-formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir**
Roberta Gagliardini, Italy
- PE8/39 **Immunological and Virological Responses to Combined Antiretroviral Treatment in Male and Female Migrants in Europe: Is Benefit Equal for All?**
Inmaculada Jarrín, Spain
- PE8/40 **Boosted versus unboosted Atazanavir/Raltegravir Dual Therapy and Immunovirological, Clinical and Pharmacological Outcomes: Results from a Prospective Multicenter Cohort of HIV-infected Individuals**
David Rey, France
- PE8/41 **Efficacy and Safety of a Kivexa® (Abacavir/Lamivudine) plus Rilpivirine Regimen for the Treatment of HIV-1 Infection in Naïve Patients (KiRiNa Study)**
Adrian Curran, Spain
- PE8/42 **Factors Associated with Switches and Interruptions of Initial Antiretroviral Therapy in the First Year**
Michaela Rappold, Austria

Scientific Programme

- PE8/43 **Risk and Determinants of Failure of a Mono-PI/r Simplification Strategy with LPV/r or DRV/r in Clinical Practice**
Alessandro Cozzi-Lepri, United Kingdom
- PE8/44 **High Treatment Retention and Success Rates of Tenofovir/Emtricitabine/Rilpivirine (Eviplera) in ART-naïve HIV-infected Persons in Clinical Practice: A Comparative Study on Determinants of Use and Treatment Outcome**
Alessandro Cozzi-Lepri, United Kingdom
- PE8/45 **Perceptions of Healthcare Providers (HCPs) and Patients around the Provision of HIV Healthcare and HCP-patient Communication: A NAM Web-based Survey**
Caspar Thomson, United Kingdom
- PE8/46 **A Year of Stribild® Use. Experience in Real Life**
Maria Arrizabalaga, Spain
- PE8/47 **Clinical Consequences of Poor Adherence to Antiretroviral Therapy in Patients with HIV Infection - A Retrospective Cohort Study**
Cátia Caldas, Portugal
- PE8/48 **Is Switching to Kivexa with Rilpivirine as Effective as Switching to Eviplera in Clinical Practice?**
Lucy Hedley, United Kingdom
- PE8/49 **Factors Related to the Durability of the First Antiretroviral Treatment**
Luis Force, Spain
- PE8/50 **Rilpivirine with Kivexa for Treatment Naïve HIV: Experience in Clinical Practice**
Lucy Hedley, United Kingdom
- PE8/51 **Switch from Atripla™ to Eviplera™: Gap between Perceived vs Compared Quality of Life**
Amedeo Capetti, Italy
- PE8/52 **Much Less Treatment Modification in Individuals Initiating Antiretroviral Therapy with Recently Approved Drugs: The Austrian HIV Cohort Study**
Michaela Rappold, Austria
- PE8/53 **First-line Antiretroviral Therapies in HIV-infected Patients in Germany: Treatment Decisions in the PROPHET Study**
Eva Wolf, Germany
- PE8/54 **Maraviroc Once Daily: Experience in Routine Clinical Practice**
Maria Saumoy, Spain
- PE8/55 **Reasons for Modification and Discontinuation of Initial Antiretroviral Treatment among Recently Diagnosed Patients in HIV-TR Cohort**
Volkan Korten, Turkey
- PE8/56 **Simplification from Unboosted Protease Inhibitor to a STR-containing Rilpivirine Improves Levels of Triglycerides**
Niccolò Riccardi, Italy

Scientific Programme

- PE8/57 **Lipid Changes and Tolerability in a Cohort of Adult HIV-infected Patients Switching to RPV/FTC/TDF, due to Intolerance to Previous cART. A Substudy of PRO-STR Study**
Antonio Ocampo, Spain
- PE8/58 **KReal Study - Real World Experience of a Nucleoside-sparing Regime - Raltegravir + Lopinavir/Ritonavir**
Frederico Duarte, Portugal
- PE8/59 **HiPeak Study - The Most Effective Therapeutic Response to Standard Antiretroviral Therapy (ART) Schemes in Naïve HIV-1 Infected Patients with High Viral Loads**
Frederico Duarte, Portugal
- PE8/60 **Does starting ART as Part of a Randomised Controlled Trial (RCT) Improve Long-term Virological and Immunological Outcomes?**
Mike Youle, United Kingdom
- PE8/61 **Switching from Abacavir/Lamivudine + Nevirapine to Abacavir/Lamivudine /Dolutegravir Single Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Subjects: 12 Weeks Outcome**
Clotilde Allavena, France
- PE8/62 **Use of Abacavir+Lamivudine+Unboosted Atazanavir (ABC/3TC+ATV) in Routine Clinical Practice: Twelve Years Experience**
Rocio Montejano, Spain
- PE8/63 **Multi-centre International Study of the Efficacy and Tolerability of Eviplera (EVA) in Routine Clinical Settings**
Mark Nelson, United Kingdom
- PE8/64 **DRV/r+3TC Bitherapy: More Than Security**
Javier Moreno Díaz, Spain
- PE8/65 **Real-world Persistence with Antiretroviral Therapy for HIV in the United Kingdom: A Multicentre Retrospective Cohort Study**
Joseph Lewis, United Kingdom
- PE8/66 **Unboosted Atazanavir (400 mg QD) in Combination with TDF/FTC or ABC/3TC is Able to Maintain Plasma Viral Load below 1 Copy/ml during 12 Months after the Use of Boosted Azatanavir (100/300 mg QD)**
Vincent Calvez, France
- PE8/67 **Efficacy and Safety of Switching to Abacavir/Lamivudine (ABC/3TC) Plus Rilpivirine (RPV) in Virologically Suppressed HIV-infected Patients on HAART. Study SAEI 00/0067**
Isabel Pérez-Hernández, Spain
- PE8/68 **Raltegravir (RAL) Based Antiretroviral Therapy (ART) in HIV-infected Solid Organ Transplant (SOT) Recipients: A Single Center Experience**
Christian Manzardo, Spain
- PE8/69 **Identifying Priorities for HIV Consultations among Healthcare Providers (HCPs) across Europe: Results of a Pan-European Survey**
Caspar Thomson, United Kingdom
- PE8/70 **Adherence to Antiretroviral Treatment in Turkey: Results from ACTIV-IST Study Group**
Dilek Yildiz Sevgi, Turkey

Scientific Programme

- PE8/71 **Inter-country Variability in the Degree of ART-induced HIV-RNA Suppression**
Kamilla Laut, Denmark
- PE8/72 **Cost Savings Associated with Rapid Virologic Response in Treatment-naïve HIV Patients**
Robert Cuffe, United Kingdom
- PE8/73 **cART-Simplification and Neuro-AIDS**
Gabriele Arendt, Germany
- PE8/74 **Reasons to Start and to Choose the Initial Antiretroviral Treatment: The Physician's and the Patient's Perspective - A Prospective Study**
Luigia Elzi, Switzerland
- PE8/75 **Diffusion Tension Image, Fractional Anisotropy and Mean Diffusivity Comparison in Patients Receiving PI Monotherapy or Triple Therapy**
Ignacio Pérez-Valero, Spain
- PE8/76 **Time to Viral Suppression for HIV-positive Patients Initiating cART with Very High Viraemia**
Annabelle Gourlay, United Kingdom
- PE8/77 **First-line NNRTI-Including cART Regimens Display Faster Immune-virologic Response in Comparison to PIs: Data from the San Paolo Infectious Diseases (SPID) Cohort, 2010-2015**
Francesca Bai, Italy
- PE8/78 **Maraviroc Use and Outcomes across Europe - The European Coreceptor (EUCCO) HIV Cohort Study**
Anna Maria Geretti, United Kingdom
- PE8/80 **Mono and Dual Antiretroviral Suppressive Strategies: Real Life Experience in Three Hospitals in Paris (COREVIH Ile-de-France-Centre)**
Marc-Antoine Valantin, France
- PE8/81 **Dual Therapy with Dolutegravir and Lamivudine Maintains Virologic Suppression in HIV-infected HAART-treated Patients: DOLULAM Pilot Study**
Jacques Reynes, France
- PE8/82 **Immuno-Virological Effects and Cost after Introduction of Generic Drugs of Efavirenz and Nevirapine. Are they Good, Safe and Cheap?**
Miguel Torralba, Spain
- PE8/83 **Eviplera (EVP) as a Treatment Option in Real-life Clinical Practice: Evidence for Efficacy and Safety**
Konstantinos Protopapas, Greece
- PE8/84 **Simplification of a 4-drug cART Started during Acute HIV Infection (Alpha study): HIV RNA and Proviral HIV DNA Levels before and after**
Adriana Ammassari, Italy
- PE8/85 **Genotypic Susceptibility Scores (GSS) of the Therapeutic Backbone in Treatment-experienced HIV-1 Patients: what Level is Required to Achieve Viral Suppression on Dolutegravir-containing cART**
Matthijs Raadsen, Netherlands

Scientific Programme

- PE8/86 **Successful Interferon-based Salvage Therapy in a Panresistant HIV+ Adolescent**
Markus Bickel, Germany
- PE9/1 **High Rate of HIV-1 Drug Resistance in Treatment Failure Patients in Taiwan, 2009-2014**
Hung-Chin Tsai, Taiwan, Republic of China
- PE9/2 **Deep Analysis of HIV-1 Natural Variability across HIV-1 Variants at Residues Associated to Integrase Inhibitors (INI) Resistance in INI-naïve Patients**
Teresa Llácer Delicado, Spain
- PE9/3 **HIV Proviral DNA is an Adequate Genetic Compartment for Detection of Resistance Mutations Associated to Integrase Strand Transfer Inhibitors (INSTIs) Therapy in Patient with Undetectable or Low HIV Viral Load**
Pablo Ferrer, Chile
- PE9/5 **Integrated Analysis of Emergent Drug Resistance by Population and Deep Sequencing through 48 Weeks from Clinical Studies of HIV-1 Treatment-naïve Subjects Receiving EVG/COBI/FTC/TAF**
Michael Miller, United States
- PE9/6 **Cumulative Genotypic Resistance to NRTIs and NNRTIs is Associated with a Higher Risk to Loose Virological Suppression in HIV-positive Patients Switching to Tenofovir/Emtricitabine/Rilpivirine Single-tablet Regimen**
Maria Mercedes Santoro, Italy
- PE9/7 **Prevalence of Transmitted Drug Mutations to Rilpivirine in HIV-infected Treatment-naïve Persons: Systematic Review of 64,466 Samples from 138 Studies**
Vincent Calvez, France
- PE9/8 **What if a New HIV Integrase Inhibitor was not Prone to the Problem of Drug Resistance?**
Mark Wainberg, Canada
- PE9/9 **Emerging Resistance Mutations in Protease Inhibitor Naïve Patients Failing Atazanavir Based Regimen (ANRS Multicentre Observational Study)**
Laurence Morand-Joubert, France
- PE9/10 **APOBEC Could Explain Low Viral Load in HIV Patient with Highly Active Therapy (HAART) with Nucleoside Analog Reverse-transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse-transcriptase Inhibitors (NNRTIs) Resistance but without Clinical Consequences**
Pablo Ferrer, Chile
- PE9/11 **Comparison of the Risk of Resistance Accumulation According to ART Switching Strategies after Virological Failure >200 Copies/mL to First cART Using the g-computation Procedure**
Alessandro Cozzi-Lepri, United Kingdom
- PE9/12 **HIV Drug Resistance among Children and Adolescents in Asia after First-line NNRTI-based Treatment Failure**
Wanatpreeya Phongsamart, Thailand

Scientific Programme

- PE9/13 **Protease Inhibitor Monotherapy: Effectiveness and Resistance in Clinical Practice**
Kate El Bouzidi, United Kingdom
- PE9/14 **Characterization of HIV Resistance in Peripheral Blood Mononuclear Cells (PBMC-DNA) in Patients with Suppressed or Low Level Viremia**
Mauro Zaccarelli, Italy
- PE9/15 **Prediction of Virological Failure by a Single Quantifiable Viral Load Below 200 Copies/mL in Treated HIV-infected Patients**
Gisela Leierer, Austria
- PE9/16 **Impact of Baseline NRTI Resistance Mutations on Virological Suppression of HIV-1 Infected Patients Treated by Elvitegravir/Cobicistat/Emtricitabine/Tenofovir**
Nolwenn Hall, France
- PE9/17 **Transmitted Drug Resistance (TDR) in Drug-naive HIV-2 Infected Patients**
Frederico Duarte, Portugal
- PE9/18 **Patterns of Viral Resistance in Patients with Virologic Failure on a Dual Agent Antiretroviral Regimen**
Dillon Benson, United States
- PE9/19 **Antiretroviral Resistance Mutations and Molecular Surveillance of HIV-1 in the Comunidad Valenciana (Spain), 2011-2013**
Manoli Torres-Puente, Spain
- PE9/20 **Evolution of Resistance Rates to RT and Protease Inhibitors in Antiretroviral-experienced HIV-infected Patients**
Anne-Geneviève Marcellin, France
- PE9/21 **Integrated Analysis of Emergent Drug Resistance through 96 & 144 Weeks from Clinical Studies of HIV-1 Treatment-naive Subjects Receiving Dolutegravir Based Regimens**
James Demarest, United States
- PE9/22 **E138A - Natural Polymorphism or Selected by 2nd Generation NNRTIs?**
Martin Obermeier, Germany
- PE9/23 **Decline in Resistance Mutations' Prevalences, Namely K65R: Frankfurt HIV-1 Database, 2005-2013**
Christoph Stephan, Germany
- PE10/1 **Discovery of Novel Diarylthiazines (DATAs) as Non-nucleoside Reverse Transcriptase Inhibitors via Extension into the Entrance Channel of HIV-1 Reverse Transcriptase**
Udaya Pratap Singh, India
- PE10/2 **Design and Discovery of Potent Hybrid 1,3,5-Triazine-1,3-Thiazine Analogs Clubbed via Amine Bridge: A Novel Lead for Next Generation NNRTI**
Amita Verma, India
- PE10/3 **Pharmacogenetic: Screening Relevant Polymorphisms on Antiretroviral Therapy in an HIV Portuguese Population**
Ana Fernandes, Portugal

Scientific Programme

- PE10/4 **Impact of Decentralized Drug Purchase on Antiretroviral Treatment Costs in Spain**
Yaiza Rivero-Montesdeoca, Spain
- PE10/5 **Impact of UGT1A1*28 Polymorphism on Raltegravir Metabolism**
Leïla Belkhir, Belgium
- PE10/6 **The Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) is Bioequivalent to Elvitegravir/Cobicistat/FTC/TAF (E/C/F/TAF) and RPV**
Julia Zack, United States
- PE10/7 **Co-medication in an Irish Infectious Diseases Clinic: The Level of Accurate Recording of co-medication and the Significance of Interactions between co-medication and Antiretrovirals (ARVs)**
Paul Hollywood, Ireland
- PE10/8 **Differential Pharmacological Impact of Abacavir Sulphate and Tenofovir on Platelet Aggregation Independent of HIV Infection**
Erica Smyth, United Kingdom
- PE10/9 **The Effect of Food on the Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) Tablet**
Julia Zack, United States
- PE10/10 **Impact of Tenofovir' (TDF) Dose Adjustment on the Estimated Glomerular Filtration Rate (eGFR) and TDF trough Concentration (Ctrough-TDF)**
Sylvie Bregigeon, France
- PE10/11 **Assessment of CYP3A5 Genotype on Maraviroc Exposure and Efficacy in a Phase 3 Study**
Manoli Vourvahis, United States
- PE10/12 **Frequency and Severity of Drug Interactions in a Cohort of HIV-infected Patients Identified through a Multidisciplinary Team**
Hernando Knobel, Spain
- PE10/13 **The Effect of Food on the Pharmacokinetics of Unboosted and Boosted Tenofovir Alafenamide**
Joseph Custodio, United States
- PE10/14 **Evaluation of Tenofovir Alafenamide Pharmacokinetics: No Influence of Demographic or HIV Disease Factors**
Joseph Custodio, United States
- PE10/15 **Pharmacology Drug Interactions and Adherence in Patients on Polypharmacy in our Hospital**
Sheila Ruiz, Spain
- PE10/16 **Risk Factors Associated with Hypersensitivity Reactions to Antiretroviral Drugs in Patients Infected with HIV**
José Antonio Mata-Marín, Mexico
- PE10/17 **What Minimal Concentration of Darunavir in Maintenance Darunavir/Ritonavir 800/100 mg Once-daily with 2 NRTIs (DAMAR study)?**
Minh Lê, France

Scientific Programme

- PE10/18 **Comparison of the in vitro Dissolution and in vivo Pharmacokinetics of Branded versus Generic Efavirenz Formulation in HIV Patients**
Cristina Gervasoni, Italy
- PE10/19 **Neuro+3 Study: Baseline Characteristics with Pharmacologic Results of HIV Patients with Neurocognitive Disorders Despite Effective Antiretroviral Therapy**
Gilles Force, France
- PE11/1 **Renal Toxicity Following Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Drug Transporters in HIV-1 Patients**
Casper Rokx, Netherlands
- PE11/2 **Simple and Practical Screening Approach to Identify HIV-infected Individuals with Current Depression or Risk of Developing Depression**
Lotte Rodkjaer, Denmark
- PE11/3 **Analysis of Neurocognitive Function and CNS Endpoints at Week 96 in the PROTEA Trial: Darunavir/Ritonavir with or without Nucleoside Analogues**
Amanda Clarke, United Kingdom
- PE11/4 **Safety, Sensory Function and Analgesic Effectiveness Following Capsaicin 8% Patch (Qutenzatm) Repeat Treatment in Peripheral Neuropathic Pain: Stride Study**
Graeme Moyle, United Kingdom
- PE11/5 **Tenofovir-associated Nephrotoxicity and Hypophosphatemia in HIV-infected Patients: A Single-centre Cohort Study**
Chien-Yu Cheng, Taiwan, Republic of China
- PE11/6 **Hepatotoxicity and Skin Rash of non-nucleoside Reverse Transcriptase Inhibitor (nNRTI) plus Nucleoside Reverse-Transcriptase Inhibitors in HIV-infected Taiwanese**
Pei-Ying Wu, Taiwan, Republic of China
- PE11/7 **Health State Utilities of Risks Associated with Antiretroviral Treatment (ART) for Human Immunodeficiency Virus (HIV)**
Louis Matza, United States
- PE11/8 **Discontinuation of Tenofovir due to Nefrotoxicity: Insight into 12 Years of Clinical Practice**
Elzbieta Bakowska, Poland
- PE11/9 **Incidence of Cancer in Individuals treated with Raltegravir-based and Non-raltegravir-based cART Regimens**
Daniel Grint, United Kingdom
- PE11/10 **Cross-sectional Multi-centre Study of Bone Mineral Density in HIV-1 Infected Patients on Antiretroviral Treatment at Risk for Osteopenia/Osteoporosis**
Frank Post, United Kingdom
- PE11/11 **Osteonecrosis and HIV Infection: The Experience of a Portuguese Center**
Rosário Serrão, Portugal
- PE11/12 **Prevalence of Sleep Disorders, Anxiety and Depression in HIV/AIDS Patients under Antiretroviral Treatment in China**
Wu Hao, China

Scientific Programme

- PE11/13 **Risk Factors of Anxiety and Depression in HIV-infected Patients during Antiretroviral Treatment**
Wu Hao, China
- PE11/14 **Abacavir Does Not Produce Vascular Inflammatory Effects in ATP Receptor-deficient Mice**
Samuel Orden, Spain
- PE11/15 **The Vascular Pro-inflammatory Effects of Abacavir Involve Interference with the Purinergic System**
Victor Collado Diaz, Spain
- PE11/16 **Abacavir Induces Platelet Adhesion to Endothelial Cells**
César Ríos-Navarro, Spain
- PE11/17 **Hepatic Safety of Maraviroc in HIV Infected Patients with HCV and/or HBV Co-infection. The Maraviroc Cohort Spanish Group**
Manuel Crespo, Spain
- PE11/18 **Breast Density Assessment in Women Living with HIV/AIDS**
Mônica Mendes, Brazil
- PE11/19 **Differences in HIV Symptom Index Questionnaire (SIQ) and Sleep/Wake Activity Inventory (SWAI) after Switching to a Rilpivirine (RPV)-containing Regimens in Combination Antiretroviral Therapy (cART)-experienced HIV-infected Patients**
Manuela Colafigli, Italy
- PE12/1 **Risk Factors for Mortality in HIV-infected Patients with CMV Disease in the Combination Antiretroviral Era**
Rafael Perello, Spain
- PE12/2 **Hospitalizations of HIV Patients in a Major Israeli HIV/AIDS Center in the Years 2000-2012**
Keren Mahlab-Guri, Israel
- PE12/3 **Low Bone Fracture Risk Measured by Frax Index in HIV Patients**
Carmen Hidalgo-Tenorio, Spain
- PE12/4 **HIV-associated versus Classic Fever of Unknown Origin 25 Years on: Spectrum and Criteria Revisited**
Paul De Munter, Belgium
- PE12/5 **Impact of Late Presentation on Short, Mid and Long-term Mortality and on Causes of Death in Spain (2004-2013)**
Paz Sobrino-Vegas, Spain
- PE12/6 **Cardiovascular-specific Mortality in HIV-positive Patients with Alcohol Use Disorders**
Robert Muga, Spain
- PE12/7 **Ongoing Contribution of AIDS Deaths in the HAART Era: Data from the UK CHIC Study**
Sophie Jose, United Kingdom
- PE12/8 **American College of Cardiology Pooled Equations and DAD Algorithm to Predict Freedom from Cardiovascular Events in HIV Patients**
Giovanni Guaraldi, Italy

Scientific Programme

- PE12/9 **Cardiovascular Risk Factors and Recommended LDL Cholesterol Goals Attainment among HIV Positive Patients: The Impact of the Metabolic Syndrome**
Elisabetta Schiaroli, Italy
- PE12/10 **Persistent HIV Low-level Viremia and Cardiovascular Risk**
Silvia Costarelli, Italy
- PE12/11 **Heart Transplantation in HIV-infected Patients: A Report of Three Cases from a Single Institution**
Fernando Agüero, Spain
- PE12/12 **Prognostic Value of DLCO in a Cohort of Middle Aged HIV Infected Patients in Terms of Mortality and Incidence of Cardiovascular Events after 6 Years of Prospective Follow-up**
Francisco Fanjul, Spain
- PE12/13 **Lower CD4/CD8 Ratio (**
Francisco Fanjul, Spain
- PE12/14 **Trends in Cardiovascular Surgery in HIV-infected Patients: A 30-year Single Center Experience**
Juan M Pericás, Spain
- PE12/15 **Review of Causes of Death in HIV Positive Patients in London in 2014**
Sharanjit Dhoot, United Kingdom
- PE12/16 **Cardiovascular Events in HIV-positive Patients over the Last Decade. The Experience of Brescia from 2000 to 2012**
Elena Raffetti, Italy
- PE12/17 **Rare Case of Adult Onset Still's Disease Inducing Hemophagocytic Lymphohistiocytosis (HLH) during Early HIV Infection: Emerging Treatment Controversies and Dilemmas**
Garyfalia Poulakou, Greece
- PE13/1 **Characteristics of the Active Drug Users Recently Infected with Hepatitis C in a Shantytown with a High Prevalence of HCV**
Pablo Ryan, Spain
- PE13/2 **Hepatic Safety of RPV/FTC/TDF Single Tablet Regimen in HIV/HCV-coinfected Subjects. The hEPatic Study**
Karin Neukam, Spain
- PE13/3 **Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-experienced Subjects with HCV Genotype 1 and HIV-co-infection (ANRS HC31 SOFTRIH Study)**
Eric Rosenthal, France
- PE13/4 **Uptake of Tenofovir-based Combination Antiretroviral Therapy (cART) among HIV/HBV Co-infected Patients in the EuroSIDA Study**
Lars Peters, Denmark
- PE13/5 **Ledipasvir/Sofosbuvir with or without Ribavirin for the Treatment of Patients with Genotype 2-6 Chronic HCV Infection: Summary Results from Four Phase II Studies**
Armand Abergel, France

Scientific Programme

- PE13/6 **The Treatment Cascade of Chronic Hepatitis C In HIV Co-infected Patients: Data from the Clinic of Infectious Diseases in Modena, Italy**
Gianluca Cuomo, Italy
- PE13/7 **Factors Associated with Changes in Liver Stiffness in HIV/HCV Co-infected Patients along 5 Years of Follow-up: Effect of Treatment Response to HCV-therapy on Liver Fibrosis**
Eva Van den Eynde, Spain
- PE13/8 **Does treatment of HCV with DAAs Affect Renal Function? Findings from the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)**
Stefan Mauss, Germany
- PE13/9 **Co-morbidities and Co-medications in HIV Patients with Hepatitis C in the Era of New Agents**
Lise Cuzin, France
- PE13/10 **Efficiency of an Integrated Management of New Treatments of HCV**
Julie Chas, France
- PE13/11 **Differential Regulation of Primary Natural Killer Cell Function by Sequence Variations in HCV Core-derived Epitope through Altered Binding of KIR2DL3 to HLA-C*03:04**
Sebastian Lunemann, Germany
- PE13/12 **CD4 and CD4/CD8 Ratio Progression in HIV-HCV Infected Patients after Achievement of SVR**
Annalisa Saracino, Italy
- PE13/13 **Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-infected Patients**
Sanjay Bhagani, United Kingdom
- PE13/14 **Incidence and Recurrence of Hepatitis C Virus Reinfection after Sustained Virological Response in a Large Cohort of Prisoners**
Andrés Marco, Spain
- PE13/15 **Differences in HCV Genotype 1a and 1b Molecular Epidemiology and NS3A Resistance Associated Variant Frequency among HIV-coinfected Patients from Poland**
Milosz Parczewski, Poland
- PE13/16 **Prognostic Value of Transient Elastography in HIV-infected Patients with Chronic Hepatitis C**
Juan Berenguer, Spain
- PE13/17 **Acute Hepatitis C in HIV Co-infected Patients in Barcelona: A Rising Epidemics**
Maria Martínez-Rebollar, Spain
- PE13/18 **Prognostic Value of Liver Stiffness in HIV/HCV-coinfected Patients with Decompensated Cirrhosis**
Juan Berenguer, Spain
- PE13/19 **Determinants and Impact of Late HCV Diagnosis among Persons with Newly Diagnosed HIV Infection**
Enrico Girardi, Italy

Scientific Programme

- PE13/20 **HCV-RNA Profiles among HIV/HCV-coinfected Individuals in the ESPRIT Study: Spontaneous HCV-RNA Clearance Documented in 9 Individuals**
Daniel Grint, United Kingdom
- PE13/21 **Seroclearance of Hepatitis B Surface Antigen is Associated with Immune Reconstitution Inflammatory Syndrome among HIV and HBV Coinfected Individuals**
Takashi Muramatsu, Japan
- PE13/22 **Boceprevir Plus Peginterferon/Ribavirin to Retreat HCV Genotype-1 in HIV-HCV coinfectd Patients. Final Results of BOC HIV-HCV Spanish Study Group**
Montserrat Laguno, Spain
- PE13/23 **HIV/HCV-coinfection across Europe**
Lars Peters, Denmark
- PE13/24 **Prevalence and Clinical Determinants of Hepatitis Delta Co-infection in a Rural Tanzanian HIV Cohort**
Annja Winter, Switzerland
- PE13/25 **Challenges of Anti HCV Treatment in Persons Living with HIV in the Era of Directly Acting Antivirals (DAA)**
Massimo Puoti, Italy
- PE13/26 **Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectiveness And Impact on Liver Fibrosis (MASTER Cohort)**
Paola Nasta, Italy
- PE13/27 **Awareness of HCV-coinfection among Newly Diagnosed HIV Individuals**
Paola Scognamiglio, Italy
- PE13/28 **Monocytes and Dendritic Cells Subsets during New Anti-HCV Treatments: IFN free and IFN Based Regimen**
Stefano Savinelli, Italy
- PE13/29 **High Efficacy of Grazoprevir/Elbasvir in HCV Genotype 1, 4, and 6-infected Patients with HIV-co-infection: The phase 3 C-EDGE Co-infection Study**
Christine Katlama, France
- PE13/30 **Safety and Efficacy of combinations of Direct Antiviral Agents (DAAs) against Hepatitis C Virus (HCV) in HIV Co-infected Patients**
Daniela Buccione, Spain
- PE13/31 **Safety and Efficacy of IFN-free, DAAs-based Therapy in HIV/HCV Solid Organ Transplanted Patients**
Ana Moreno, Spain
- PE13/32 **Real-world Effectiveness of Ledipasvir/sofosbuvir 8 Weeks Chronic Hepatitis C Treatment**
Karsten Wursthorn, Germany
- PE13/33 **Interferon-gamma (IFN- γ)-inducible Protein-10 (IP-10) and sCD163 in HCV Monoinfected and HIV/HCV-coinfected Subjects: A Potential Role as Markers of Fibrosis and Response to Therapy**
Claudia Mascia, Italy

Scientific Programme

- PE13/34 **Safety and Efficacy of SOF-based Therapy in HIV/HCV-coinfected Patients with Chronic Kidney Disease (CKD) in “Real Life”**
- PE13/35 **Reduced CD4 Monitoring in Stable and Virologically Suppressed HIV/HCV-coinfected Patients from the PISCIS Cohort (Spain)**
David Nicolás, Spain
- PE13/36 **Linkage to Care after Routine HIV, Hepatitis B (HBV) & C (HCV) Testing in the Emergency Department (ED) - The ‘Going Viral’ Campaign**
Rageshri Dhairyawan, United Kingdom
- PE13/37 **Prevalence of Hepatitis B Virus and Hepatic Fibrosis Progression after ART Initiation among ART-naïve Individuals in a Rural Tanzanian HIV Cohort**
Adrià Ramírez-Mena, Spain
- PE13/38 **Effectiveness of New Direct-acting Antivirals in a Real-life Cohort of Difficult-to-Treat HCV and HIV/HCV-coinfected Patients**
María Jesús Vivancos Gallego, Spain
- PE13/39 **Directly-acting Agents against the Hepatitis C Virus (HCV) for HCV-monoinfected and HIV-HCV-coinfected Patients with HCV Genotypes 1, 2, 3 and 4 - Results from the German Hepatitis C Cohort (GECCO)**
Stefan Christensen, Germany
- PE13/40 **High Proportion of Advanced Liver Fibrosis and Cirrhosis Requiring Hepatitis C Treatment in HIV-HCV Coinfected Patients in Hai Phong, Northern Vietnam**
Tam Nguyen Truong, Viet Nam
- PE13/41 **Are there any Variables that Predict a Rapid Progression to Liver Fibrosis in HIV-HCV infected patients?**
David Rial, Spain
- PE13/42 **Spontaneous Hepatitis C Virus (HCV) Clearance: Epidemiological and Clinical Characterization and Identification of Predictive Factors of Clearance in a Portuguese Cohort**
Nina Fernandes, Portugal
- PE13/43 **Significant Reductions in Costs of Generic Production of Sofosbuvir and Daclatasvir for Hepatitis C Treatment in Low- and Middle-income Countries**
Andrew Hill, United Kingdom
- PE13/44 **Differential Effects of HCV Therapy with Direct Acting Antiviral Agents on Lipids in the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)**
Stefan Mauss, Germany
- PE13/45 **Correlates of Successful HCV Treatment in HIV Co-infected Vulnerable Populations**
Syune Hakobyan, Canada
- PE13/46 **High Prevalence of Undiagnosed Hepatitis C Virus (HCV) Infection in Attendees of the Emergency Department of a Central London Hospital**
Daniel Bradshaw, United Kingdom

Scientific Programme

- PE14/1 **Infectious Complication Rate in a Cohort of HIV-infected Kidney Transplant Recipients**
Oana Alilioaie, Romania
- PE14/2 **Antiretroviral and Cotrimoxazole Prophylactic Therapies among HIV-TB Co-infected Patients**
Olatunji Adetokunboh, South Africa
- PE14/3 **Resistance to Antituberculous Drugs and Outcome among TB/HIV Co-infected Adults in Ghana - Detect HIV/TB study**
Stephanie Bjerrum, Denmark
- PE14/4 **HIV/TB Coinfection**
Mariana Hualde, Argentina
- PE14/5 **Use of IGRA Tests for Heavy Immunosuppressed HIV-patients**
Aleksander Panteleev, Russian Federation
- PE14/6 **FDG-PET/CT: A Non-invasive Tool in Diagnosis and Monitoring of Therapeutic Response in HIV Patients with Extra-pulmonary Tuberculosis**
Charlotte Martin, Belgium
- PE14/7 **Drug Resistant TB in HIV-infected Patients in St Petersburg: Problems and Perspectives**
Aleksander Panteleev, Russian Federation
- PE14/8 **Has Tuberculosis in HIV-infected Patients the Same Clinical and Epidemiological Features than Tuberculosis in HIV-negative Patients?**
Javier Martinez-Sanz, Spain
- PE14/9 **Consecutive Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis in a Spanish cohort of HIV-infected Individuals**
Adrià Ramírez-Mena, Spain
- PE14/10 **Computed Tomography in the Diagnosis of Bowel Diseases in Patients with HIV/Tuberculosis co-infection**
Irina Sokolina, Russian Federation
- PE15/1 **Human Immunodeficiency Virus Infection and Stroke: A Case-control Study in a Portuguese Hospital**
André Silva-Pinto, Portugal
- PE15/2 **Prevalence of Hypertension and Obesity among HIV Patients in a Care Program in Nairobi: A Case for Integration of Care**
Moses Masika, Kenya
- PE15/3 **Brain-related Voice Emotion Processing Deficits in HIV-infected Patients**
Alicia González-Baeza, Spain
- PE15/4 **Burden of Chronic Obstructive Pulmonary Disease (COPD) and its Determinants in an African HIV Cohort**
Attannon Arnauld Fiogbé, Togo
- PE15/5 **Ageing with HIV: Do Comorbidities and Poly-medication Drive Treatment Optimizations?**
Lise Cuzin, France

Scientific Programme

- PE15/6 **Central Obesity and Correlating Factors in Vojvodina's Cohort**
Daniela Maric, Serbia
- PE15/7 **Prevalence and Risk Factors for Chronic Kidney Disease (CKD) among Ambulatory ART Naïve HIV-1 Infected Patients in a Rural Kenyan Population**
Paul Yonga, Kenya
- PE15/8 **Has CXCL13 an Added Value in the Diagnosis of Neurosyphilis?**
Khutso Mothapo, Netherlands
- PE15/9 **Associations between Cognitive Impairment and Patient-reported Measures of Physical/Mental Functioning in Older People Living with HIV**
Jonathan Underwood, United Kingdom
- PE15/10 **Metabolic Syndrome and Sub Clinical Cardiovascular Disease Detected on Cardiac MRI in HIV Infected Patients**
Aisling Loy, Ireland
- PE15/11 **Increased Markers of Endothelial Dysfunction in Untreated HIV Infection Are Associated with Viral Replication but Not with Platelet Aggregation**
Judith Haissman, Denmark
- PE15/12 **Evaluation of a Physiotherapy-led Group Rehabilitation Intervention for Adults Living with HIV: Referrals, Adherence and Outcomes**
Darren Brown, United Kingdom
- PE15/13 **Aging on cART: No Worsening of Bone Mineral Density over 12 Years**
Clotilde Allavena, France
- PE15/14 **Gastroesophageal Reflux Disease among Adults with HIV: Prevalence and Risk Factors of Severe or Frequent Symptoms**
Mazen Bader, Canada
- PE15/15 **Evaluation and Management of Fracture Risk of HIV Patients in the US Veterans Health Care System**
Roger Bedimo, United States
- PE15/16 **Nephrology Consultations Incorporated into HIV Care - Non-compliance is an Important Issue**
Bartłomiej Matłosz, Poland
- PE15/17 **Cardiovascular Risk Assessment in HIV-1 Infected Patients and a Comparison of Framingham, SCORE, and DAD Risk Methods**
Zev Sthoeger, Israel
- PE15/18 **Absence of Pneumocystis jirovecii Colonization in HIV-infected Persons**
Andreas Ronit, Denmark
- PE15/19 **COPD Symptom and Disease Screening in an HIV Population**
Nadine Kronfli, Canada
- PE15/20 **Epidemiology and Costs for Comorbidities in People Living with Human Immunodeficiency Virus (PLWHIV) - A Systematic Review**
Julie Glanville, United Kingdom

Scientific Programme

- PE15/21 **A Calibration of the Framingham Coronary Risk Function Adapted to the Characteristics of Spanish HIV-infected Patients**
Vicente Estrada, Spain
- PE15/22 **Evaluation of HIV Testing Recommendations In Specialty Guidelines for the Management of HIV Indicator Conditions**
Emily Lord, United Kingdom
- PE15/23 **The Prevalence and Outcome of HIV-associated Neurocognitive Impairment in a Clinical Setting**
Francesca Ferretti, United Kingdom
- PE15/24 **Characteristics and Outcome of Patients Diagnosed with HIV at Older Age**
Ilan Asher, Israel
- PE15/25 **Improvement of the Estimation Performance of Ischemic Heart Events Risk in Mediterranean HIV-infected Patients by Means of the Adapted Framingham Function (REGICOR)**
Hernando Knobel, Spain
- PE15/26 **Analysis of Co-morbidities in HIV Infection**
Svetlana Buzunova, Russian Federation
- PE15/27 **Comorbidities and Disability Experienced among Adults Living with HIV in Canada: Results from the HIV Health and Rehabilitation Survey**
Kelly O'Brien, Canada
- PE15/28 **Clinical Evaluation is Better than Risk Prediction Algorithms to Identify Patients who Need Statin Therapy**
Giovanni Guaraldi, Italy
- PE15/29 **cIMT Progression in 90 Patients Starting Their First Highly Active Antiretroviral Therapy: 48 Months Observation**
Sergio Ferrara, Italy
- PE15/30 **Cannabis Exposure Increases the Risk of Liver Fibrosis in HIV-infected Patients**
Olivia Zaegel-Faucher, France
- PE15/31 **Epidemiology of Acute Myocardial Infarction in HIV-infected Patients in Spain during the Combination Antiretroviral Therapy Era (1997-2011)**
Juan Berenguer, Spain
- PE15/32 **Ageing Perception and Attitudes in HIV Patients in Italy**
Mariangela Errico, Italy
- PE15/33 **Impact of Maraviroc, Dolutegravir and Darunavir/Ritonavir on Human Coronary Endothelial Cell Functions According to Age**
Jacqueline Capeau, France
- PE15/34 **Statins and Aspirin in HIV-infected People: Gap between Guidelines and Clinical Practice. The Results of the HIV-HY Study**
- PE15/35 **The Metabolome in HIV-associated Chronic Obstructive Pulmonary Disease**
Chris Wendt, United States

Scientific Programme

- PE15/36 **Low Prevalence of HIV-associated Neurocognitive Disorder (HAND) in a Swedish Cohort of HIV-1 Infected Individuals**
Åsa Mellgren, Sweden
- PE15/37 **Non-viral Liver Disease Burden in HIV Positive Individuals. A Prospective Cohort Study: Preliminary Results**
Yishi Tan, United Kingdom
- PE15/38 **Impact of HIV and Type 2 Diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction**
Hedda Hoel, Norway
- PE15/39 **Apolipoprotein E (ApoE) e2 Genetic Variant is Associated with Favorable Lipid Profile on cART among HIV-1 Infected Patients**
Magdalena Witak-Jedra, Poland
- PE15/40 **CD4/CD8 Ratio for Monitoring the Immunological Response to Combined Antiretroviral Therapy in Ageing HIV+ Patients**
Maria Nikolova, Bulgaria
- PE15/41 **Description of a Male to Female Transgender HIV Positive Population in the North-West of France in 2013**
Jeremie Leporrier, France
- PE15/42 **Lack of Association between Liver Stiffness and Bone Mineral Density in HIV/HCV-coinfected Patients**
Juan Berenguer, Spain
- PE15/43 **Should We Screen for NAFLD/NASH in HIV Patients?**
Giovanni Guaraldi, Italy
- PE15/44 **Human Papillomavirus Infection in HIV Positive and HIV Negative Men Who Have Sex with Men in Non Metropolitan Area of Central Italy: Prevalence and Genotypes Distribution**
Claudio Ucciferri, Italy
- PE15/45 **The Characteristics, Prevalence and Progression of Insulin Resistance in Patients with HIV and HIV/HCV Coinfection**
Opass Putcharoen, Thailand
- PE15/46 **Trends in Myocardial Infarction among HIV-1-infected Individuals in France between 2000 and 2009 Compared to the General Population: Results from FHDH-ANRS CO4**
Dominique Costagliola, France
- PE15/47 **Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIV-positive and HIV-negative Subjects**
Elena Alvarez, Ireland
- PE15/48 **Effectiveness of Progressive Resistive Exercise for Adults Living with HIV: A Cochrane Collaboration Systematic Review**
Kelly O'Brien, Canada
- PE15/49 **Relationship between Surface Activation Markers on Peripheral Monocyte/Macrophage and Evolution of Cognitive Performance in HIV-infected Patients under Suppressive Antiretroviral Therapy**
Alessandra Bandera, Italy

Scientific Programme

- PE15/50 **A Systematic Review of Psychiatric Illness and Sleep Disturbance Prevalence as Comorbidity with HIV in the UK, with Comparison to the UK General Population**
Masautso Chaponda, United Kingdom
- PE15/51 **Vaginal Shedding of Herpesviridae Does Not Influence the Coronary Microcirculation in HIV-infected Women**
Andreas Knudsen, Denmark
- PE15/52 **Prevalence of Central Obesity and Metabolic Complications among Adults Living with HIV in Ireland**
Laura Kelly, Ireland
- PE15/53 **Association with Statin Use in Individuals with and without Cardiovascular Disease**
Gisela Leierer, Austria
- PE15/54 **A Study of the Effect of Early, Untreated HIV on Cerebral Perfusion and Arterial Transit Time in the Basal Ganglia Using Arterial Spin Labelling**
Lewis Haddow, United Kingdom
- PE15/55 **Plasma Osteoprotegerin Concentration in HIV Infected Men and its Association with Hypertriglyceridemia**
Anita Olczak, Poland
- PE15/56 **Anaemia and HIV - An Old New Study Opportunity**
- PE15/57 **Increased Incidence of Cancer and Cancer-related Mortality among HIV/HCV-coinfected Patients, 1993-2014**
Alvaro Mena, Spain
- PE15/58 **Neuroimaging Findings in Effectively Suppressed HIV+ Patients with Symptomatic Neurocognitive Dysfunction: A Cross-sectional Sub-study from the PIVOT Trial**
Alejandro Arenas-Pinto, United Kingdom
- PE15/59 **Age-related Polypharmacy in HIV-infected Patients in a Spanish University Hospital**
Angels Andreu - Crespo, Spain
- PE15/60 **The "Bone Status" in under 40 HIV Positive Patients**
Ermelinda Guerra, Italy
- PE15/61 **White Matter Abnormalities Are Associated with Neurocognitive Disorders in HIV-positive Patients**
Andrea Calcagno, Italy
- PE15/62 **Blood Brain Barrier Impairment is Associated with CSF Neopterin in Late-presenters and with Neurodegeneration and Astrocytosis in Patients with CSF HIV RNA**
Andrea Calcagno, Italy
- PE15/63 **Weight Loss as a Potential Benefit of Liraglutide for Treatment of Diabetes Mellitus in HIV Patients**
Amanda McAneny, United States
- PE15/64 **How do Frailty Mediate and Moderate Pathway Leading to Disability**
Andrea Malagoli, Italy

Scientific Programme

- PE15/65 **Loss of Bone Mineral Density on Long-term Antiretroviral Therapy: Protective Effect of Nevirapine?**
François Raffi, France
- PE15/66 **Neurological Complications in HIV+ Patients**
Goffredo Angioni, Italy
- PE15/67 **Should We Still Use the “Three Questions Test” as a Screening of HIV-associated Neurocognitive Disorders? Evaluation of Sensitivity, Specificity, Positive and Negative Predictive Value and Association with Altered Quality of Life**
Francesca Bai, Italy
- PE15/68 **HIV Infection is Associated with Reduced Bone Quality Independently of Bone Mineral Density and Antiretroviral Treatment**
Robert Güerri-Fernández, Spain
- PE15/69 **Increased Urinary Albumin-to-creatinine Ratio and the Metabolic Syndrome Contribute to Endothelial Dysfunction in HIV+ Patients with Normal Renal Function**
Elisabetta Schiaroli, Italy
- PE15/70 **Dyslipidemia and Fasting Glucose Impairment among HIV-infected Patients 48-weeks after the First Antiretroviral Regimen**
José Antonio Mata-Marín, Mexico
- PE15/71 **Risk Factors for Chronic Kidney Disease in HIV-1 Infected Mexican Patients Initiating Antiretroviral Therapy**
Ricardo Rojas-Aguilar, Mexico
- PE15/73 **A Cross-sectional Study of Co-morbidities in HIV-infected Patients Receiving cART in Taiwan: A Nationwide Surveillance**
Chia-Jui Yang, Taiwan, Republic of China
- PE15/74 **Prevalence of Low 25-hydroxy-vitamin D levels and Factors Associated with 25-hydroxy-vitamin D Insufficiency in a Large European HIV Cohort**
Rocio Montejano, Spain
- PE15/75 **Prevalence of Respiratory Symptoms and Screening for Chronic Obstructive Pulmonary Disease: Results from an Italian Multicenter Study**
Giordano Madeddu, Italy
- PE15/76 **Cerebrospinal Fluid (CSF) HIV Escape is Associated with Progressive Neurologic Deterioration in Patients on Virologically Suppressive Antiretroviral Therapy (ART) in Western India**
Ameet Dravid, India
- PE15/77 **Health Transitions in HIV-seropositive Individuals Undergoing NRTI-based and NRTI-sparing Treatment Strategies**
Stefano Zona, Italy
- PE15/78 **Brain Functioning and Neurocognitive Disorders among Young HIV-positive MSM Treated with cART. Preliminary Results**
Bogna Szymañska, Poland
- PE15/79 **Lopinavir Alone and Ritonavir-boosted Lopinavir Induce Adipocyte Toxicity at Nanomolar Concentrations in vitro**
Robert Maughan, Ireland

Scientific Programme

- PE15/80 **Active HCV Replication is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV**
Andrea De Luca, Italy
- PE15/81 **Improvement of Bone Mineral Density after Switching from Triple Therapy with Lopinavir and Ritonavir Plus Two Nucleos(t)ide Reverse Transcriptase Inhibitors to Lopinavir and Ritonavir Plus Lamivudine: OLE-lip Substudy**
Manuel Crespo, Spain
- PE15/82 **Neuropsychological Performance and Self-Reported Function in HIV Positive Patients in Five European Clinics**
Lewis Haddow, United Kingdom
- PE15/83 **Secondary Hyperparathyroidism in Patients Presenting Low 25-hydroxy-vitamin D: Prevalence and Associated Factors**
Ignacio Pérez-Valero, Spain
- PE15/84 **Effect of Aging in the Neuropsychological Profile of HIV-infected Patients**
Alicia González-Baeza, Spain
- PE15/85 **Prospective Assessment of Bone Mineral Density among a Cohort of Middle-aged HIV-infected and Uninfected Women: Evaluation of a Population at High Risk**
Anna Pia Lassandro, Italy
- PE15/86 **HIV and Subclinical Atherosclerosis**
Argyro Lazarini, Greece
- PE15/87 **Higher HIV Viral Load is Associated with Lower Levels of Vitamin D in Treatment-naive HIV Patients**
María Elena Ceballos, Chile
- PE15/88 **Self-Reported Prevalence of Co-morbidities and Use of Non-HIV Related Medications among People Living with HIV in England and Wales: Results from the Positive Voices Survey**
Meaghan Kall, United Kingdom
- PE15/89 **Relapse of Cerebrospinal Fluid Escape Following Optimization and Subsequent Simplification of Antiretroviral Therapy**
Francesca Ferretti, United Kingdom
- PE15/90 **Study of Comorbidities in HIV Patients over 50 Years Old**
Violeta Alastrué del Castaño, Spain
- PE15/91 **Will the Next Generation of Rehabilitation Professionals Be Ready to Treat People Living with HIV? Results of a Survey of UK Higher Education Institutions**
Will Chegwiddden, United Kingdom
- PE15/92 **Changes in Renal Biomarkers Following Tenofovir Discontinuation in HIV-infected Viral-suppressed Patients, Montreal, Canada**
Annie Talbot, Canada
- PE16/1 **Cervical Squamous Intraepithelial Lesion and Risk Factors among HIV-infected Nigerian Women**
Chidinma Vivian Gab-Okafor, Nigeria

Scientific Programme

- PE16/2 **Diagnostic Value of Anal Cytology, HPV Testing and High Resolution Anoscopy (HRA) in Screening for Anal Intraepithelial Neoplasia (AIN) in HIV Positive Individuals**
Deepa Grover, United Kingdom
- PE16/3 **Low Clearance and High Acquisition Rate of High-risk Human Papillomavirus (HR-HPV) in a Cohort of 260 Spanish HIV-positive Men Who have Sex With Men (MSM)**
Carmen Hidalgo-Tenorio, Spain
- PE16/4 **Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies**
Nicola Squillace, Italy
- PE16/5 **Value of Prostate-specific Antigen (PSA) Screening for Prostate Cancer Detection in aging People Living with HIV (PLWHIV)**
David Zucman, France
- PE16/6 **Incidence and Survival in HIV Infected patients with Malignancies: A 7 Year Romanian Single Center Experience**
Cristiana Oprea, Romania
- PE16/7 **Detection of High Risk HPV in HIV Positive MSM Using Multiple Technologies - Implications for Immunisation and Disease Prevention**
Deepa Grover, United Kingdom
- PE16/8 **Increased risk of Radiation Induced Adverse Effects in Patients on NNRTI Based Antiretroviral Treatment**
Markus Hecht, Germany
- PE16/9 **Maintaining Dose Intensity of R-CHOP Improves Survival in HIV Associated Lymphoma**
Alessia Dalla Pria, United Kingdom
- PE16/10 **Incidence of Cancer in HIV-infected Patients along 30 Years (1983-2013)**
Carolina Tudela, Spain
- PE16/11 **CD4+ and CD8+ T-Cell Kinetics in Aviremic HIV-infected Patients Developing Hodgkin or Non Hodgkin Lymphoma**
Christian Hoffmann, Germany
- PE16/12 **Prevalence and Incidence of Anal Dysplasia and High-risk Human Papillomavirus (HR-HPV) in a Prospective Cohort of Spanish Women Living with HIV (WLHIV)**
Carmen Hidalgo-Tenorio, Spain
- PE16/13 **Is There Evidence for T-cell Activation Prior to HIV-associated Lymphoma in Aviremic Patients?**
Christian Hoffmann, Germany
- PE16/14 **Evaluation of Hematologic and Hepatic Toxicity in HIV-associated Non-Hodgkin Lymphoma: A Cohort Study**
Alessandra Bandera, Italy
- PE16/15 **Prevalence and Persistence of HPV Infection and Citological Abnormalities in a Cohort of HIV Infected Patients**
Nicola Squillace, Italy

Scientific Programme

- PE16/16 **Screening for Anal Intraepithelial Neoplasia (AIN) in HIV-positive Patients: The Practical Uptake of a New Guideline**
Robert Jablonka, Germany
- PE17/1 **Health Seeking Behaviour among Youth with Sexually Transmitted Infection in Nigeria**
Orobosa Enadeghe, Nigeria
- PE17/2 **"A One Stop Shop" STD Service for MSM in Croatia/South East Europe - A New Approach**
Šime Zekan, Croatia
- PE17/3 **Factors Associated with Urinary Tract Infections among HIV-1 Infected Patients - Is Active HCV Infection a Risk Factor?**
Agata Skrzat-Wojdacz, Poland
- PE17/4 **Anal Cytology (AC) and Sexually Transmitted Infection (STI) Screening in Ageing People Living with HIV (PLWH)**
Malika Mohabeer Hart, United Kingdom
- PE17/5 **HIV-1 Vaginal Shedding is Suppressed among HIV-1 Infected Women on Modern Combined Antiretroviral Therapy**
Sara Grignolo, Italy
- PE17/6 **Human Papillomavirus 58: An Emerging High-risk Genotype in Italian HIV-infected Men Who Have Sex with Men?**
Claudio Ucciferri, Italy
- PE17/7 **Men Who Have Sex with Men from Paris. Argument for Universal HPV Vaccination**
Hugues Cordel, France
- PE17/8 **High Rates of Sexually Transmitted Infections (STIs) and Recreational Drug Use (RDU) amongst HIV-positive Men Who Have Sex with Men (MSM) Attending Outpatients across London (UK)**
Selena Singh, United Kingdom
- PE17/9 **Long-term Hepatic Safety and Impact of Maraviroc on Fibrosis Progression: A 148 week Randomised, Double-blind Study of Maraviroc versus Placebo in Combination with Other Antiretroviral Agents in HIV-1 Patients Co-infected with Hepatitis C and/or Hepatitis B Virus**
Frank Plonski, United States
- PE17/10 **HIV and Syphilis: When Do we Need to Perform a Lumbar Puncture?**
Agnès Libois, Belgium
- PE17/11 **Detection of Anal HPV Infection by Two Techniques in HIV+ MSM Individuals and Correlation with Pathologic Findings in Cytology and Biopsy**
Elena Ferrer, Spain
- PE17/12 **Should Screening of Asymptomatic Sexually Transmitted Infections Be Performed to All HIV-infected Men Who Have Sex with Men?**
Irene Sanchez, Spain
- PE17/13 **Prevalence of Anal High-risk Human Papillomavirus Infections among HIV-positive Men Who Have Sex With Men in Istanbul**
Alper Gündüz, Turkey

Scientific Programme

- PE17/14 **Acute Kidney Injury in Shigella Infection in an HIV-positive Cohort**
Nadia Ahmed, United Kingdom
- PE17/15 **The Serum TRUST Titer $\geq 1:16$ is a Predictor for Asymptomatic Neurosyphilis among HIV/Syphilis Co-infected Patients**
Jianjun Sun, China
- PE18/1 **Sexual Risk and Sexually Transmitted Infections among Chinese HIV-positive MSM after Engagement in Care**
Kenny CW Chan, China
- PE18/2 **"One Shouldn't Convict People for Hypothetical Risks": Developments in European Criminal Law and Policy following Increased Knowledge and Awareness of the Additional Prevention Benefit of Antiretroviral Therapy**
Edwin Bernard, United Kingdom
- PE18/3 **A Finger-stick Whole Blood HIV Self-test as an HIV Screening Tool Adapted to the General Public**
Thierry Prazuck, France
- PE18/4 **Choice of nPEP Regimens and Completion Rates in a MSM Population in Sydney, Australia: Provision of Drugs at what Cost?**
Rohan Bopage, Australia
- PE18/5 **Acceptability of Pre-exposure Prophylaxis (PrEP) and Reported Adherence to Non HIV Medication Regimens in HIV Negative Portuguese Men who Have Sex with Men (MSM) Eligible to PrEP**
Luis-Miguel Rocha, Portugal
- PE18/6 **Human Immunodeficiency Virus (HIV): Continuum of Care in Europe and Central Asia**
Teymur Noori, Sweden
- PE18/7 **Predictors of Knowledge of Non-occupational HIV Post Exposure Prophylaxis among Men Who Have Sex with Men Attending a Suburban Sexual Health Clinic in Sydney, Australia**
Rasanga Liyanage, Australia
- PE18/8 **Acceptable Rates of Acute HIV Detection Using a Fourth-generation Point of Care HIV Test**
Naomi Fitzgerald, United Kingdom
- PE18/9 **Evaluation of a Strategy to Improve Linkage to Care in Newly Diagnosed HIV Patients**
Miguel Raffo, Spain
- PE18/10 **A New Strategy to Avoid HIV Patient's Loss of Follow-up: Intervention at First Visit Failure**
Jose Fajardo, Spain
- PE18/11 **Randomised Controlled Trial of the Tolerability and Completion of Maraviroc Compared to Kaletra® in Combination with Truvada® for HIV Post Exposure Prophylaxis (MiPEP Trial)**
Ana Milinkovic, United Kingdom
- PE18/12 **Recording of the Professional Exposure to Blood Transmitted Agents at a Tertiary University Hospital in Greece, during 2007-2013**
Anestis Ganitis, Greece

Scientific Programme

- PE18/13 **Knowledge and Use of Post-exposure Prophylaxis (PEP) among Men Who Have Sex with Men (MSM) in Portugal**
Maria-José Campos, Portugal
- PE18/14 **Cohort for MSM as a Useful Tool to Assure Cost Effectiveness during the Implementation of PrEP**
Michael Meulbroek, Spain
- PE19/1 **Using Quality Improvement to Address High Default from PMTCT Services (Early Infant Diagnosis) at State Hospital Ijebu Ode, Nigeria**
Foluwaso Olaoluwa-Moronkeji, Nigeria
- PE19/2 **Higher Risks of Mother-to-Child HIV Transmission (MTCT) in Countries with Lower Prevalence: UNAIDS 2013 Results for 33 Countries with Generalised Epidemics**
Andrew Hill, United Kingdom
- PE19/3 **Experience of Prevention of Mother to Child Transmission of HIV in Georgia**
Ketevan Shermadini, Georgia
- PE19/4 **Regional Disparity of Maternal-paediatric Antiretroviral Coverage among African Priority Countries**
Olatunji Adetokunboh, South Africa
- PE19/5 **UK National Clinical Audit 2014: Management of Pregnancies in Women with HIV**
Sonia Raffe, United Kingdom
- PE19/7 **Drug Resistance Mutations (DRM) among Pregnant HIV-positive Women in the Duesseldorf University Hospital, Germany, 2009-2015**
Ulrike Haars, Germany
- PE19/8 **Mode of Delivery in Pregnant Women Living with HIV in Denmark: A Risk Assessment of Emergency Caesarean Sections**
Mathilde Ørbæk, Denmark
- PE19/9 **Evaluation of 10 Years of a Mother to Child Transmission Prevention Program in a Community Health Center in Bamako, Mali**
Karamoko Tounkara, Mali
- PE19/10 **HIV Perinatally Exposed Children in Romania - Review**
Alina Maria Cibea, Romania
- PE20/1 **The Effects of Toxic Impact of Tenofovir on the Bone Mineral Density in Children**
Natalya Rymarenko, Ukraine
- PE20/2 **Prevalence and Characteristics of Group B Streptococcus Colonization in HIV-infected Pregnant Women in Belgium**
Nicolas Dauby, Belgium
- PE20/3 **Resistance Mutations to Antiretroviral Drugs on HIV Strains of Treated HIV-1 Infectious Pediatric Patients in Venezuela**
Diana Lopez, Venezuela

Scientific Programme

- PE20/4 **Associations between Paediatric HIV Clients, Their Caregivers and Retention: Evidence from the EMBRACE Cohort, Eastern Cape, South Africa**
Hugh Adler, Ireland
- PE20/5 **The One-stop Clinic of Ifakara: Implementing a Bundle of Measures for Paediatric HIV Services in Rural Africa to Reach the UNAIDS' Target "90-90-90"**
Anna Gamell, Switzerland
- PE20/6 **Long-term Prognosis of Children Born to HIV-1 Infected Mothers in Japan**
Mizue Tanaka, Japan
- PE20/7 **Abnormal Neurometabolite Levels Reflect Poorer Cognitive Performance in HIV-infected Children**
Yvonne Wilma van Dalen, Netherlands
- PE20/8 **The Eye as a Window to the Brain: Retinal Structure Associated with Cerebral Injury in Perinatally HIV-infected Children**
Charlotte Blokhuis, Netherlands
- PE20/9 **Threatening Levels of Acquired HIV Drug Resistance and Virologic Failure in Children and Adolescents in Rural Tanzania - An Emerging Public Health Concern**
Lukas Muri, Switzerland
- PE20/11 **Educational Intervention Increases Acceptability and Knowledge of Newborn Male Circumcision (NMC) among Parents of Newborn Boys in Port-au-Prince, Haiti**
Jessy Dévieux, United States
- PE21/1 **Evolution of HIV-infected Injecting Drug Users in Spain during 2004-2013: Persistence of Poor Engagement to Care and Worse Clinical Outcomes**
Inés Suárez-García, Spain
- PE21/2 **Are Immigrant Men who Have Sex with Men (MSM) who Visited an HIV Checkpoint (Actuel-sur-Rue) in Montreal, Canada, More Vulnerable to HIV?**
David Lessard, Canada
- PE21/3 **Weight Changes and Prognosis for People Living with HIV Initiating Highly Active Antiretroviral Therapy in the APROCO Cohort Study**
Victoire Fokom Defo, Cameroon
- PE21/4 **Expansion of the CRF19_cpx Variant in Spain**
Fernando Gonzalez-Candelas, Spain
- PE21/5 **A Decade of HIV Care and Treatment in Rural Tanzania: Trends in Treatment, Opportunistic Infections and Laboratory Abnormalities among HIV-positive Adults**
Tracy Glass, Switzerland
- PE21/6 **Missed Opportunities for Earlier HIV Diagnosis in Men who Have Sex with Men (MSM) - A Service Evaluation of HIV Testing in UK Sexual Health Clinics**
Emily Clarke, United Kingdom

Scientific Programme

- PE21/7 **A Universal Testing Programme for Blood Borne Viruses (BBV) in an Urban Emergency Department (ED) - A Call for Widespread Testing in Ireland**
Sarah O'Connell, Ireland
- PE21/8 **Missed Opportunities for HIV Testing and Factors Associated with Delayed Diagnosis**
Rosa de Miguel Buckley, Spain
- PE21/9 **Intervention Packages against HIV and HCV Infections for People who Inject Drug in Georgia: A Modeling and Cost-effectiveness Study**
Guillaume Mabileau, France
- PE21/10 **The Continuum of HIV Care in Catalonia**
Colin Campbell, Spain
- PE21/11 **From Pills to Patients: Determination of the Number of People Living with HIV who Are Receiving Antiretroviral Therapy, Costs and Potential Cost-savings in Germany**
Daniel Schmidt, Germany
- PE21/12 **HIV Infection among Persons Aged 50 Years and over in the EU, 2004-2013: Missed Opportunities for Earlier Diagnosis?**
Lara Tavoschi, Sweden
- PE21/13 **Use of 3 HIV Testing Methods in French Primary Care: Classical ELISA Laboratory Screening versus 2 Rapid Finger-stick HIV Tests with Result under 5 Minutes (INSTI) and up to 30 Minutes (VIKIA)**
Angela Daiana Papadima, France
- PE21/14 **CD4+T-cell Count at cART Initiation among Migrant Men and Women Living in Western Europe**
Susana Monge, Spain
- PE21/15 **Linkage to Care Following HIV Diagnosis in Europe: A Review of the Literature**
Sara Croxford, United Kingdom
- PE21/16 **Comparing a 'Multi Assay Algorithm' with the BED Capture Enzyme Immunoassay for the Testing of Recent HIV-1 Infections in Germany**
Andrea Hauser, Germany
- PE21/17 **Coverage and Acceptability of a Targeted Testing Strategy, Resourced by an External Program Intervention, DRIVE Study (Rapid Diagnosis of HIV infection in Spain)**
María Jesús Pérez Elías, Spain
- PE21/18 **Unselected, Emergency Department-based Rapid HIV Screening Detects High Proportion of Early, Asymptomatic HIV Infection**
Marilia Rita Pinzone, Italy
- PE21/19 **Recreational Drug Consumption in People Living with HIV in Europe: A Systematic Review**
Cesar Velasco, Spain
- PE21/20 **HIV Late Presentation in Southern Sardinia, Italy**
Goffredo Angioni, Italy

Scientific Programme

- PE21/21 **Travel to the Tropics and its Impact on Viral Control in HIV Patients in the Swiss HIV Cohort Study**
Hiwot Gebreselassie, Switzerland
- PE21/22 **Recent HIV-infections in Germany 2008-2014: What Do we Know?**
Andrea Hauser, Germany
- PE21/23 **High Rate of Transmission Clusters among Men Who Have Sex with Men (MSM) with Acute-recent HIV Infection in Barcelona**
Juan Ambrosioni, Spain
- PE21/24 **Developments in the Delay of HIV Detection and Treatment Initiation in Recent Years**
Borja Carmelo Gracia Tello, Spain
- PE21/25 **Transmission Clustering among Kiev HIV Sequences**
Esther Fearnhill, United Kingdom
- PE21/26 **HIV Subtypes: The Same Disease, Different Stories?**
Claudia Afonso, Portugal
- PE21/27 **HIV Testing in Innovative Environments Mexico**
Nalleli Delgadillo, Mexico
- PE21/28 **Ongoing Mononucleosis-like Illness - A Clear Indicator Condition for HIV Testing: Results from the HIDES 2 Study - Single Arm Extension**
Dorthe Raben, Denmark
- PE21/29 **The Acute/Recent HIV Infection Cohort from Hospital Clinic, Barcelona: Epidemiological and Virological Trends from 1997 to 2014**
David Nicolás, Spain
- PE21/30 **Healthcare Related Costs of Missed Opportunities for HIV Diagnosis: A Potential Driver to Increase Indicator Condition Guided HIV Testing**
Caroline Rae, United Kingdom
- PE21/31 **Current Epidemiology and Outcomes of HIV-infected Patients Admitted to an Intensive Care Unit (ICU) in Barcelona, Spain**
Veronica Rico, Spain
- PE21/32 **Over Half of People in HIV Care in the United Kingdom by 2028 Will Be Aged 50 Years or Above**
Zheng Yin, United Kingdom
- PE21/33 **Trends and Causes of Hospitalization among HIV-infected People from 1998 to 2015 in a Single Italian Tertiary Care Centre**
Alberto Borghetti, Italy
- PE21/34 **Recent HIV Infection: Epidemiologic, Clinical and Therapeutic Evolution of a Portuguese Cohort**
Bernardo Neves, Portugal
- PE21/35 **Retention in Care of a Population of Migrant HIV-infected IDUs in Greece (Single Center Experience)**
Eleni Kakalou, Greece

Scientific Programme

- PE21/36 **Is It Feasible to Reduce the Number of Determinations Performed on Viral Load and CD4 T-lymphocytes in an HIV Specialized Consultation Unit?**
Alberto Díaz-De Santiago, Spain
- PE21/37 **Clinical and Epidemiological Characteristics of HIV Infection Newly Diagnosed in People over 59 Years of the Spanish Cohort VACH**
Dolores Merino Muñoz, Spain
- PE21/38 **Asymptomatic Late Presenters: 12 Years Trend in CD4+ Cell Counts at HIV Diagnosis in a Single Testing Site in Buenos Aires**
Mariana Kundro, Argentina
- PE21/39 **Analysis of New HIV Diagnoses among Young People**
Borja Carmelo Gracia Tello, Spain
- PE21/40 **Dynamics of Transmission Trends in 30 Years of HIV Epidemic in Romania**
Mariana Mardarescu, Romania
- PE22/2 **Late HIV Diagnosis in Georgia: Public Health and Economic Implications**
Nikoloz Chkhartishvili, Georgia
- PE22/4 **Using Mixed-methods to Understand HIV Treatment Cascade among OST Patients and PWIDs in Five Ukrainian Cities**
Alyona Mazhnaya, Ukraine
- PE22/5 **High Proportion of Viral Suppression with Frequent Changes of Antiretroviral Treatment in Newly Diagnosed Patients in Santo Andre Aids Program, Sao Paulo, Brazil**
Elaine Matsuda, Brazil
- PE22/6 **High Proportion of Virological Failure and HIV Drug Resistance among TB/HIV Co-infected Ugandan Adults**
Amrei von Braun, Uganda
- PE22/7 **First -line Antiretroviral Therapy in Resource-limited Settings: the Experience of Serbia**
Gordana Dragovic, Serbia
- PE22/8 **Direct Costs of HIV/AIDS Care in Estonia**
Liis Lemsalu, Estonia
- PE22/9 **Treating HCV with Interferon-free Regimens in Correctional Settings: An Italian Experience**
Antonella Foschi, Italy
- PE22/11 **Deferring CD4 Cell Count Monitoring in HIV+ Treated Patients with More than 350 or 500 CD4 Lymphocyte/ μ l is a Safe and Cheap Strategy**
Benedetto Celesia, Italy
- PE23/1 **Sexual Risk Behaviours of High School Students in an Urban Town of Cameroon**
Tarkang Elvis, Cameroon
- PE23/2 **Assessing Parental Knowledge and Attitudes towards Disclosure of HIV**
Conor Lyons, Ireland

Scientific Programme

- PE23/3 **HIV Prevalence and Factors Associated with HIV Infection among Injection Drug Users, Uzbekistan**
Shukhrat Umarkhojaev, Uzbekistan
- PE23/4 **Stigma towards People Living with HIV/AIDS among Healthcare Practitioners and Medical Students**
Julia Dabravolskaj, Canada
- PE23/5 **Lost Opportunities for Early ART**
Anastasia Pokrovskaya, Russian Federation
- PE23/6 **SM@RT-@IDS: The Digital Prevention for the Smart Generations**
Carmine Falanga, Italy
- PE23/7 **HIV Disclosure and Stigma among Women Living with HIV in Denmark - Results from the SHADE Cohort**
Maria Wessman, Denmark
- PE23/8 **Barriers to Accessing HIV Testing, Treatment and Healthcare for Migrants Living with HIV in Europe**
Ibidun Fakoya, United Kingdom
- PE23/9 **Barriers to HIV Routine Screening in Primary Care: What Do Patients Think about it ?**
Guillaume Conort, France
- PE23/10 **Disutilities Associated with Central Nervous System (CNS) Side Effects of Antiretroviral Therapy (ART) in HIV: Results from the UK, France and Spain**
Rodolphe Perard, United Kingdom
- PE23/11 **The StigmaIndexUK-2015: A New Methodology for Measuring the Experiences of Stigma among People Living with HIV**
Jo Jefferies, United Kingdom
- PE23/12 **Differences in Patients and Physicians Adherence Evaluation - Results from the German Adherence Cohort Study**
Christoph Spinner, Germany
- PE23/13 **The Impact of Antiretroviral Therapy on Treatment Satisfaction and Quality of Life of PLWH in Europe**
Miranda Murray, United Kingdom
- PE23/14 **HIV/AIDS-related Knowledge and Behaviors of Precarised Migrants in the Geneva Area, Switzerland**
Deborah Glejser, Switzerland
- PE23/15 **Health Workers in B&H and HIV Stigma and Discrimination**
Stela Stojisavljevic, Bosnia and Herzegovina
- PE23/16 **A New International Questionnaire to Assess Health-related Quality of Life (HRQL) Specific to Viral Hepatitis C: Proqol-HCV**
Martin Duracinsky, France
- PE23/17 **Reduced CD4 Count Monitoring: Potential for Large Cost Savings but is it Acceptable to Patients?**
Sophie Flavell, United Kingdom

Scientific Programme

- PE23/18 **Prediction of the Factors Influencing the HIV Test Utilisation among Young People Aged between 17-25 Years in Saudi Arabia**
Abdullah Almilaibary, United Kingdom
- PE23/19 **Clinical and Community Views of the Instant Result HIV Self-testing: Barriers and Facilitators for Effective Implementation amongst MSM (Men who Have Sex with Men)**
Jamie Frankis, United Kingdom
- PE23/20 **Clinical, Psychological and Behavioural Barriers to HIV Testing amongst MSM (Men who Have Sex with Men) who Use Social and Sociosexual Media: Implications for HIV Prevention Programmes**
Jamie Frankis, United Kingdom
- PE24/1 **Integrated HIV and Gynaecological Services for HIV-positive Women in Warsaw - A Luxury or Standard of Care?**
Justyna Kowalska, Poland
- PE24/2 **Gender Differences in Baseline Epidemiological Profile and Clinical Characteristics and its Evolution in the Spanish AIDS Research Network Cohort (CoRIS)**
Constanza Muñoz, Spain
- PE24/3 **Facts on Contraception Use and Unintended Pregnancies in HIV-infected Women on Antiretroviral Therapy in Switzerland**
Valentina Mercanti, Switzerland
- PE24/4 **Epidemiological Trends of HIV Infection in Women Spanish Cohort Vach**
Dolores Merino Muñoz, Spain

Special Session
13:00 - 14:00

Room Barcelona

BPD1, Best Poster Discussion 1 - Clinical Science - Treatment

Chairs:

Pedro Cahn, Argentina
Linos Vandekerckhove, Belgium

- BPD1/1 **Patients' Characteristics and Prescription Practices of Post-exposure Prophylaxis for HIV in a Large Metropolitan Emergency Room in Switzerland, 2007-2013** 13:00 - 13:06
Alex Marzel, Switzerland
- BPD1/2 **People Living with HIV who Visited AIDS Centers in Russia** 13:06 - 13:12
Anastasia Pokrovskaya, Russian Federation
- BPD1/3 **Healthcare Provider Communication Training Program Improves Adherence Assessment in HIV-infected Patients Treated with Antiretroviral Therapy (ART) in Rural Tanzania** 13:12 - 13:18
Stefan Erb, Switzerland

Scientific Programme

BPD1/4	The Efficacy and Safety of Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) and Ritonavir (RTV) Boosted Atazanavir (ATV) plus FTC/TDF in Treatment Naïve Women with HIV-1 Infection: Week 48 Analysis of the Phase 3, Randomized, Double Blind Study Cissy Kityo, Uganda	13:18 - 13:24
LBBPD1/1	A Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 96 Results David Wohl, United States	13:24 - 13:30
BPD1/5	Week 48 Results of the Randomised, Multicentre Maraviroc Switch Study (MARCH) Sarah Pett, Australia	13:30 - 13:36
BPD1/6	Simplification to Atazanavir/Ritonavir + Lamivudine versus Maintaining Atazanavir/Ritonavir + 2NRTIs in Virologically Suppressed HIV-infected Patients: 48-weeks Data of the ATLAS-M Trial Andrea De Luca, Italy	13:36 - 13:42
BPD1/7	Estimation of Renal Function by CKD-EPI versus MDRD Equations in a Cohort of HIV-infected Patients: A Cross-sectional Analysis Marina Cristelli, Brazil	13:42 - 13:48
LBBPD1/2	High SVR12 Results after 12-week Boceprevir, Peginterferon and Ribavirin in the Dutch Acute Hepatitis C in HIV Study (DAHHS) Sebastiaan Hullegie, Netherlands	13:48 - 13:54

Special Session
13:00 - 14:00

Room Cologne

BPD2, Best Poster Discussion 2 - Clinical Science - Epidemiology

Chairs:

Stéphane De Wit, Belgium
Anne-Geneviève Marcelin, France

ML1	HIV Resistance - Where Are We Heading Mark Wainberg, Canada	13:00 - 13:06
BPD2/1	Regional Differences in Transmission of HIV Drug Resistance Mutations in Europe Laura Marije Hofstra, Netherlands	13:06 - 13:12
BPD2/2	The Mater-Bronx Rapid HIV Testing (M-BRIHT): A Randomized, Controlled Study Exploring Factors Associated with Decision to undergo HIV Testing Marilia Rita Pinzone, Italy	13:12 - 13:18
BPD2/4	Age, Gender, Risk Group, Cohort Size and Year of Study Effect on the Performance Indicator of CD4 Count at HIV Presentation: A UK CHIC Study on Late Diagnosis Performance Skevi Michael, United Kingdom	13:18 - 13:24

Scientific Programme

BPD2/5	Are Modes of HIV Acquisition in Romanian Pregnant Women Correlated with HIV Mother-to-Child Transmission Rates and Pregnancy Outcomes? Cristiana Oprea, Romania	13:24 - 13:30
BPD2/6	HIV-1 Local Transmission Networks in 9 European Countries and Canada: Association with Demographic and Clinical Factors Dimitrios Paraskevis, Greece	13:30 - 13:36
BPD2/7	No Decline in Hepatitis C Virus (HCV) Incidence among HIV-positive Men who Have Sex with Men (MSM) within CASCADE: 1990-2014 Maria Prins, Netherlands	13:36 - 13:42
BPD2/8	ChemSex: Data on Recreational Drug Use and Sexual Behavior in Men Who Have Sex with Men (MSM) from a Busy Sexual Health Clinic in London, UK David Stuart, United Kingdom	13:42 - 13:48

Special Session
13:00 - 14:00

Room Brussels

BPD3, Best Poster Discussion 3 - Basic Science

Chairs:

Maria Buzon, Spain
Marylyn Addo, Germany

BPD3/1	Pre-cART Pro-inflammatory milieu, Microbial Translocation (MT) and Risk of Disease Progression in HIV-infected Patients Starting Their First cART: Data from the Icona Foundation Cohort Giulia Marchetti, Italy	13:00 - 13:06
BPD3/2	MicroRNA-210, microRNA-7 and miRNA-331 is Upregulated in HIV Infection and Associated with Systemic Inflammation Vibe Ballegaard, Denmark	13:06 - 13:12
BPD3/3	Immunological Ageing in HIV-1 Positive Individuals on Combination Antiretroviral Therapy (cART) Compared to Appropriately Selected Controls and Blood Bank Donors Neeltje Kootstra, Netherlands	13:12 - 13:18
BPD3/4	Assessment of Early Kinetics of Sequential Gag mRNA and Protein Expression Following HIV-1 Latency Reversal Using Flow-based Techniques Gloria Martrus, Germany	13:18 - 13:24
BPD3/5	Selection of an HLA-C*03:04-restricted HIV-1 p24 Gag sequence variant is associated with viral escape from KIR2DL3pos NK cells Angelique Hoelzemer, United States	13:24 - 13:30
BPD3/6	Soluble TLR2 and 4 Are Associated with HIV/SIV Related Neuroinflammation and Neuropathology Khutso Mothapo, Netherlands	13:30 - 13:36
BPD3/7	Plasma Interferon-inducible Protein-10 Levels, T-cell Activation and Regulation Are Increased in HIV Immunological Non-responders Birgitte Stiksrud, Norway	13:36 - 13:42

Scientific Programme

BPD3/8	Restoration of B Cell Phenotype and Function on ART during Chronic HIV Infection Ramla Tanko, South Africa	13:42 - 13:48
BPD3/9	HIV-1 CRF02_AG Infected Patients Show a Lower Response to a PI Based First Line HAART: A Role of Specific Natural Polymorphisms Daniele Armenia, Italy	13:48 - 13:54

Special Session
13:00 - 14:00

Room Belgrade

Is Europe Buying into PrEP? The New Prevention Landscape from a Community Perspective - Session Convened by EATG

Chairs:

Cristina Mussini, Italy
Rebekah Webb, United Kingdom

Is PrEP for HIV Prevention Cost-Effective in MSM? Valentina Cambiano, United Kingdom	13:00 - 13:15
Challenges to Implementing PrEP in European Health Systems Anastasia Pharris, Sweden	13:15 - 13:30
Community Involvement in the IPERGAY Study Daniela Rojas Castro, France	13:30 - 13:45
Q&A Community Panel on National Initiatives on PrEP in Europe Gus Cairns, United Kingdom Nicholas Feustel, Germany Michael Meulbroek, Spain Rebecca Mbewe, United Kingdom	13:45 - 14:00

Special Session
13:00 - 14:00

Room Madrid

EACS General Assembly

Parallel Session
14:00 - 16:00

Room Barcelona

PS4, Antiretroviral Therapy I

Chairs:

Georg Behrens, Germany
Annemarie Wensing, Netherlands

ML1	Cost Efficacy of Recommended ART Regimes (GESIDA) José M. Gatell, Spain	14:00 - 14:15
-----	---	---------------

Scientific Programme

PS4/1	Integrated and Total HIV-1 DNA Correlate Well and Predict ex vivo Viral Outgrowth Linos Vandekerckhove, Belgium	14:15 - 14:30
PS4/2	Low-level Viremia (LLV) Ranging from 50 to 500 Copies/mL is Associated to an Increased Risk of AIDS Events in the Icona Foundation Cohort Andrea Antinori, Italy	14:30 - 14:45
PS4/3	Effectiveness of Maintenance Combination Antiretroviral Therapy Using Half-dose Efavirenz Plus 2 Nucleoside Reverse-transcriptase Inhibitors with the Guidance of Therapeutic Drug Monitoring Chien-Ching Hung, Taiwan, Republic of China	14:45 - 15:00
LBPS4/1	Dolutegravir-Lamivudine as Initial Therapy in HIV-infected, ARV Naive Patients: First Results of the PADDLE Trial Pedro Cahn, Argentina	15:00 - 15:15
LBPS4/2	Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral Suppression: A 24-week Pilot Study Esteban Martínez, Spain	15:15 - 15:30
PS4/4	Dolutegravir Monotherapy in HIV-infected Patients with Suppressed HIV Viremia Christine Katlama, France	15:30 - 15:45
ML2	Should We Lower Drug Burden (Pro/Con Debate, Virological/Clinical Point of View) Andrea De Luca, Italy Christoph Wyen, Germany	15:45 - 16:00

Parallel Session
14:00 - 16:00

Room Cologne

PS5, Opportunistic Infections and Tumours

Chairs:

Vincent Calvez, France
Cristina Mussini, Italy

ML1	Who is at Risk for Opportunistic Infections Nina Khanna, Switzerland	14:00 - 14:15
PS5/1	AIDS Defining Opportunistic Diseases in the Swiss HIV Cohort Study: A Comprehensive Review 1988-2013 Hansjakob Furrer, Switzerland	14:15 - 14:30
PS5/2	HIV Replication is a Major Predictor of Primary and Recurrent Pneumocystis Pneumonia - Implications for Prophylaxis Recommendations Hansjakob Furrer, Switzerland	14:30 - 14:45
PS5/3	Recurrent Disease in HIV-infected Patients with Hodgkin Lymphoma (HL) or Non-Hodgkin Lymphoma (NHL) in the German AIDS-related Lymphoma Cohort Study Philipp Schommers, Germany	14:45 - 15:00

Scientific Programme

PS5/4	Long Lasting Viral Suppression and Immune Reconstitution of a Great Magnitude Reduce the Risk of Cervical Dysplasia in HIV-positive Women Déborah Konopnicki, Belgium	15:00 - 15:15
PS5/5	Prostate-specific Antigen (PSA) Testing Patterns for Prostate Cancer (PCa) in HIV+ Men. Does One Size Fit All? Leah Shepherd, United Kingdom	15:15 - 15:30
PS5/6	Prevalence and Distribution of Cervical Human Papillomavirus and Dysplasia in Women Living with HIV in Denmark - Results from the SHADE Cohort Kristina Thorsteinsson, Denmark	15:30 - 15:45
ML2	HPV - To Vaccinate or Not? (Pro/Con Debate) Déborah Konopnicki, Belgium Maarten Schim van der Loeff, Netherlands	15:45 - 16:00

Parallel Session
 14:00 - 16:00

Room Brussels

PS6, Gender Issues in HIV

Chairs:

Anna Maria Geretti, United Kingdom
 Fiona Mulcahy, Ireland

ML1	Models of Care: The Way Forward Fiona Lyons, Ireland	14:00 - 14:15
PS6/1	Key Interventions and Populations to Target to Facilitate Engagement in HIV Care among Women Living with HIV: Findings from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) Nadine Kronfli, Canada	14:15 - 14:30
PS6/2	Sex-specific Regulation of Type I Interferons in pDC Upon TLR7 Stimulation Susanne Ziegler, Germany	14:30 - 14:45
PS6/3	Is the Gender Difference in Viral Load Response to ART Narrowing over Time? Lisa Burch, United Kingdom	14:45 - 15:00
PS6/4	Outcomes after 2 Years on Antiretroviral Therapy (ART): Comparison of Women who were ART-naïve and Women who Previously Used Short-course ART in Pregnancy Susie Huntington, United Kingdom	15:00 - 15:15
PS6/5	Do Socio-economic Factors Explain Gender Differences in Virological Response to ART in the UK? Rebecca O'Connell, United Kingdom	15:15 - 15:30
PS6/6	Sex Differences in Depressive Symptoms: Data from the Frankfurt HIV-cohort Claus Philippe Küpper-Tetzl, Germany	15:30 - 15:45

Scientific Programme

ML2 **Making WAVEs - Women Against Viruses in Europe** 15:45 - 16:00
 Anna Maria Geretti, United Kingdom

Industry Sponsored Session
16:30 - 18:00

Room Cologne

Industry Sponsored Session

(For more details, please visit the http://www.eacs-conference2015.com/index.php?article_id=47>EACS Conference website)

Industry Sponsored Session
18:15 - 19:45

Room Cologne

Industry Sponsored Session

(For more details, please visit the http://www.eacs-conference2015.com/index.php?article_id=47>EACS Conference website)

Scientific Programme

Friday, 23 October 2015

Meet the Expert
07:45 - 08:45

Room Madrid

Meet the Expert, - Management of TB in HIV Patients

Management of TB in HIV Patients

Roxana Cernat, Romania
Santiago Moreno, Spain

07:45 - 08:45

Meet the Expert
07:45 - 08:45

Room Dublin

Meet the Expert, - Pitfalls in Neurocognitive Disease

Pitfalls in Neurocognitive Disease

Jordi Blanch, Spain
Paola Cinque, Italy

07:45 - 08:45

Meet the Expert
07:45 - 08:45

Room Warsaw

Meet the Expert, - Prevention of Bone Disease in HIV

Prevention of Bone Disease in HIV

Eugenia Negredo, Spain
Philip Tarr, Switzerland

07:45 - 08:45

Meet the Expert
07:45 - 08:45

Room Athens

Meet the Expert, - Management of Co-morbidities in HIV Aging Patients

Management of Co-morbidities in HIV Aging Patients

Giovanni Guaraldi, Italy
Ana Milinkovic, United Kingdom

07:45 - 08:45

Scientific Programme

Plenary Session
09:00 - 09:30

Room Barcelona

PL3, PrEP ! - From Science to Implementation

Prof. Martin Fisher in Memoriam Lecture

Chairs:

Jean-Michel Molina, France
Jürgen Rockstroh, Germany

PrEP ! - From Science to Implementation

Sheena McCormack, United Kingdom

09:00 - 09:30

Plenary Session
09:30 - 10:00

Room Barcelona

PL4, HCV DAAs in Europe - Making it Happen

Chairs:

Jean-Michel Molina, France
Jürgen Rockstroh, Germany

HCV DAAs in Europe - Making it Happen

Markus Peck, Austria

09:30 - 10:00

Parallel Session
10:30 - 12:30

Room Barcelona

PS7, Liver Disease and Hepatitis in HIV-infected Patients

Chairs:

José Mallolas, Spain
Massimo Puoti, Italy

ML1	Hepatitis B Cure Strategies Mala Maini, United Kingdom	10:30 - 10:45
PS7/1	Hepatitis Delta in the Swiss HIV Cohort Study (SHCS): Clinical Characteristics and Long-term Outcomes Charles Béguelin, Switzerland	10:45 - 11:00
PS7/2	Trends in Incidence and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus Co-infected Individuals from 2001 to 2014: A Multi-cohort Study Lars Iversen Gjørde, Denmark	11:00 - 11:15
PS7/3	How Many Patients Treated? The Number of Patients with Statutory Health Insurance Receiving Antiviral Hepatitis C Therapy Determined by Drug Prescriptions Data Daniel Schmidt, Germany	11:15 - 11:30
PS7/4	Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients? Lars Peters, Denmark	11:30 - 11:45

Scientific Programme

LBPS7/1	TURQUOISE-I Study: Use of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin in Patients with HCV/HIV-1 Co-infection on Stable Darunavir-containing Antiretroviral Therapy Roger Trinh, United States	11:45 - 12:00
PS7/5	Sofosbuvir Plus Ledipasvir for 8 Weeks in HCV-mono- and HIV-HCV-coinfected Patients - Results from the German Hepatitis C Cohort (GECCO) Patrick Ingiliz, Germany	12:00 - 12:15
ML2	HCV Eradication - Everything Solved? (Pro/Con Debate) Juan Berenguer, Spain Stefan Mauss, Germany	12:15 - 12:30

Parallel Session
10:30 - 12:30

Room Cologne

PS8, Cohort Studies - Contribution to Clinical Care

Chairs:

Dominique Costagliola, France
Ian Weller, United Kingdom

ML1	What Cohort Studies Contribute to Clinical Care in Adults Stéphane De Wit, Belgium	10:30 - 10:45
ML2	What Cohort Studies Contribute to Clinical Care in Children Claire Thorne, United Kingdom	10:45 - 11:00
PS8/1	Long-Term Evolution and Determinants for the Restoration of the CD4/CD8 Ratio in HIV-1 Infected Individuals on Efficient Antiretroviral Therapy Fabienne Caby, France	11:00 - 11:15
PS8/2	Transient Viral Rebounds as a Prognostic Factor for Control Loss among 1075 HIV-controllers Followed in COHERE Collaboration Fanny Chereau, France	11:15 - 11:30
PS8/3	Current Stage of HIV Epidemic in Ukraine: HIV in Men who Acquired HIV through Heterosexual Mode of Transmission Nataliya Nizova, Ukraine	11:30 - 11:45
PS8/4	Poor Linkage to Care Despite Significant Improvement in Access To Early cART - Data from Test and Keep in Care (TAK) Project Justyna Kowalska, Poland	11:45 - 12:00
PS8/5	Excess of Short and Long-term overall and Cause-specific Mortality in HIV Positive Subjects Compared to the General Population: Differences by HCV-coinfection Belén Alejos, Spain	12:00 - 12:15
PS8/6	Where is the Greatest Impact of Uncontrolled HIV Infection on Clinical Disease Progression? Amanda Mocroft, United Kingdom	12:15 - 12:30

Scientific Programme

Parallel Session
10:30 - 12:30

Room Brussels

PS9, Pharmacology, Pharmacogenomics and Drug-Drug Interactions

Chairs:

Saye Khoo, United Kingdom
Catia Marzolini, Switzerland

ML1	The Prospect of Long-Acting Agents Marco Siccardi, United Kingdom	10:30 - 10:45
PS9/1	A Population Pharmacokinetic Model for a Long-acting Injectable Nanosuspension of Rilpivirine for Intramuscular Injection Herta Crauwels, Belgium	10:45 - 11:00
ML2	Drug-Drug Interactions - Still Complex Caroline Solas, France	11:00 - 11:15
PS9/2	Assesment of Drug-Drug Interaction between New Antiretroviral Drugs and Combined Oral Contraceptives Emilie Blavier, Belgium	11:15 - 11:30
PS9/3	Efavirenz Simultaneous Induction and Inhibition of Multiple Cytochromes Impacts the Magnitude of Drug-Drug Interactions Catia Marzolini, Switzerland	11:30 - 11:45
ML3	Recreational Drugs - An Uprising Issue Marta Boffito, United Kingdom	11:45 - 12:00
PS9/4	Elvitegravir Concentrations in Seminal Plasma in HIV-1 Infected Patients Arkaitz Imaz, Spain	12:00 - 12:07
PS9/5	HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen Arkaitz Imaz, Spain	12:07 - 12:14
PS9/6	Pharmacokinetics of Once-daily Ritonavir Boosted Atazanavir or Darunavir in Combination with a Dual Nucleos(t)ide Analogs Backbone among HIV-1-naive Patients with Severe Immunosuppression: IMEA 040-DATA Sub-study Minh Lê, France	12:14 - 12:29

Special Session
12:00 - 14:00

Exhibition Area

Poster Session

PE1/2	Characterization of the Near Full Length Genetic Constellation of a Unique HIV 1 A1/C Recombinant Strain in South Africa Andrew Musyoki, South Africa
PE1/3	APOBEC3 Host Factors Modulate Viral Production and Infectivity of HIV-2 Susana Bandarra, Portugal
PE1/4	Does the Presence of a Mutation at Position V179 Impact on Clinical Outcome in Patients Taking Antiretroviral Medication?

Scientific Programme

- PE1/5 **Performance of Genotypic Algorithms for Predicting Tropism for HIV-1 CRF02_AG Subtype**
Cathia Soulié, France
- PE1/6 **HIV-1 Subtype B Transmission Networks in Poland Indicate Frequent Clustering and Interregional Spread of Infection among Men-Having-Sex-with-Men**
Milosz Parczewski, Poland
- PE1/7 **HIV-1 Diversity and Transmitted Drug Resistance Mutations among Heterosexuals with HIV-1 in Bulgaria**
Ivailo Alexiev, Bulgaria
- PE1/8 **Clinical, Virological and Phylogenetic Characterization of a Multiresistant HIV-1 Strain Outbreak in Naïve Patients in Southern Spain**
Isabel Viciano, Spain
- PE1/9 **Tumor Suppressor p53 Protein Removes the Ribonucleotides Incorporated by HIV-1 RT into DNA**
Mary Bakhanashvili, Israel
- PE1/10 **Dolutegravir based Regimens (DBRs) Viral Load Decay at Week 4 Could Predict Sustained Viral Suppression at Week 96**
Romina Quercia, United Kingdom
- PE1/11 **Viruses Causing Breakthrough Infections in Women Assigned to Tenofovir Gel in the CAPRISA 004 Microbicide Trial Did Not Demonstrate a Higher Replication Capacity**
Philippe Selhorst, South Africa
- PE1/12 **Cellular Proviral HIV DNA in Patients on Stable Combination Antiretroviral Therapy: Correlation with Immunovirological Parameters and Antiretroviral Regimens**
Isabella Bon, Italy
- PE1/13 **Evidence that an Amino Acid Substitution in the HIV-2 Env Protein Lead to a Lack of Tetherin Antagonism**
François Dufrasne, Belgium
- PE1/14 **Characterization of HIV-1C gp120 in Recently and Chronically Infected Individuals in Botswana**
Terence Mohammed, Botswana
- PE1/15 **Comparison of the Analytical Performance of the Cepheid Xpert HIV-1 Viral Load Real-time PCR with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0 Assay**
Brice Dubouil, France
- PE1/16 **Validation of the Xpert VIH-1 Viral Load Real-time PCR (GeneXpert®, Cepheid) for Organ Transplantations**
Aleksandra Maleska, France
- PE1/17 **HIV-1 Genetic Diversity and Divergency and its Correlation with Disease Progression among Recently Infected Individuals Using Next Generation Sequencing**
Ana Rachel Leda, Brazil
- PE2/1 **Responses of NK Cell Subsets to Anti-HIV Antibody Mediated Activation**
Irene Lisovsky, Canada

Scientific Programme

- PE2/2 **Influence of HLA Glycosylation on the Binding of HLA-B*57:01 to KIR3DL1**
Wilhelm Salzberger, Germany
- PE2/3 **Optimization of KIR2DS1 Reporter Cell Assay to Identify HIV-peptide Specific Binding of HLA-C*06:02**
Anais Chapel, Germany
- PE2/4 **Analysis of Cross-recognition of HIV-1-Nef-Specific CTL to Human FAT3 Protein**
Thomas Harrer, Germany
- PE2/5 **Identification of HLA-C Restricted, HIV-1-Specific CTL Epitopes by Peptide Induced Upregulation of HLA-C Expression**
Thomas Harrer, Germany
- PE2/7 **NK Cells Expressing Self-Inhibitory KIR2DL Receptors Display Reduced Ability to Inhibit HIV-1 Replication in vitro**
Korner Christian, United States
- PE3/1 **Plasma L-carnitine and L-lysine Concentrations in HIV-infected Patients at Clinical Stages of the Disease**
Evgeny Butorov, Russian Federation
- PE3/2 **Plasmatic Cytokine Levels in Rapid and Slow Progressors HIV-1 Infected**
Rúbia de Medeiros, Brazil
- PE3/3 **Evaluation of Some of Oxidative and Inflammatory Stress Biomarkers in People Living with HIV/AIDS before and after the Initial Antiretroviral Therapy**
Mônica Mendes, Brazil
- PE3/5 **Changes in Peripheral T-cell Homeostasis, Gut Inflammation, Intestinal Permeability and Fecal Microbiota in the First Year of Combination Antiretroviral Therapy (cART)**
Camilla Tincati, Italy
- PE3/6 **Peripheral Blood Pre-erythroidal Cells in HIV-1 Infection**
Maciej Stanislaw Tarkowski, Italy
- PE3/7 **Frequently Low Serum Immunoglobuline M Levels on Long-term Suppressive ART - A Possible Indicator of a Functional B-cell Defect Demasked by ART**
Hans-Jürgen Stellbrink, Germany
- PE3/9 **HIV gp120 Enhances CXCR4/SDF-1 Mediated MSC Migration through Activation of ERK and FAK Pathways**
Nicholas Chew, Singapore
- PE3/10 **The Role of miRNA-33 in HIV-mediated Impairment of Cholesterol Efflux in THP-1 Cells**
Mireia Arnedo, Spain
- PE3/11 **Long-Term Immune Recovery in HIV-infected Patients with Candida esophagitis is Impaired Despite Combination Antiretroviral Therapy**
Nina Khanna, Switzerland

Scientific Programme

- PE4/1 **Analysis of Gut Microbiota Diversity in Chronic AIDS Patients Living in China Using the QIIME Pipeline**
Yang Sun, China
- PE4/2 **The Impact of HLAB*5701 on Viral Replication among Patients Infected with HIV-1 B and Non-B Subtypes - Interplay between Host and HIV Genetics**
Małgorzata Dawidek, Poland
- PE4/3 **Circulating MicroRNA Modulations in HIV-1 Patients under Long-term ARV Treatment**
Marjorie Monleau, France
- PE5/1 **Definition of HIV-1 CTL Epitopes Designed from Archived Virus and Exhibiting Affinity to HLA Groove: The Provir Vaccine Strategy**
Herve Fleury, France
- PE5/2 **Kinetic of Total HIV-Dna during Interferon Based Anti-HCV Therapies in Coinfected Patients**
Giancarlo Orofino, Italy
- PE5/3 **Development of Community-led Education about Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns**
Karamoko Tounkara, Mali
- PE5/4 **Inhibitory Role of CD16+ Inflammatory Monocytes on Vaccine-induced Antibody Responses**
Anne Nolting, Germany
- PE5/5 **Impact of Economic Crisis on Immunization of HIV-1 Population in Greece**
Olga Tsachouridou, Greece
- PE6/1 **Novel and Effective Vaginal Microbicide Delivery System Using Nanoparticle Entrapped Microbicides**
Mahesh Sherkar, India
- PE6/2 **Second-generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity Toward Non-B Subtype HIV-1 Viruses**
Ira Dicker, United States
- PE6/3 **Targeted Cleavage of the HIV-1 Proviral Genome Using AAV Vector-mediated CRISPR**
Manuela Nickl, Germany
- PE6/4 **AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro**
Stefan Proniuk, United States
- PE7/1 **Patient Reported Outcomes (PRO) over 48 Weeks in a Randomized, Open-label Trial of Patients with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF)**
David Budd, United States
- PE7/2 **Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy versus Darunavir/Ritonavir with Two Nucleoside Analogues: The PROTEA Trial**
Pierre-Marie Girard, France

Scientific Programme

- PE7/3 **Does Two-drug Therapy Show Equivalent Efficacy to Standard Three-drug Combinations? Meta-Analysis of 14 Randomised Trials in 3323 Patients**
Pierre-Marie Girard, France
- PE7/4 **Safety and Antiviral Effect of Elpida (VM1500), a Novel NNRTI (+Truvada) in Treatment-naïve HIV-1 Infected Patients**
Alexey Kravtchenko, Russian Federation
- PE7/5 **HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-experienced Subjects: Week 48 Safety Analysis**
Bonaventura Clotet, Spain
- PE7/6 **Dual Treatment with Atazanavir/r+3TC vs. Triple Treatment with Atazanavir/r+2 Nucleos(t)ides in Virologically Stable Patients with HIV-1 (SALT Study): 96-week Results from a Randomised, Open Label, Non-inferiority Trial**
Jose Perez-Molina, Spain
- PE7/7 **A Switch to Once Daily Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed HIV-infected Rwandans is Non-inferior to Continued Nevirapine-based Antiretroviral Therapy**
Sean Collins, United States
- PE7/8 **A NRTI Sparing Two-drugs Maintenance cART is Effective and is Well Tolerated (PROBE Study)**
Franco Maggiolo, Italy
- PE7/9 **Comparative Effectiveness of Tenofovir in Treatment-naïve HIV-infected Patients: Systematic Review and Meta-analysis**
Heiner Bucher, Switzerland
- PE7/10 **Atazanavir plus Cobicistat (ATV+c) versus Atazanavir plus Ritonavir (ATV+r), Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-blind, Active-controlled Trial**
Graeme Moyle, United Kingdom
- PE7/11 **Lipid Profile and Inflammatory Markers of Lipoproteins in Virologically Suppressed Patients with Triple Therapy Switching to Lopinavir/R Plus Lamivudine**
Maria Saumoy, Spain
- PE7/12 **The MONOD-ANRS-12206 Trial: Efavirenz May Simplify a Successful Lopinavir-based Therapy Initiated before the Age of 2 in HIV-infected Children from West-Africa**
Carole Seguin-Devaux, Luxembourg
- PE7/13 **Improved Safety and Efficacy of TAF vs. TDF Single-tablet Regimen in HIV-1 Treatment-naïve Women through Week 48**
Chloe Orkin, United Kingdom
- PE7/14 **Switch to Maraviroc (MVC) + Darunavir/Ritonavir (DRV/r) in Virologically Suppressed Patients with R5-Tropic Virus is Associated with an Excess of Virological Failures: 48 Weeks Results of the GUSTA Study**
Barbara Rossetti, Italy
- PE8/1 **High Efavirenz Serum Concentrations in TB/HIV Co-infected Ugandan Adults Receiving Rifampicin-Based Anti-TB Therapy**
Amrei von Braun, Uganda

Scientific Programme

- PE8/2 **Comparison of Serum Levels of Vitamin A in HIV Positive and HIV Negative Adults in Yenagoa Nigeria**
Okechukwu Anene, Nigeria
- PE8/3 **The Efficacy of Second-line Antiretroviral Therapy for AIDS in China: A Retrospective Study**
Qingxia Zhao, China
- PE8/4 **Association between Estimated Cumulative Viraemia and CD4/CD8 Ratio in HIV Patients on Long Term Antiretroviral Therapy**
Kenny CW Chan, China
- PE8/5 **Long Term Virologic Superiority of Emtricitabine over Lamivudine when Used in Fixed Dose Combination with Tenofovir/Efavirenz Among Patients with Low Baseline CD4 Counts in Resource Limited Settings (RLS)**
Ameet Dravid, India
- PE8/6 **Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive Individuals?**
- PE8/7 **Toll-like Receptor 4 Polymorphism Influence on the Antiretroviral Therapy Effectiveness in HIV-Positive Patients**
Tetiana Kyrychenko, Ukraine
- PE8/8 **Cost Effectiveness of Antiretroviral Therapy in HIV-infected Patients in Kazakhstan**
Rafail Kipshakbayev, Kazakhstan
- PE8/9 **Role of the Decentralization of ART Services in Expansion of Access for HIV-positive IDUs to Treatment**
Nataliya Nizova, Ukraine
- PE8/10 **Real World Experience with Raltegravir and Etravirine as Dual Agent Treatment of HIV**
Dillon Benson, United States
- PE8/11 **Darunavir-Containing Antiretroviral Regimens in Pregnancy: Findings from the Antiretroviral Pregnancy Registry**
William Short, United States
- PE8/12 **Prevalence and Risk Factors Associated with Adherence to Antiretroviral Therapy in HIV-infected Adults in a Tertiary Care Hospital In Mexico**
Juan Domínguez, Mexico
- PE8/13 **Once versus Twice Daily ARV Regimens: Virological and Immunological Outcomes at 48 Weeks**
Guillermo Vilorio, Argentina
- PE8/14 **Factors Associated with Unstructured Antiretroviral Therapy Interruption during the First Year of Treatment**
Mariana Kundro, Argentina
- PE8/15 **Durability of First Antiretrovirals Treatment between 2012-2013 in HIV-patients. Has it Improved with New Drugs?**
Javier De La Torre Lima, Spain
- PE8/16 **Analysis of Toxicity as a Cause of Change of the First Current Antiretroviral Treatments in HIV Patients**
Javier De La Torre Lima, Spain

Scientific Programme

- PE8/17 **48 Week Data of Atripla®, Eviplera® (EPA) or Stribild® in Routine Clinical Use: Efficiency and Safety of Single Tablet Regimens (STRs) in HIV-infected Patients Included in the German STRike Cohort**
Stefan Esser, Germany
- PE8/18 **The Determinants of HIV+ Social Costs: An Empirical Survey in the Italian Setting**
Mariangela Errico, Italy
- PE8/19 **Non-nucleosid Reverse Transcriptase Inhibitor (NNRTI) + Integrase Inhibitor (INI): A Well-tolerated Combination for HIV Maintenance Treatment, a Combination Hypothesized to Have Few or No Long Term Side Effects**
Oswald Moling, Italy
- PE8/20 **Dual Therapy with Lopinavir/r and Raltegravir (LPV/r+RAL) in Treatment-experienced HIV-infected Patients: Data from the German Multicenter PROTEKT Cohort**
Johannes Huelsenbeck, Germany
- PE8/21 **Efficacy of Darunavir/Ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)**
Andrea Antinori, Italy
- PE8/22 **Determinants of Virological Failure in a Large French Cohort in 2014**
Gwenael Le Moal, France
- PE8/23 **Durability of Darunavir/ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)**
Paola Meraviglia, Italy
- PE8/24 **The Position of Rilpivirine in Antiretroviral Therapy: Early Evaluation of its Use in the Swiss HIV Cohort Study**
Delphine Sculier, Switzerland
- PE8/25 **Although Aging HIV-infected Patients Are Burdened with Higher Rates of Co-morbidities and Co-medications, their Response to Raltegravir-based ART is Similar to that of Younger Subjects: An Analysis of a German Real Life Cohort**
Stefan Mauss, Germany
- PE8/26 **Effectiveness and Safety of Fixed Dose ABC/3TC plus Rilpivirine in a Multicenter Cohort of HIV-infected Patients. SIMRIKI Study, GESIDA-8314**
Jesús Troya, Spain
- PE8/27 **Persistency of Single Tablet Regimens (STRs) in Daily Clinical Routine - a Comparison between FTC/TDF-based STRs for Treatment of HIV-infected Patients: Data from the German STRike Cohort**
Eva Wolf, Germany
- PE8/28 **Metabolic Syndrome, Cardiovascular Risk and Renal Impairment in HIV-infected Patients Initiating Antiretroviral Therapy in Portugal**
Ana Lebre, Portugal
- PE8/29 **Potential Cost Savings Associated with Switches from 1st & 2nd-line ART Regimens to Less Expensive Regime; Bichat-Claude Bernard University Hospital Clinic, Paris, France 2014 (ANRS-GOTA)**
Emmanuelle Papot, France

Scientific Programme

- PE8/30 **Durability and Predictive Factors of Discontinuation of Tenofovir-containing Antiretroviral Therapy Regimens in a Cohort of HIV-positive Patients**
Marco Franzetti, Italy
- PE8/31 **Clinical Data and Patient-Reported Outcomes (PRO) in HIV-infected Adults Switching to RPV/FTC/TDF, due to a Previous Intolerance to cART. Interim Analysis of the PRO-STR Study**
Daniel Podzamczar, Spain
- PE8/32 **Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (STRIBILD®) in Patients Treated during Primary HIV Infection Compared to Recent HIV Infection**
Silvia Nozza, Italy
- PE8/33 **Long-term Virological Outcomes of ART-experienced Patients Receiving Raltegravir in a Large European Cohort Study**
Anna Schultze, United Kingdom
- PE8/34 **Maraviroc plus Protease Inhibitor as a Switching Regimen in Clinical Practice**
Marianna Menozzi, Italy
- PE8/35 **Early Start of Antiretroviral Therapy during Primary HIV Infection is Associated with Faster Virological Suppression**
Marco Ripa, Italy
- PE8/36 **Experience of Dolutegravir (DTG) in HIV Infected Treatment Naïve Patients from a Tertiary Care University Hospital in Ireland**
John Lambert, Ireland
- PE8/37 **Simplification for Dolutegravir as a Mono- or Bitherapy Maintains High Proportion of Viral Suppression Even in Highly-experienced HIV-1-infected Patients**
Laurent Hocqueloux, France
- PE8/38 **Switch to Single Tablet Regimen (STR) in Virologically Suppressed Patients: A Comparison between Co-formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir**
Roberta Gagliardini, Italy
- PE8/39 **Immunological and Virological Responses to Combined Antiretroviral Treatment in Male and Female Migrants in Europe: Is Benefit Equal for All?**
Inmaculada Jarrín, Spain
- PE8/40 **Boosted versus unboosted Atazanavir/Raltegravir Dual Therapy and Immunovirological, Clinical and Pharmacological Outcomes: Results from a Prospective Multicenter Cohort of HIV-infected Individuals**
David Rey, France
- PE8/41 **Efficacy and Safety of a Kivexa® (Abacavir/Lamivudine) plus Rilpivirine Regimen for the Treatment of HIV-1 Infection in Naïve Patients (KiRiNa Study)**
Adrian Curran, Spain
- PE8/42 **Factors Associated with Switches and Interruptions of Initial Antiretroviral Therapy in the First Year**
Michaela Rappold, Austria

Scientific Programme

- PE8/43 **Risk and Determinants of Failure of a Mono-PI/r Simplification Strategy with LPV/r or DRV/r in Clinical Practice**
Alessandro Cozzi-Lepri, United Kingdom
- PE8/44 **High Treatment Retention and Success Rates of Tenofovir/Emtricitabine/Rilpivirine (Eviplera) in ART-naïve HIV-infected Persons in Clinical Practice: A Comparative Study on Determinants of Use and Treatment Outcome**
Alessandro Cozzi-Lepri, United Kingdom
- PE8/45 **Perceptions of Healthcare Providers (HCPs) and Patients around the Provision of HIV Healthcare and HCP-patient Communication: A NAM Web-based Survey**
Caspar Thomson, United Kingdom
- PE8/46 **A Year of Stribild® Use. Experience in Real Life**
Maria Arrizabalaga, Spain
- PE8/47 **Clinical Consequences of Poor Adherence to Antiretroviral Therapy in Patients with HIV Infection - A Retrospective Cohort Study**
Cátia Caldas, Portugal
- PE8/48 **Is Switching to Kivexa with Rilpivirine as Effective as Switching to Eviplera in Clinical Practice?**
Lucy Hedley, United Kingdom
- PE8/49 **Factors Related to the Durability of the First Antiretroviral Treatment**
Luis Force, Spain
- PE8/50 **Rilpivirine with Kivexa for Treatment Naïve HIV: Experience in Clinical Practice**
Lucy Hedley, United Kingdom
- PE8/51 **Switch from Atripla™ to Eviplera™: Gap between Perceived vs Compared Quality of Life**
Amedeo Capetti, Italy
- PE8/52 **Much Less Treatment Modification in Individuals Initiating Antiretroviral Therapy with Recently Approved Drugs: The Austrian HIV Cohort Study**
Michaela Rappold, Austria
- PE8/53 **First-line Antiretroviral Therapies in HIV-infected Patients in Germany: Treatment Decisions in the PROPHET Study**
Eva Wolf, Germany
- PE8/54 **Maraviroc Once Daily: Experience in Routine Clinical Practice**
Maria Saumoy, Spain
- PE8/55 **Reasons for Modification and Discontinuation of Initial Antiretroviral Treatment among Recently Diagnosed Patients in HIV-TR Cohort**
Volkan Korten, Turkey
- PE8/56 **Simplification from Unboosted Protease Inhibitor to a STR-containing Rilpivirine Improves Levels of Triglycerides**
Niccolò Riccardi, Italy

Scientific Programme

- PE8/57 **Lipid Changes and Tolerability in a Cohort of Adult HIV-infected Patients Switching to RPV/FTC/TDF, due to Intolerance to Previous cART. A Substudy of PRO-STR Study**
Antonio Ocampo, Spain
- PE8/58 **KReal Study - Real World Experience of a Nucleoside-sparing Regime - Raltegravir +Lopinavir/Ritonavir**
Frederico Duarte, Portugal
- PE8/59 **HiPeak Study - The Most Effective Therapeutic Response to Standard Antiretroviral Therapy (ART) Schemes in Naïve HIV-1 Infected Patients with High Viral Loads**
Frederico Duarte, Portugal
- PE8/60 **Does starting ART as Part of a Randomised Controlled Trial (RCT) Improve Long-term Virological and Immunological Outcomes?**
Mike Youle, United Kingdom
- PE8/61 **Switching from Abacavir/Lamivudine + Nevirapine to Abacavir/Lamivudine /Dolutegravir Single Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Subjects: 12 Weeks Outcome**
Clotilde Allavena, France
- PE8/62 **Use of Abacavir+Lamivudine+Unboosted Atazanavir (ABC/3TC+ATV) in Routine Clinical Practice: Twelve Years Experience**
Rocio Montejano, Spain
- PE8/63 **Multi-centre International Study of the Efficacy and Tolerability of Eviplera (EVA) in Routine Clinical Settings**
Mark Nelson, United Kingdom
- PE8/64 **DRV/r+3TC Bitherapy: More Than Security**
Javier Moreno Díaz, Spain
- PE8/65 **Real-world Persistence with Antiretroviral Therapy for HIV in the United Kingdom: A Multicentre Retrospective Cohort Study**
Joseph Lewis, United Kingdom
- PE8/66 **Unboosted Atazanavir (400 mg QD) in Combination with TDF/FTC or ABC/3TC is Able to Maintain Plasma Viral Load below 1 Copy/ml during 12 Months after the Use of Boosted Azatanavir (100/300 mg QD)**
Vincent Calvez, France
- PE8/67 **Efficacy and Safety of Switching to Abacavir/Lamivudine (ABC/3TC) Plus Rilpivirine (RPV) in Virologically Suppressed HIV-infected Patients on HAART. Study SAEI 00/0067**
Isabel Pérez-Hernández, Spain
- PE8/68 **Raltegravir (RAL) Based Antiretroviral Therapy (ART) in HIV-infected Solid Organ Transplant (SOT) Recipients: A Single Center Experience**
Christian Manzardo, Spain
- PE8/69 **Identifying Priorities for HIV Consultations among Healthcare Providers (HCPs) across Europe: Results of a Pan-European Survey**
Caspar Thomson, United Kingdom
- PE8/70 **Adherence to Antiretroviral Treatment in Turkey: Results from ACTIV-IST Study Group**
Dilek Yildiz Sevgi, Turkey

Scientific Programme

- PE8/71 **Inter-country Variability in the Degree of ART-induced HIV-RNA Suppression**
Kamilla Laut, Denmark
- PE8/72 **Cost Savings Associated with Rapid Virologic Response in Treatment-naïve HIV Patients**
Robert Cuffe, United Kingdom
- PE8/73 **cART-Simplification and Neuro-AIDS**
Gabriele Arendt, Germany
- PE8/74 **Reasons to Start and to Choose the Initial Antiretroviral Treatment: The Physician's and the Patient's Perspective - A Prospective Study**
Luigia Elzi, Switzerland
- PE8/75 **Diffusion Tension Image, Fractional Anisotropy and Mean Diffusivity Comparison in Patients Receiving PI Monotherapy or Triple Therapy**
Ignacio Pérez-Valero, Spain
- PE8/76 **Time to Viral Suppression for HIV-positive Patients Initiating cART with Very High Viraemia**
Annabelle Gourlay, United Kingdom
- PE8/77 **First-line NNRTI-Including cART Regimens Display Faster Immune-virologic Response in Comparison to PIs: Data from the San Paolo Infectious Diseases (SPID) Cohort, 2010-2015**
Francesca Bai, Italy
- PE8/78 **Maraviroc Use and Outcomes across Europe - The European Coreceptor (EUCCO) HIV Cohort Study**
Anna Maria Geretti, United Kingdom
- PE8/80 **Mono and Dual Antiretroviral Suppressive Strategies: Real Life Experience in Three Hospitals in Paris (COREVIH Ile-de-France-Centre)**
Marc-Antoine Valantin, France
- PE8/81 **Dual Therapy with Dolutegravir and Lamivudine Maintains Virologic Suppression in HIV-infected HAART-treated Patients: DOLULAM Pilot Study**
Jacques Reynes, France
- PE8/82 **Immuno-Virological Effects and Cost after Introduction of Generic Drugs of Efavirenz and Nevirapine. Are they Good, Safe and Cheap?**
Miguel Torralba, Spain
- PE8/83 **Evipera (EVP) as a Treatment Option in Real-life Clinical Practice: Evidence for Efficacy and Safety**
Konstantinos Protopapas, Greece
- PE8/84 **Simplification of a 4-drug cART Started during Acute HIV Infection (Alpha study): HIV RNA and Proviral HIV DNA Levels before and after**
Adriana Ammassari, Italy
- PE8/85 **Genotypic Susceptibility Scores (GSS) of the Therapeutic Backbone in Treatment-experienced HIV-1 Patients: what Level is Required to Achieve Viral Suppression on Dolutegravir-containing cART**
Matthijs Raadsen, Netherlands

Scientific Programme

- PE8/86 **Successful Interferon-based Salvage Therapy in a Panresistant HIV+ Adolescent**
Markus Bickel, Germany
- PE9/1 **High Rate of HIV-1 Drug Resistance in Treatment Failure Patients in Taiwan, 2009-2014**
Hung-Chin Tsai, Taiwan, Republic of China
- PE9/2 **Deep Analysis of HIV-1 Natural Variability across HIV-1 Variants at Residues Associated to Integrase Inhibitors (INI) Resistance in INI-naïve Patients**
Teresa Llácer Delicado, Spain
- PE9/3 **HIV Proviral DNA is an Adequate Genetic Compartment for Detection of Resistance Mutations Associated to Integrase Strand Transfer Inhibitors (INSTIs) Therapy in Patient with Undetectable or Low HIV Viral Load**
Pablo Ferrer, Chile
- PE9/5 **Integrated Analysis of Emergent Drug Resistance by Population and Deep Sequencing through 48 Weeks from Clinical Studies of HIV-1 Treatment-naïve Subjects Receiving EVG/COBI/FTC/TAF**
Michael Miller, United States
- PE9/6 **Cumulative Genotypic Resistance to NRTIs and NNRTIs is Associated with a Higher Risk to Loose Virological Suppression in HIV-positive Patients Switching to Tenofovir/Emtricitabine/Rilpivirine Single-tablet Regimen**
Maria Mercedes Santoro, Italy
- PE9/7 **Prevalence of Transmitted Drug Mutations to Rilpivirine in HIV-infected Treatment-naïve Persons: Systematic Review of 64,466 Samples from 138 Studies**
Vincent Calvez, France
- PE9/8 **What if a New HIV Integrase Inhibitor was not Prone to the Problem of Drug Resistance?**
Mark Wainberg, Canada
- PE9/9 **Emerging Resistance Mutations in Protease Inhibitor Naïve Patients Failing Atazanavir Based Regimen (ANRS Multicentre Observational Study)**
Laurence Morand-Joubert, France
- PE9/10 **APOBEC Could Explain Low Viral Load in HIV Patient with Highly Active Therapy (HAART) with Nucleoside Analog Reverse-transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse-transcriptase Inhibitors (NNRTIs) Resistance but without Clinical Consequences**
Pablo Ferrer, Chile
- PE9/11 **Comparison of the Risk of Resistance Accumulation According to ART Switching Strategies after Virological Failure >200 Copies/mL to First cART Using the g-computation Procedure**
Alessandro Cozzi-Lepri, United Kingdom
- PE9/12 **HIV Drug Resistance among Children and Adolescents in Asia after First-line NNRTI-based Treatment Failure**
Wanatpreeya Phongsamart, Thailand

Scientific Programme

- PE9/13 **Protease Inhibitor Monotherapy: Effectiveness and Resistance in Clinical Practice**
Kate El Bouzidi, United Kingdom
- PE9/14 **Characterization of HIV Resistance in Peripheral Blood Mononuclear Cells (PBMC-DNA) in Patients with Suppressed or Low Level Viremia**
Mauro Zaccarelli, Italy
- PE9/15 **Prediction of Virological Failure by a Single Quantifiable Viral Load Below 200 Copies/mL in Treated HIV-infected Patients**
Gisela Leierer, Austria
- PE9/16 **Impact of Baseline NRTI Resistance Mutations on Virological Suppression of HIV-1 Infected Patients Treated by Elvitegravir/Cobicistat/Emtricitabine/Tenofovir**
Nolwenn Hall, France
- PE9/17 **Transmitted Drug Resistance (TDR) in Drug-naive HIV-2 Infected Patients**
Frederico Duarte, Portugal
- PE9/18 **Patterns of Viral Resistance in Patients with Virologic Failure on a Dual Agent Antiretroviral Regimen**
Dillon Benson, United States
- PE9/19 **Antiretroviral Resistance Mutations and Molecular Surveillance of HIV-1 in the Comunidad Valenciana (Spain), 2011-2013**
Manoli Torres-Puente, Spain
- PE9/20 **Evolution of Resistance Rates to RT and Protease Inhibitors in Antiretroviral-experienced HIV-infected Patients**
Anne-Geneviève Marcellin, France
- PE9/21 **Integrated Analysis of Emergent Drug Resistance through 96 & 144 Weeks from Clinical Studies of HIV-1 Treatment-naive Subjects Receiving Dolutegravir Based Regimens**
James Demarest, United States
- PE9/22 **E138A - Natural Polymorphism or Selected by 2nd Generation NNRTIs?**
Martin Obermeier, Germany
- PE9/23 **Decline in Resistance Mutations' Prevalences, Namely K65R: Frankfurt HIV-1 Database, 2005-2013**
Christoph Stephan, Germany
- PE10/1 **Discovery of Novel Diaryltriazenes (DATAs) as Non-nucleoside Reverse Transcriptase Inhibitors via Extension into the Entrance Channel of HIV-1 Reverse Transcriptase**
Udaya Pratap Singh, India
- PE10/2 **Design and Discovery of Potent Hybrid 1,3,5-Triazine-1,3-Thiazine Analogs Clubbed via Amine Bridge: A Novel Lead for Next Generation NNRTI**
Amita Verma, India
- PE10/3 **Pharmacogenetic: Screening Relevant Polymorphisms on Antiretroviral Therapy in an HIV Portuguese Population**
Ana Fernandes, Portugal

Scientific Programme

- PE10/4 **Impact of Decentralized Drug Purchase on Antiretroviral Treatment Costs in Spain**
Yaiza Rivero-Montesdeoca, Spain
- PE10/5 **Impact of UGT1A1*28 Polymorphism on Raltegravir Metabolism**
Leïla Belkhir, Belgium
- PE10/6 **The Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) is Bioequivalent to Elvitegravir/Cobicistat/FTC/TAF (E/C/F/TAF) and RPV**
Julia Zack, United States
- PE10/7 **Co-medication in an Irish Infectious Diseases Clinic: The Level of Accurate Recording of co-medication and the Significance of Interactions between co-medication and Antiretrovirals (ARVs)**
- PE10/8 **Differential Pharmacological Impact of Abacavir Sulphate and Tenofovir on Platelet Aggregation Independent of HIV Infection**
Erica Smyth, United Kingdom
- PE10/9 **The Effect of Food on the Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) Tablet**
- PE10/10 **Impact of Tenofovir' (TDF) Dose Adjustment on the Estimated Glomerular Filtration Rate (eGFR) and TDF trough Concentration (C_{trough}-TDF)**
Sylvie Bregigeon, France
- PE10/11 **Assessment of CYP3A5 Genotype on Maraviroc Exposure and Efficacy in a Phase 3 Study**
Manoli Vourvahis, United States
- PE10/12 **Frequency and Severity of Drug Interactions in a Cohort of HIV-infected Patients Identified through a Multidisciplinary Team**
Hernando Knobel, Spain
- PE10/13 **The Effect of Food on the Pharmacokinetics of Unboosted and Boosted Tenofovir Alafenamide**
Joseph Custodio, United States
- PE10/14 **Evaluation of Tenofovir Alafenamide Pharmacokinetics: No Influence of Demographic or HIV Disease Factors**
Joseph Custodio, United States
- PE10/15 **Pharmacology Drug Interactions and Adherence in Patients on Polypharmacy in our Hospital**
Sheila Ruiz, Spain
- PE10/16 **Risk Factors Associated with Hypersensitivity Reactions to Antiretroviral Drugs in Patients Infected with HIV**
José Antonio Mata-Marín, Mexico
- PE10/17 **What Minimal Concentration of Darunavir in Maintenance Darunavir/Ritonavir 800/100 mg Once-daily with 2 NRTIs (DAMAR study)?**
Minh Lê, France
- PE10/18 **Comparison of the in vitro Dissolution and in vivo Pharmacokinetics of Branded versus Generic Efavirenz Formulation in HIV Patients**
Cristina Gervasoni, Italy

Scientific Programme

- PE10/19 **Neuro+3 Study: Baseline Characteristics with Pharmacologic Results of HIV Patients with Neurocognitive Disorders Despite Effective Antiretroviral Therapy**
Gilles Force, France
- PE11/1 **Renal Toxicity Following Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Drug Transporters in HIV-1 Patients**
Casper Rokx, Netherlands
- PE11/2 **Simple and Practical Screening Approach to Identify HIV-infected Individuals with Current Depression or Risk of Developing Depression**
Lotte Rodkjaer, Denmark
- PE11/3 **Analysis of Neurocognitive Function and CNS Endpoints at Week 96 in the PROTEA Trial: Darunavir/Ritonavir with or without Nucleoside Analogues**
Amanda Clarke, United Kingdom
- PE11/4 **Safety, Sensory Function and Analgesic Effectiveness Following Capsaicin 8% Patch (Qutenzatm) Repeat Treatment in Peripheral Neuropathic Pain: Stride Study**
Graeme Moyle, United Kingdom
- PE11/5 **Tenofovir-associated Nephrotoxicity and Hypophosphatemia in HIV-infected Patients: A Single-centre Cohort Study**
Chien-Yu Cheng, Taiwan, Republic of China
- PE11/6 **Hepatotoxicity and Skin Rash of non-nucleoside Reverse Transcriptase Inhibitor (nNRTI) plus Nucleoside Reverse-Transcriptase Inhibitors in HIV-infected Taiwanese**
Pei-Ying Wu, Taiwan, Republic of China
- PE11/7 **Health State Utilities of Risks Associated with Antiretroviral Treatment (ART) for Human Immunodeficiency Virus (HIV)**
Louis Matza, United States
- PE11/8 **Discontinuation of Tenofovir due to Nefrotoxicity: Insight into 12 Years of Clinical Practice**
Elzbieta Bakowska, Poland
- PE11/9 **Incidence of Cancer in Individuals treated with Raltegravir-based and Non-raltegravir-based cART Regimens**
Daniel Grint, United Kingdom
- PE11/10 **Cross-sectional Multi-centre Study of Bone Mineral Density in HIV-1 Infected Patients on Antiretroviral Treatment at Risk for Osteopenia/Osteoporosis**
Frank Post, United Kingdom
- PE11/11 **Osteonecrosis and HIV Infection: The Experience of a Portuguese Center**
Rosário Serrão, Portugal
- PE11/12 **Prevalence of Sleep Disorders, Anxiety and Depression in HIV/AIDS Patients under Antiretroviral Treatment in China**
Wu Hao, China
- PE11/13 **Risk Factors of Anxiety and Depression in HIV-infected Patients during Antiretroviral Treatment**
Wu Hao, China

Scientific Programme

- PE11/14 **Abacavir Does Not Produce Vascular Inflammatory Effects in ATP Receptor-deficient Mice**
Samuel Orden, Spain
- PE11/15 **The Vascular Pro-inflammatory Effects of Abacavir Involve Interference with the Purinergic System**
Victor Collado Diaz, Spain
- PE11/16 **Abacavir Induces Platelet Adhesion to Endothelial Cells**
César Ríos-Navarro, Spain
- PE11/17 **Hepatic Safety of Maraviroc in HIV Infected Patients with HCV and/or HBV Co-infection. The Maraviroc Cohort Spanish Group**
Manuel Crespo, Spain
- PE11/18 **Breast Density Assessment in Women Living with HIV/AIDS**
Mônica Mendes, Brazil
- PE11/19 **Differences in HIV Symptom Index Questionnaire (SIQ) and Sleep/Wake Activity Inventory (SWAI) after Switching to a Rilpivirine (RPV)-containing Regimens in Combination Antiretroviral Therapy (cART)-experienced HIV-infected Patients**
Manuela Colafigli, Italy
- PE12/1 **Risk Factors for Mortality in HIV-infected Patients with CMV Disease in the Combination Antiretroviral Era**
Rafael Perello, Spain
- PE12/2 **Hospitalizations of HIV Patients in a Major Israeli HIV/AIDS Center in the Years 2000-2012**
Keren Mahlab-Guri, Israel
- PE12/3 **Low Bone Fracture Risk Measured by Frax Index in HIV Patients**
Carmen Hidalgo-Tenorio, Spain
- PE12/4 **HIV-associated versus Classic Fever of Unknown Origin 25 Years on: Spectrum and Criteria Revisited**
Paul De Munter, Belgium
- PE12/5 **Impact of Late Presentation on Short, Mid and Long-term Mortality and on Causes of Death in Spain (2004-2013)**
Paz Sobrino-Vegas, Spain
- PE12/6 **Cardiovascular-specific Mortality in HIV-positive Patients with Alcohol Use Disorders**
Robert Muga, Spain
- PE12/7 **Ongoing Contribution of AIDS Deaths in the HAART Era: Data from the UK CHIC Study**
Sophie Jose, United Kingdom
- PE12/8 **American College of Cardiology Pooled Equations and DAD Algorithm to Predict Freedom from Cardiovascular Events in HIV Patients**
Giovanni Guaraldi, Italy

Scientific Programme

- PE12/9 **Cardiovascular Risk Factors and Recommended LDL Cholesterol Goals Attainment among HIV Positive Patients: The Impact of the Metabolic Syndrome**
Elisabetta Schiaroli, Italy
- PE12/10 **Persistent HIV Low-level Viremia and Cardiovascular Risk**
Silvia Costarelli, Italy
- PE12/11 **Heart Transplantation in HIV-infected Patients: A Report of Three Cases from a Single Institution**
Fernando Agüero, Spain
- PE12/12 **Prognostic Value of DLCO in a Cohort of Middle Aged HIV Infected Patients in Terms of Mortality and Incidence of Cardiovascular Events after 6 Years of Prospective Follow-up**
Francisco Fanjul, Spain
- PE12/13 **Lower CD4/CD8 Ratio (**
Francisco Fanjul, Spain
- PE12/14 **Trends in Cardiovascular Surgery in HIV-infected Patients: A 30-year Single Center Experience**
Juan M Pericás, Spain
- PE12/15 **Review of Causes of Death in HIV Positive Patients in London in 2014**
Sharanjit Dhoot, United Kingdom
- PE12/16 **Cardiovascular Events in HIV-positive Patients over the Last Decade. The Experience of Brescia from 2000 to 2012**
Elena Raffetti, Italy
- PE12/17 **Rare Case of Adult Onset Still's Disease Inducing Hemophagocytic Lymphohistiocytosis (HLH) during Early HIV Infection: Emerging Treatment Controversies and Dilemmas**
Garyfalia Poulakou, Greece
- PE13/1 **Characteristics of the Active Drug Users Recently Infected with Hepatitis C in a Shantytown with a High Prevalence of HCV**
Pablo Ryan, Spain
- PE13/2 **Hepatic Safety of RPV/FTC/TDF Single Tablet Regimen in HIV/HCV-coinfected Subjects. The hEPatic Study**
Karin Neukam, Spain
- PE13/3 **Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-experienced Subjects with HCV Genotype 1 and HIV-co-infection (ANRS HC31 SOFTRIH Study)**
Eric Rosenthal, France
- PE13/4 **Uptake of Tenofovir-based Combination Antiretroviral Therapy (cART) among HIV/HBV Co-infected Patients in the EuroSIDA Study**
Lars Peters, Denmark
- PE13/5 **Ledipasvir/Sofosbuvir with or without Ribavirin for the Treatment of Patients with Genotype 2-6 Chronic HCV Infection: Summary Results from Four Phase II Studies**
Armand Abergel, France

Scientific Programme

- PE13/6 **The Treatment Cascade of Chronic Hepatitis C In HIV Co-infected Patients: Data from the Clinic of Infectious Diseases in Modena, Italy**
Gianluca Cuomo, Italy
- PE13/7 **Factors Associated with Changes in Liver Stiffness in HIV/HCV Co-infected Patients along 5 Years of Follow-up: Effect of Treatment Response to HCV-therapy on Liver Fibrosis**
Eva Van den Eynde, Spain
- PE13/8 **Does treatment of HCV with DAAs Affect Renal Function? Findings from the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)**
Stefan Mauss, Germany
- PE13/9 **Co-morbidities and Co-medications in HIV Patients with Hepatitis C in the Era of New Agents**
Lise Cuzin, France
- PE13/10 **Efficiency of an Integrated Management of New Treatments of HCV**
Julie Chas, France
- PE13/11 **Differential Regulation of Primary Natural Killer Cell Function by Sequence Variations in HCV Core-derived Epitope through Altered Binding of KIR2DL3 to HLA-C*03:04**
Sebastian Lunemann, Germany
- PE13/12 **CD4 and CD4/CD8 Ratio Progression in HIV-HCV Infected Patients after Achievement of SVR**
Annalisa Saracino, Italy
- PE13/13 **Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-infected Patients**
Sanjay Bhagani, United Kingdom
- PE13/14 **Incidence and Recurrence of Hepatitis C Virus Reinfection after Sustained Virological Response in a Large Cohort of Prisoners**
Andrés Marco, Spain
- PE13/15 **Differences in HCV Genotype 1a and 1b Molecular Epidemiology and NS3A Resistance Associated Variant Frequency among HIV-coinfected Patients from Poland**
Milosz Parczewski, Poland
- PE13/16 **Prognostic Value of Transient Elastography in HIV-infected Patients with Chronic Hepatitis C**
Juan Berenguer, Spain
- PE13/17 **Acute Hepatitis C in HIV Co-infected Patients in Barcelona: A Rising Epidemics**
Maria Martínez-Rebollar, Spain
- PE13/18 **Prognostic Value of Liver Stiffness in HIV/HCV-coinfected Patients with Decompensated Cirrhosis**
Juan Berenguer, Spain
- PE13/19 **Determinants and Impact of Late HCV Diagnosis among Persons with Newly Diagnosed HIV Infection**
Enrico Girardi, Italy

Scientific Programme

- PE13/20 **HCV-RNA Profiles among HIV/HCV-coinfected Individuals in the ESPRIT Study: Spontaneous HCV-RNA Clearance Documented in 9 Individuals**
Daniel Grint, United Kingdom
- PE13/21 **Seroclearance of Hepatitis B Surface Antigen is Associated with Immune Reconstitution Inflammatory Syndrome among HIV and HBV Coinfected Individuals**
Takashi Muramatsu, Japan
- PE13/22 **Boceprevir Plus Peginterferon/Ribavirin to Retreat HCV Genotype-1 in HIV-HCV coinfectd Patients. Final Results of BOC HIV-HCV Spanish Study Group**
Montserrat Laguno, Spain
- PE13/23 **HIV/HCV-coinfection across Europe**
Lars Peters, Denmark
- PE13/24 **Prevalence and Clinical Determinants of Hepatitis Delta Co-infection in a Rural Tanzanian HIV Cohort**
Annja Winter, Switzerland
- PE13/25 **Challenges of Anti HCV Treatment in Persons Living with HIV in the Era of Directly Acting Antivirals (DAA)**
Massimo Puoti, Italy
- PE13/26 **Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectiveness And Impact on Liver Fibrosis (MASTER Cohort)**
Paola Nasta, Italy
- PE13/27 **Awareness of HCV-coinfection among Newly Diagnosed HIV Individuals**
Paola Scognamiglio, Italy
- PE13/28 **Monocytes and Dendritic Cells Subsets during New Anti-HCV Treatments: IFN free and IFN Based Regimen**
Stefano Savinelli, Italy
- PE13/29 **High Efficacy of Grazoprevir/Elbasvir in HCV Genotype 1, 4, and 6-infected Patients with HIV-co-infection: The phase 3 C-EDGE Co-infection Study**
Christine Katlama, France
- PE13/30 **Safety and Efficacy of combinations of Direct Antiviral Agents (DAAs) against Hepatitis C Virus (HCV) in HIV Co-infected Patients**
Daniela Buccione, Spain
- PE13/31 **Safety and Efficacy of IFN-free, DAAs-based Therapy in HIV/HCV Solid Organ Transplanted Patients**
Ana Moreno, Spain
- PE13/32 **Real-world Effectiveness of Ledipasvir/sofosbuvir 8 Weeks Chronic Hepatitis C Treatment**
Karsten Wursthorn, Germany
- PE13/33 **Interferon-gamma (IFN- γ)-inducible Protein-10 (IP-10) and sCD163 in HCV Monoinfected and HIV/HCV-coinfected Subjects: A Potential Role as Markers of Fibrosis and Response to Therapy**
Claudia Mascia, Italy

Scientific Programme

- PE13/34 **Safety and Efficacy of SOF-based Therapy in HIV/HCV-coinfected Patients with Chronic Kidney Disease (CKD) in "Real Life"**
- PE13/35 **Reduced CD4 Monitoring in Stable and Virologically Suppressed HIV/HCV-coinfected Patients from the PISCIS Cohort (Spain)**
David Nicolás, Spain
- PE13/36 **Linkage to Care after Routine HIV, Hepatitis B (HBV) & C (HCV) Testing in the Emergency Department (ED) - The 'Going Viral' Campaign**
Rageshri Dhairyawan, United Kingdom
- PE13/37 **Prevalence of Hepatitis B Virus and Hepatic Fibrosis Progression after ART Initiation among ART-naïve Individuals in a Rural Tanzanian HIV Cohort**
Adrià Ramírez-Mena, Spain
- PE13/38 **Effectiveness of New Direct-acting Antivirals in a Real-life Cohort of Difficult-to-Treat HCV and HIV/HCV-coinfected Patients**
María Jesús Vivancos Gallego, Spain
- PE13/39 **Directly-acting Agents against the Hepatitis C Virus (HCV) for HCV-monoinfected and HIV-HCV-coinfected Patients with HCV Genotypes 1, 2, 3 and 4 - Results from the German Hepatitis C Cohort (GECCO)**
Stefan Christensen, Germany
- PE13/40 **High Proportion of Advanced Liver Fibrosis and Cirrhosis Requiring Hepatitis C Treatment in HIV-HCV Coinfected Patients in Hai Phong, Northern Vietnam**
Tam Nguyen Truong, Viet Nam
- PE13/41 **Are there any Variables that Predict a Rapid Progression to Liver Fibrosis in HIV-HCV infected patients?**
David Rial, Spain
- PE13/42 **Spontaneous Hepatitis C Virus (HCV) Clearance: Epidemiological and Clinical Characterization and Identification of Predictive Factors of Clearance in a Portuguese Cohort**
Nina Fernandes, Portugal
- PE13/43 **Significant Reductions in Costs of Generic Production of Sofosbuvir and Daclatasvir for Hepatitis C Treatment in Low- and Middle-income Countries**
Andrew Hill, United Kingdom
- PE13/44 **Differential Effects of HCV Therapy with Direct Acting Antiviral Agents on Lipids in the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)**
Stefan Mauss, Germany
- PE13/45 **Correlates of Successful HCV Treatment in HIV Co-infected Vulnerable Populations**
Syune Hakobyan, Canada
- PE13/46 **High Prevalence of Undiagnosed Hepatitis C Virus (HCV) Infection in Attendees of the Emergency Department of a Central London Hospital**
Daniel Bradshaw, United Kingdom

Scientific Programme

- PE14/1 **Infectious Complication Rate in a Cohort of HIV-infected Kidney Transplant Recipients**
Oana Alilioaie, Romania
- PE14/2 **Antiretroviral and Cotrimoxazole Prophylactic Therapies among HIV-TB Co-infected Patients**
Olatunji Adetokunboh, South Africa
- PE14/3 **Resistance to Antituberculous Drugs and Outcome among TB/HIV Co-infected Adults in Ghana - Detect HIV/TB study**
Stephanie Bjerrum, Denmark
- PE14/4 **HIV/TB Coinfection**
Mariana Hualde, Argentina
- PE14/5 **Use of IGRA Tests for Heavy Immunosuppressed HIV-patients**
Aleksander Panteleev, Russian Federation
- PE14/6 **FDG-PET/CT: A Non-invasive Tool in Diagnosis and Monitoring of Therapeutic Response in HIV Patients with Extra-pulmonary Tuberculosis**
Charlotte Martin, Belgium
- PE14/7 **Drug Resistant TB in HIV-infected Patients in St Petersburg: Problems and Perspectives**
Aleksander Panteleev, Russian Federation
- PE14/8 **Has Tuberculosis in HIV-infected Patients the Same Clinical and Epidemiological Features than Tuberculosis in HIV-negative Patients?**
Javier Martinez-Sanz, Spain
- PE14/9 **Consecutive Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis in a Spanish cohort of HIV-infected Individuals**
Adrià Ramírez-Mena, Spain
- PE14/10 **Computed Tomography in the Diagnosis of Bowel Diseases in Patients with HIV/Tuberculosis co-infection**
Irina Sokolina, Russian Federation
- PE15/1 **Human Immunodeficiency Virus Infection and Stroke: A Case-control Study in a Portuguese Hospital**
André Silva-Pinto, Portugal
- PE15/2 **Prevalence of Hypertension and Obesity among HIV Patients in a Care Program in Nairobi: A Case for Integration of Care**
Moses Masika, Kenya
- PE15/3 **Brain-related Voice Emotion Processing Deficits in HIV-infected Patients**
Alicia González-Baeza, Spain
- PE15/4 **Burden of Chronic Obstructive Pulmonary Disease (COPD) and its Determinants in an African HIV Cohort**
Attannon Arnauld Fiogbé, Togo
- PE15/5 **Ageing with HIV: Do Comorbidities and Poly-medication Drive Treatment Optimizations?**
Lise Cuzin, France

Scientific Programme

- PE15/6 **Central Obesity and Correlating Factors in Vojvodina's Cohort**
Daniela Maric, Serbia
- PE15/7 **Prevalence and Risk Factors for Chronic Kidney Disease (CKD) among Ambulatory ART Naïve HIV-1 Infected Patients in a Rural Kenyan Population**
Paul Yonga, Kenya
- PE15/8 **Has CXCL13 an Added Value in the Diagnosis of Neurosyphilis?**
Khutso Mothapo, Netherlands
- PE15/9 **Associations between Cognitive Impairment and Patient-reported Measures of Physical/Mental Functioning in Older People Living with HIV**
Jonathan Underwood, United Kingdom
- PE15/10 **Metabolic Syndrome and Sub Clinical Cardiovascular Disease Detected on Cardiac MRI in HIV Infected Patients**
Aisling Loy, Ireland
- PE15/11 **Increased Markers of Endothelial Dysfunction in Untreated HIV Infection Are Associated with Viral Replication but Not with Platelet Aggregation**
Judith Haissman, Denmark
- PE15/12 **Evaluation of a Physiotherapy-led Group Rehabilitation Intervention for Adults Living with HIV: Referrals, Adherence and Outcomes**
Darren Brown, United Kingdom
- PE15/13 **Aging on cART: No Worsening of Bone Mineral Density over 12 Years**
Clotilde Allavena, France
- PE15/14 **Gastroesophageal Reflux Disease among Adults with HIV: Prevalence and Risk Factors of Severe or Frequent Symptoms**
Mazen Bader, Canada
- PE15/15 **Evaluation and Management of Fracture Risk of HIV Patients in the US Veterans Health Care System**
Roger Bedimo, United States
- PE15/16 **Nephrology Consultations Incorporated into HIV Care - Non-compliance is an Important Issue**
Bartłomiej Matłosz, Poland
- PE15/17 **Cardiovascular Risk Assessment in HIV-1 Infected Patients and a Comparison of Framingham, SCORE, and DAD Risk Methods**
Zev Sthoeger, Israel
- PE15/18 **Absence of Pneumocystis jirovecii Colonization in HIV-infected Persons**
Andreas Ronit, Denmark
- PE15/19 **COPD Symptom and Disease Screening in an HIV Population**
Nadine Kronfli, Canada
- PE15/20 **Epidemiology and Costs for Comorbidities in People Living with Human Immunodeficiency Virus (PLWHIV) - A Systematic Review**
Julie Glanville, United Kingdom

Scientific Programme

- PE15/21 **A Calibration of the Framingham Coronary Risk Function Adapted to the Characteristics of Spanish HIV-infected Patients**
Vicente Estrada, Spain
- PE15/22 **Evaluation of HIV Testing Recommendations In Specialty Guidelines for the Management of HIV Indicator Conditions**
Emily Lord, United Kingdom
- PE15/23 **The Prevalence and Outcome of HIV-associated Neurocognitive Impairment in a Clinical Setting**
Francesca Ferretti, United Kingdom
- PE15/24 **Characteristics and Outcome of Patients Diagnosed with HIV at Older Age**
Ilan Asher, Israel
- PE15/25 **Improvement of the Estimation Performance of Ischemic Heart Events Risk in Mediterranean HIV-infected Patients by Means of the Adapted Framingham Function (REGICOR)**
Hernando Knobel, Spain
- PE15/26 **Analysis of Co-morbidities in HIV Infection**
Svetlana Buzunova, Russian Federation
- PE15/27 **Comorbidities and Disability Experienced among Adults Living with HIV in Canada: Results from the HIV Health and Rehabilitation Survey**
Kelly O'Brien, Canada
- PE15/28 **Clinical Evaluation is Better than Risk Prediction Algorithms to Identify Patients who Need Statin Therapy**
Giovanni Guaraldi, Italy
- PE15/29 **cIMT Progression in 90 Patients Starting Their First Highly Active Antiretroviral Therapy: 48 Months Observation**
Sergio Ferrara, Italy
- PE15/30 **Cannabis Exposure Increases the Risk of Liver Fibrosis in HIV-infected Patients**
Olivia Zaegel-Faucher, France
- PE15/31 **Epidemiology of Acute Myocardial Infarction in HIV-infected Patients in Spain during the Combination Antiretroviral Therapy Era (1997-2011)**
Juan Berenguer, Spain
- PE15/32 **Ageing Perception and Attitudes in HIV Patients in Italy**
Mariangela Errico, Italy
- PE15/33 **Impact of Maraviroc, Dolutegravir and Darunavir/Ritonavir on Human Coronary Endothelial Cell Functions According to Age**
Jacqueline Capeau, France
- PE15/34 **Statins and Aspirin in HIV-infected People: Gap between Guidelines and Clinical Practice. The Results of the HIV-HY Study**
Paolo Bonfanti, Italy
- PE15/35 **The Metabolome in HIV-associated Chronic Obstructive Pulmonary Disease**
Chris Wendt, United States

Scientific Programme

- PE15/36 **Low Prevalence of HIV-associated Neurocognitive Disorder (HAND) in a Swedish Cohort of HIV-1 Infected Individuals**
Åsa Mellgren, Sweden
- PE15/37 **Non-viral Liver Disease Burden in HIV Positive Individuals. A Prospective Cohort Study: Preliminary Results**
Yishi Tan, United Kingdom
- PE15/38 **Impact of HIV and Type 2 Diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction**
Hedda Hoel, Norway
- PE15/39 **Apolipoprotein E (ApoE) e2 Genetic Variant is Associated with Favorable Lipid Profile on cART among HIV-1 Infected Patients**
Magdalena Witak-Jedra, Poland
- PE15/40 **CD4/CD8 Ratio for Monitoring the Immunological Response to Combined Antiretroviral Therapy in Ageing HIV+ Patients**
Maria Nikolova, Bulgaria
- PE15/41 **Description of a Male to Female Transgender HIV Positive Population in the North-West of France in 2013**
Jeremie Leporrier, France
- PE15/42 **Lack of Association between Liver Stiffness and Bone Mineral Density in HIV/HCV-coinfected Patients**
Juan Berenguer, Spain
- PE15/43 **Should We Screen for NAFLD/NASH in HIV Patients?**
Giovanni Guaraldi, Italy
- PE15/44 **Human Papillomavirus Infection in HIV Positive and HIV Negative Men Who Have Sex with Men in Non Metropolitan Area of Central Italy: Prevalence and Genotypes Distribution**
Claudio Ucciferri, Italy
- PE15/45 **The Characteristics, Prevalence and Progression of Insulin Resistance in Patients with HIV and HIV/HCV Coinfection**
Opass Putcharoen, Thailand
- PE15/46 **Trends in Myocardial Infarction among HIV-1-infected Individuals in France between 2000 and 2009 Compared to the General Population: Results from FHDH-ANRS CO4**
Dominique Costagliola, France
- PE15/47 **Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIV-positive and HIV-negative Subjects**
Elena Alvarez, Ireland
- PE15/48 **Effectiveness of Progressive Resistive Exercise for Adults Living with HIV: A Cochrane Collaboration Systematic Review**
Kelly O'Brien, Canada
- PE15/49 **Relationship between Surface Activation Markers on Peripheral Monocyte/Macrophage and Evolution of Cognitive Performance in HIV-infected Patients under Suppressive Antiretroviral Therapy**
Alessandra Bandera, Italy

Scientific Programme

- PE15/50 **A Systematic Review of Psychiatric Illness and Sleep Disturbance Prevalence as Comorbidity with HIV in the UK, with Comparison to the UK General Population**
Masautso Chaponda, United Kingdom
- PE15/51 **Vaginal Shedding of Herpesviridae Does Not Influence the Coronary Microcirculation in HIV-infected Women**
Andreas Knudsen, Denmark
- PE15/52 **Prevalence of Central Obesity and Metabolic Complications among Adults Living with HIV in Ireland**
Laura Kelly, Ireland
- PE15/53 **Association with Statin Use in Individuals with and without Cardiovascular Disease**
Gisela Leierer, Austria
- PE15/54 **A Study of the Effect of Early, Untreated HIV on Cerebral Perfusion and Arterial Transit Time in the Basal Ganglia Using Arterial Spin Labelling**
Lewis Haddow, United Kingdom
- PE15/55 **Plasma Osteoprotegerin Concentration in HIV Infected Men and its Association with Hypertriglyceridemia**
Anita Olczak, Poland
- PE15/56 **Anaemia and HIV - An Old New Study Opportunity**
Joana Silva, Portugal
- PE15/57 **Increased Incidence of Cancer and Cancer-related Mortality among HIV/HCV-coinfected Patients, 1993-2014**
Alvaro Mena, Spain
- PE15/58 **Neuroimaging Findings in Effectively Suppressed HIV+ Patients with Symptomatic Neurocognitive Dysfunction: A Cross-sectional Sub-study from the PIVOT Trial**
Alejandro Arenas-Pinto, United Kingdom
- PE15/59 **Age-related Polypharmacy in HIV-infected Patients in a Spanish University Hospital**
Angels Andreu - Crespo, Spain
- PE15/60 **The "Bone Status" in under 40 HIV Positive Patients**
Ermelinda Guerra, Italy
- PE15/61 **White Matter Abnormalities Are Associated with Neurocognitive Disorders in HIV-positive Patients**
Andrea Calcagno, Italy
- PE15/62 **Blood Brain Barrier Impairment is Associated with CSF Neopterin in Late-presenters and with Neurodegeneration and Astrocytosis in Patients with CSF HIV RNA**
Andrea Calcagno, Italy
- PE15/63 **Weight Loss as a Potential Benefit of Liraglutide for Treatment of Diabetes Mellitus in HIV Patients**
Amanda McAneny, United States

Scientific Programme

- PE15/64 **How do Frailty Mediate and Moderate Pathway Leading to Disability**
Andrea Malagoli, Italy
- PE15/65 **Loss of Bone Mineral Density on Long-term Antiretroviral Therapy: Protective Effect of Nevirapine?**
François Raffi, France
- PE15/66 **Neurological Complications in HIV+ Patients**
Goffredo Angioni, Italy
- PE15/67 **Should We Still Use the “Three Questions Test” as a Screening of HIV-associated Neurocognitive Disorders? Evaluation of Sensitivity, Specificity, Positive and Negative Predictive Value and Association with Altered Quality of Life**
Francesca Bai, Italy
- PE15/68 **HIV Infection is Associated with Reduced Bone Quality Independently of Bone Mineral Density and Antiretroviral Treatment**
Robert Güerri-Fernández, Spain
- PE15/69 **Increased Urinary Albumin-to-creatinine Ratio and the Metabolic Syndrome Contribute to Endothelial Dysfunction in HIV+ Patients with Normal Renal Function**
Elisabetta Schiaroli, Italy
- PE15/70 **Dyslipidemia and Fasting Glucose Impairment among HIV-infected Patients 48-weeks after the First Antiretroviral Regimen**
José Antonio Mata-Marín, Mexico
- PE15/71 **Risk Factors for Chronic Kidney Disease in HIV-1 Infected Mexican Patients Initiating Antiretroviral Therapy**
Ricardo Rojas-Aguilar, Mexico
- PE15/73 **A Cross-sectional Study of Co-morbidities in HIV-infected Patients Receiving cART in Taiwan: A Nationwide Surveillance**
Chia-Jui Yang, Taiwan, Republic of China
- PE15/74 **Prevalence of Low 25-hydroxy-vitamin D levels and Factors Associated with 25-hydroxy-vitamin D Insufficiency in a Large European HIV Cohort**
Rocio Montejano, Spain
- PE15/75 **Prevalence of Respiratory Symptoms and Screening for Chronic Obstructive Pulmonary Disease: Results from an Italian Multicenter Study**
Giordano Madeddu, Italy
- PE15/76 **Cerebrospinal Fluid (CSF) HIV Escape is Associated with Progressive Neurologic Deterioration in Patients on Virologically Suppressive Antiretroviral Therapy (ART) in Western India**
Ameet Dravid, India
- PE15/77 **Health Transitions in HIV-seropositive Individuals Undergoing NRTI-based and NRTI-sparing Treatment Strategies**
Stefano Zona, Italy
- PE15/78 **Brain Functioning and Neurocognitive Disorders among Young HIV-positive MSM Treated with cART. Preliminary Results**
Bogna Szymańska, Poland

Scientific Programme

- PE15/79 **Lopinavir Alone and Ritonavir-boosted Lopinavir Induce Adipocyte Toxicity at Nanomolar Concentrations in vitro**
Robert Maughan, Ireland
- PE15/80 **Active HCV Replication is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV**
Andrea De Luca, Italy
- PE15/81 **Improvement of Bone Mineral Density after Switching from Triple Therapy with Lopinavir and Ritonavir Plus Two Nucleos(t)ide Reverse Transcriptase Inhibitors to Lopinavir and Ritonavir Plus Lamivudine: OLE-lip Substudy**
Manuel Crespo, Spain
- PE15/82 **Neuropsychological Performance and Self-Reported Function in HIV Positive Patients in Five European Clinics**
Lewis Haddow, United Kingdom
- PE15/83 **Secondary Hyperparathyroidism in Patients Presenting Low 25-hydroxy-vitamin D: Prevalence and Associated Factors**
Ignacio Pérez-Valero, Spain
- PE15/84 **Effect of Aging in the Neuropsychological Profile of HIV-infected Patients**
Alicia González-Baeza, Spain
- PE15/85 **Prospective Assessment of Bone Mineral Density among a Cohort of Middle-aged HIV-infected and Uninfected Women: Evaluation of a Population at High Risk**
Anna Pia Lassandro, Italy
- PE15/86 **HIV and Subclinical Atherosclerosis**
Argyro Lazarini, Greece
- PE15/87 **Higher HIV Viral Load is Associated with Lower Levels of Vitamin D in Treatment-naive HIV Patients**
María Elena Ceballos, Chile
- PE15/88 **Self-Reported Prevalence of Co-morbidities and Use of Non-HIV Related Medications among People Living with HIV in England and Wales: Results from the Positive Voices Survey**
Meaghan Kall, United Kingdom
- PE15/89 **Relapse of Cerebrospinal Fluid Escape Following Optimization and Subsequent Simplification of Antiretroviral Therapy**
Francesca Ferretti, United Kingdom
- PE15/90 **Study of Comorbidities in HIV Patients over 50 Years Old**
Violeta Alastrué del Castaño, Spain
- PE15/91 **Will the Next Generation of Rehabilitation Professionals Be Ready to Treat People Living with HIV? Results of a Survey of UK Higher Education Institutions**
Will Chegwiddden, United Kingdom
- PE15/92 **Changes in Renal Biomarkers Following Tenofovir Discontinuation in HIV-infected Viral-suppressed Patients, Montreal, Canada**
Annie Talbot, Canada

Scientific Programme

- PE16/1 **Cervical Squamous Intraepithelial Lesion and Risk Factors among HIV-infected Nigerian Women**
Chidinma Vivian Gab-Okafor, Nigeria
- PE16/2 **Diagnostic Value of Anal Cytology, HPV Testing and High Resolution Anoscopy (HRA) in Screening for Anal Intraepithelial Neoplasia (AIN) in HIV Positive Individuals**
Deepa Grover, United Kingdom
- PE16/3 **Low Clearance and High Acquisition Rate of High-risk Human Papillomavirus (HR-HPV) in a Cohort of 260 Spanish HIV-positive Men Who have Sex With Men (MSM)**
Carmen Hidalgo-Tenorio, Spain
- PE16/4 **Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies**
Nicola Squillace, Italy
- PE16/5 **Value of Prostate-specific Antigen (PSA) Screening for Prostate Cancer Detection in aging People Living with HIV (PLWHIV)**
David Zucman, France
- PE16/6 **Incidence and Survival in HIV Infected patients with Malignancies: A 7 Year Romanian Single Center Experience**
Cristiana Oprea, Romania
- PE16/7 **Detection of High Risk HPV in HIV Positive MSM Using Multiple Technologies - Implications for Immunisation and Disease Prevention**
Deepa Grover, United Kingdom
- PE16/8 **Increased risk of Radiation Induced Adverse Effects in Patients on NNRTI Based Antiretroviral Treatment**
Markus Hecht, Germany
- PE16/9 **Maintaining Dose Intensity of R-CHOP Improves Survival in HIV Associated Lymphoma**
Alessia Dalla Pria, United Kingdom
- PE16/10 **Incidence of Cancer in HIV-infected Patients along 30 Years (1983-2013)**
Carolina Tudela, Spain
- PE16/11 **CD4+ and CD8+ T-Cell Kinetics in Aviremic HIV-infected Patients Developing Hodgkin or Non Hodgkin Lymphoma**
Christian Hoffmann, Germany
- PE16/12 **Prevalence and Incidence of Anal Dysplasia and High-risk Human Papillomavirus (HR-HPV) in a Prospective Cohort of Spanish Women Living with HIV (WLHIV)**
Carmen Hidalgo-Tenorio, Spain
- PE16/13 **Is There Evidence for T-cell Activation Prior to HIV-associated Lymphoma in Aviremic Patients?**
Christian Hoffmann, Germany
- PE16/14 **Evaluation of Hematologic and Hepatic Toxicity in HIV-associated Non-Hodgkin Lymphoma: A Cohort Study**
Alessandra Bandera, Italy

Scientific Programme

- PE16/15 **Prevalence and Persistence of HPV Infection and Cytological Abnormalities in a Cohort of HIV Infected Patients**
Nicola Squillace, Italy
- PE16/16 **Screening for Anal Intraepithelial Neoplasia (AIN) in HIV-positive Patients: The Practical Uptake of a New Guideline**
Robert Jablonka, Germany
- PE17/1 **Health Seeking Behaviour among Youth with Sexually Transmitted Infection in Nigeria**
Orobosa Enadeghe, Nigeria
- PE17/2 **"A One Stop Shop" STD Service for MSM in Croatia/South East Europe - A New Approach**
Šime Zekan, Croatia
- PE17/3 **Factors Associated with Urinary Tract Infections among HIV-1 Infected Patients - Is Active HCV Infection a Risk Factor?**
Agata Skrzat-Wojdacz, Poland
- PE17/4 **Anal Cytology (AC) and Sexually Transmitted Infection (STI) Screening in Ageing People Living with HIV (PLWH)**
Malika Mohabeer Hart, United Kingdom
- PE17/5 **HIV-1 Vaginal Shedding is Suppressed among HIV-1 Infected Women on Modern Combined Antiretroviral Therapy**
Sara Grignolo, Italy
- PE17/6 **Human Papillomavirus 58: An Emerging High-risk Genotype in Italian HIV-infected Men Who Have Sex with Men?**
Claudio Ucciferri, Italy
- PE17/7 **Men Who Have Sex with Men from Paris. Argument for Universal HPV Vaccination**
Hugues Cordel, France
- PE17/8 **High Rates of Sexually Transmitted Infections (STIs) and Recreational Drug Use (RDU) amongst HIV-positive Men Who Have Sex with Men (MSM) Attending Outpatients across London (UK)**
Selena Singh, United Kingdom
- PE17/9 **Long-term Hepatic Safety and Impact of Maraviroc on Fibrosis Progression: A 148 week Randomised, Double-blind Study of Maraviroc versus Placebo in Combination with Other Antiretroviral Agents in HIV-1 Patients Co-infected with Hepatitis C and/or Hepatitis B Virus**
Frank Plonski, United States
- PE17/10 **HIV and Syphilis: When Do we Need to Perform a Lumbar Puncture?**
Agnès Libois, Belgium
- PE17/11 **Detection of Anal HPV Infection by Two Techniques in HIV+ MSM Individuals and Correlation with Pathologic Findings in Cytology and Biopsy**
Elena Ferrer, Spain
- PE17/12 **Should Screening of Asymptomatic Sexually Transmitted Infections Be Performed to All HIV-infected Men Who Have Sex with Men?**
Irene Sanchez, Spain

Scientific Programme

- PE17/13 **Prevalence of Anal High-risk Human Papillomavirus Infections among HIV-positive Men Who Have Sex With Men in Istanbul**
Alper Gündüz, Turkey
- PE17/14 **Acute Kidney Injury in Shigella Infection in an HIV-positive Cohort**
Nadia Ahmed, United Kingdom
- PE17/15 **The Serum TRUST Titer $\geq 1:16$ is a Predictor for Asymptomatic Neurosyphilis among HIV/Syphilis Co-infected Patients**
Jianjun Sun, China
- PE18/1 **Sexual Risk and Sexually Transmitted Infections among Chinese HIV-positive MSM after Engagement in Care**
Kenny CW Chan, China
- PE18/2 **"One Shouldn't Convict People for Hypothetical Risks": Developments in European Criminal Law and Policy following Increased Knowledge and Awareness of the Additional Prevention Benefit of Antiretroviral Therapy**
Edwin Bernard, United Kingdom
- PE18/3 **A Finger-stick Whole Blood HIV Self-test as an HIV Screening Tool Adapted to the General Public**
Thierry Prazuck, France
- PE18/4 **Choice of nPEP Regimens and Completion Rates in a MSM Population in Sydney, Australia: Provision of Drugs at what Cost?**
Rohan Bopage, Australia
- PE18/5 **Acceptability of Pre-exposure Prophylaxis (PrEP) and Reported Adherence to Non HIV Medication Regimens in HIV Negative Portuguese Men who Have Sex with Men (MSM) Eligible to PrEP**
Luis-Miguel Rocha, Portugal
- PE18/6 **Human Immunodeficiency Virus (HIV): Continuum of Care in Europe and Central Asia**
Teymur Noori, Sweden
- PE18/7 **Predictors of Knowledge of Non-occupational HIV Post Exposure Prophylaxis among Men Who Have Sex with Men Attending a Suburban Sexual Health Clinic in Sydney, Australia**
Rasanga Liyanage, Australia
- PE18/8 **Acceptable Rates of Acute HIV Detection Using a Fourth-generation Point of Care HIV Test**
Naomi Fitzgerald, United Kingdom
- PE18/9 **Evaluation of a Strategy to Improve Linkage to Care in Newly Diagnosed HIV Patients**
Miguel Raffo, Spain
- PE18/10 **A New Strategy to Avoid HIV Patient's Loss of Follow-up: Intervention at First Visit Failure**
Jose Fajardo, Spain
- PE18/11 **Randomised Controlled Trial of the Tolerability and Completion of Maraviroc Compared to Kaletra® in Combination with Truvada® for HIV Post Exposure Prophylaxis (MiPEP Trial)**
Ana Milinkovic, United Kingdom

Scientific Programme

- PE18/12 **Recording of the Professional Exposure to Blood Transmitted Agents at a Tertiary University Hospital in Greece, during 2007-2013**
Anestis Ganitis, Greece
- PE18/13 **Knowledge and Use of Post-exposure Prophylaxis (PEP) among Men Who Have Sex with Men (MSM) in Portugal**
Maria-José Campos, Portugal
- PE18/14 **Cohort for MSM as a Useful Tool to Assure Cost Effectiveness during the Implementation of PrEP**
Michael Meulbroek, Spain
- PE19/1 **Using Quality Improvement to Address High Default from PMTCT Services (Early Infant Diagnosis) at State Hospital Ijebu Ode, Nigeria**
Foluwaso Olaoluwa-Moronkeji, Nigeria
- PE19/2 **Higher Risks of Mother-to-Child HIV Transmission (MTCT) in Countries with Lower Prevalence: UNAIDS 2013 Results for 33 Countries with Generalised Epidemics**
Andrew Hill, United Kingdom
- PE19/3 **Experience of Prevention of Mother to Child Transmission of HIV in Georgia**
Ketevan Shermadini, Georgia
- PE19/4 **Regional Disparity of Maternal-paediatric Antiretroviral Coverage among African Priority Countries**
Olatunji Adetokunboh, South Africa
- PE19/5 **UK National Clinical Audit 2014: Management of Pregnancies in Women with HIV**
Sonia Raffae, United Kingdom
- PE19/7 **Drug Resistance Mutations (DRM) among Pregnant HIV-positive Women in the Duesseldorf University Hospital, Germany, 2009-2015**
Ulrike Haars, Germany
- PE19/8 **Mode of Delivery in Pregnant Women Living with HIV in Denmark: A Risk Assessment of Emergency Caesarean Sections**
Mathilde Ørbæk, Denmark
- PE19/9 **Evaluation of 10 Years of a Mother to Child Transmission Prevention Program in a Community Health Center in Bamako, Mali**
Karamoko Tounkara, Mali
- PE19/10 **HIV Perinatally Exposed Children in Romania - Review**
Alina Maria Cibea, Romania
- PE20/1 **The Effects of Toxic Impact of Tenofovir on the Bone Mineral Density in Children**
Natalya Rymarenko, Ukraine
- PE20/2 **Prevalence and Characteristics of Group B Streptococcus Colonization in HIV-infected Pregnant Women in Belgium**
Nicolas Dauby, Belgium

Scientific Programme

- PE20/3 **Resistance Mutations to Antiretroviral Drugs on HIV Strains of Treated HIV-1 Infectious Pediatric Patients in Venezuela**
Diana Lopez, Venezuela
- PE20/4 **Associations between Paediatric HIV Clients, Their Caregivers and Retention: Evidence from the EMBRACE Cohort, Eastern Cape, South Africa**
Hugh Adler, Ireland
- PE20/5 **The One-stop Clinic of Ifakara: Implementing a Bundle of Measures for Paediatric HIV Services in Rural Africa to Reach the UNAIDS' Target "90-90-90"**
Anna Gamell, Switzerland
- PE20/6 **Long-term Prognosis of Children Born to HIV-1 Infected Mothers in Japan**
Mizue Tanaka, Japan
- PE20/7 **Abnormal Neurometabolite Levels Reflect Poorer Cognitive Performance in HIV-infected Children**
Yvonne Wilma van Dalen, Netherlands
- PE20/8 **The Eye as a Window to the Brain: Retinal Structure Associated with Cerebral Injury in Perinatally HIV-infected Children**
Charlotte Blokhuis, Netherlands
- PE20/9 **Threatening Levels of Acquired HIV Drug Resistance and Virologic Failure in Children and Adolescents in Rural Tanzania - An Emerging Public Health Concern**
Lukas Muri, Switzerland
- PE20/11 **Educational Intervention Increases Acceptability and Knowledge of Newborn Male Circumcision (NMC) among Parents of Newborn Boys in Port-au-Prince, Haiti**
Jessy Dévieux, United States
- PE21/1 **Evolution of HIV-infected Injecting Drug Users in Spain during 2004-2013: Persistence of Poor Engagement to Care and Worse Clinical Outcomes**
Inés Suárez-García, Spain
- PE21/2 **Are Immigrant Men who Have Sex with Men (MSM) who Visited an HIV Checkpoint (Actuel-sur-Rue) in Montreal, Canada, More Vulnerable to HIV?**
David Lessard, Canada
- PE21/3 **Weight Changes and Prognosis for People Living with HIV Initiating Highly Active Antiretroviral Therapy in the APROCO Cohort Study**
Victoire Fokom Defo, Cameroon
- PE21/4 **Expansion of the CRF19_cpx Variant in Spain**
Fernando Gonzalez-Candelas, Spain
- PE21/5 **A Decade of HIV Care and Treatment in Rural Tanzania: Trends in Treatment, Opportunistic Infections and Laboratory Abnormalities among HIV-positive Adults**
Tracy Glass, Switzerland

Scientific Programme

- PE21/6 **Missed Opportunities for Earlier HIV Diagnosis in Men who Have Sex with Men (MSM) - A Service Evaluation of HIV Testing in UK Sexual Health Clinics**
Emily Clarke, United Kingdom
- PE21/7 **A Universal Testing Programme for Blood Borne Viruses (BBV) in an Urban Emergency Department (ED) - A Call for Widespread Testing in Ireland**
Sarah O'Connell, Ireland
- PE21/8 **Missed Opportunities for HIV Testing and Factors Associated with Delayed Diagnosis**
Rosa de Miguel Buckley, Spain
- PE21/9 **Intervention Packages against HIV and HCV Infections for People who Inject Drug in Georgia: A Modeling and Cost-effectiveness Study**
Guillaume Mabileau, France
- PE21/10 **The Continuum of HIV Care in Catalonia**
Colin Campbell, Spain
- PE21/11 **From Pills to Patients: Determination of the Number of People Living with HIV who Are Receiving Antiretroviral Therapy, Costs and Potential Cost-savings in Germany**
Daniel Schmidt, Germany
- PE21/12 **HIV Infection among Persons Aged 50 Years and over in the EU, 2004-2013: Missed Opportunities for Earlier Diagnosis?**
Lara Tavoschi, Sweden
- PE21/13 **Use of 3 HIV Testing Methods in French Primary Care: Classical ELISA Laboratory Screening versus 2 Rapid Finger-stick HIV Tests with Result under 5 Minutes (INSTI) and up to 30 Minutes (VIKIA)**
Angela Daiana Papadima, France
- PE21/14 **CD4+T-cell Count at cART Initiation among Migrant Men and Women Living in Western Europe**
Susana Monge, Spain
- PE21/15 **Linkage to Care Following HIV Diagnosis in Europe: A Review of the Literature**
Sara Croxford, United Kingdom
- PE21/16 **Comparing a 'Multi Assay Algorithm' with the BED Capture Enzyme Immunoassay for the Testing of Recent HIV-1 Infections in Germany**
Andrea Hauser, Germany
- PE21/17 **Coverage and Acceptability of a Targeted Testing Strategy, Resourced by an External Program Intervention, DRIVE Study (Rapid Diagnosis of HIV infection in Spain)**
María Jesús Pérez Elías, Spain
- PE21/18 **Unselected, Emergency Department-based Rapid HIV Screening Detects High Proportion of Early, Asymptomatic HIV Infection**
Marilia Rita Pinzone, Italy
- PE21/19 **Recreational Drug Consumption in People Living with HIV in Europe: A Systematic Review**
Cesar Velasco, Spain

Scientific Programme

- PE21/20 **HIV Late Presentation in Southern Sardinia, Italy**
Goffredo Angioni, Italy
- PE21/21 **Travel to the Tropics and its Impact on Viral Control in HIV Patients in the Swiss HIV Cohort Study**
Hiwot Gebreselassie, Switzerland
- PE21/22 **Recent HIV-infections in Germany 2008-2014: What Do we Know?**
Andrea Hauser, Germany
- PE21/23 **High Rate of Transmission Clusters among Men Who Have Sex with Men (MSM) with Acute-recent HIV Infection in Barcelona**
Juan Ambrosioni, Spain
- PE21/24 **Developments in the Delay of HIV Detection and Treatment Initiation in Recent Years**
Borja Carmelo Gracia Tello, Spain
- PE21/25 **Transmission Clustering among Kiev HIV Sequences**
Esther Fearnhill, United Kingdom
- PE21/26 **HIV Subtypes: The Same Disease, Different Stories?**
Claudia Afonso, Portugal
- PE21/27 **HIV Testing in Innovative Environments Mexico**
Nalleli Delgadillo, Mexico
- PE21/28 **Ongoing Mononucleosis-like Illness - A Clear Indicator Condition for HIV Testing: Results from the HIDES 2 Study - Single Arm Extension**
Dorthe Raben, Denmark
- PE21/29 **The Acute/Recent HIV Infection Cohort from Hospital Clinic, Barcelona: Epidemiological and Virological Trends from 1997 to 2014**
David Nicolás, Spain
- PE21/30 **Healthcare Related Costs of Missed Opportunities for HIV Diagnosis: A Potential Driver to Increase Indicator Condition Guided HIV Testing**
Caroline Rae, United Kingdom
- PE21/31 **Current Epidemiology and Outcomes of HIV-infected Patients Admitted to an Intensive Care Unit (ICU) in Barcelona, Spain**
Veronica Rico, Spain
- PE21/32 **Over Half of People in HIV Care in the United Kingdom by 2028 Will Be Aged 50 Years or Above**
Zheng Yin, United Kingdom
- PE21/33 **Trends and Causes of Hospitalization among HIV-infected People from 1998 to 2015 in a Single Italian Tertiary Care Centre**
Alberto Borghetti, Italy
- PE21/34 **Recent HIV Infection: Epidemiologic, Clinical and Therapeutic Evolution of a Portuguese Cohort**
Bernardo Neves, Portugal
- PE21/35 **Retention in Care of a Population of Migrant HIV-infected IDUs in Greece (Single Center Experience)**
Eleni Kakalou, Greece

Scientific Programme

- PE21/36 **Is It Feasible to Reduce the Number of Determinations Performed on Viral Load and CD4 T-lymphocytes in an HIV Specialized Consultation Unit?**
Alberto Díaz-De Santiago, Spain
- PE21/37 **Clinical and Epidemiological Characteristics of HIV Infection Newly Diagnosed in People over 59 Years of the Spanish Cohort VACH**
Dolores Merino Muñoz, Spain
- PE21/38 **Asymptomatic Late Presenters: 12 Years Trend in CD4+ Cell Counts at HIV Diagnosis in a Single Testing Site in Buenos Aires**
Mariana Kundro, Argentina
- PE21/39 **Analysis of New HIV Diagnoses among Young People**
Borja Carmelo Gracia Tello, Spain
- PE21/40 **Dynamics of Transmission Trends in 30 Years of HIV Epidemic in Romania**
Mariana Mardarescu, Romania
- PE22/2 **Late HIV Diagnosis in Georgia: Public Health and Economic Implications**
Nikoloz Chkhartishvili, Georgia
- PE22/4 **Using Mixed-methods to Understand HIV Treatment Cascade among OST Patients and PWIDs in Five Ukrainian Cities**
Alyona Mazhnaya, Ukraine
- PE22/5 **High Proportion of Viral Suppression with Frequent Changes of Antiretroviral Treatment in Newly Diagnosed Patients in Santo Andre Aids Program, Sao Paulo, Brazil**
Elaine Matsuda, Brazil
- PE22/6 **High Proportion of Virological Failure and HIV Drug Resistance among TB/HIV Co-infected Ugandan Adults**
Amrei von Braun, Uganda
- PE22/7 **First -line Antiretroviral Therapy in Resource-limited Settings: the Experience of Serbia**
Gordana Dragovic, Serbia
- PE22/8 **Direct Costs of HIV/AIDS Care in Estonia**
Liis Lemsalu, Estonia
- PE22/9 **Treating HCV with Interferon-free Regimens in Correctional Settings: An Italian Experience**
Antonella Foschi, Italy
- PE22/11 **Deferring CD4 Cell Count Monitoring in HIV+ Treated Patients with More than 350 or 500 CD4 Lymphocyte/ μ l is a Safe and Cheap Strategy**
Benedetto Celesia, Italy
- PE23/1 **Sexual Risk Behaviours of High School Students in an Urban Town of Cameroon**
Tarkang Elvis, Cameroon
- PE23/2 **Assessing Parental Knowledge and Attitudes towards Disclosure of HIV**
Conor Lyons, Ireland

Scientific Programme

- PE23/3 **HIV Prevalence and Factors Associated with HIV Infection among Injection Drug Users, Uzbekistan**
Shukhrat Umarkhojaev, Uzbekistan
- PE23/4 **Stigma towards People Living with HIV/AIDS among Healthcare Practitioners and Medical Students**
Julia Dabravolskaj, Canada
- PE23/5 **Lost Opportunities for Early ART**
Anastasia Pokrovskaya, Russian Federation
- PE23/6 **SM@RT-@IDS: The Digital Prevention for the Smart Generations**
Carmine Falanga, Italy
- PE23/7 **HIV Disclosure and Stigma among Women Living with HIV in Denmark - Results from the SHADE Cohort**
Maria Wessman, Denmark
- PE23/8 **Barriers to Accessing HIV Testing, Treatment and Healthcare for Migrants Living with HIV in Europe**
Ibidun Fakoya, United Kingdom
- PE23/9 **Barriers to HIV Routine Screening in Primary Care: What Do Patients Think about it ?**
Guillaume Conort, France
- PE23/10 **Disutilities Associated with Central Nervous System (CNS) Side Effects of Antiretroviral Therapy (ART) in HIV: Results from the UK, France and Spain**
Rodolphe Perard, United Kingdom
- PE23/11 **The StigmaIndexUK-2015: A New Methodology for Measuring the Experiences of Stigma among People Living with HIV**
Jo Jefferies, United Kingdom
- PE23/12 **Differences in Patients and Physicians Adherence Evaluation - Results from the German Adherence Cohort Study**
Christoph Spinner, Germany
- PE23/13 **The Impact of Antiretroviral Therapy on Treatment Satisfaction and Quality of Life of PLWH in Europe**
Miranda Murray, United Kingdom
- PE23/14 **HIV/AIDS-related Knowledge and Behaviors of Precarised Migrants in the Geneva Area, Switzerland**
Deborah Glejser, Switzerland
- PE23/15 **Health Workers in B&H and HIV Stigma and Discrimination**
Stela Stojisavljevic, Bosnia and Herzegovina
- PE23/16 **A New International Questionnaire to Assess Health-related Quality of Life (HRQL) Specific to Viral Hepatitis C: Proqol-HCV**
Martin Duracinsky, France
- PE23/17 **Reduced CD4 Count Monitoring: Potential for Large Cost Savings but is it Acceptable to Patients?**
Sophie Flavell, United Kingdom

Scientific Programme

- PE23/18 **Prediction of the Factors Influencing the HIV Test Utilisation among Young People Aged between 17-25 Years in Saudi Arabia**
Abdullah Almilaibary, United Kingdom
- PE23/19 **Clinical and Community Views of the Instant Result HIV Self-testing: Barriers and Facilitators for Effective Implementation amongst MSM (Men who Have Sex with Men)**
Jamie Frankis, United Kingdom
- PE23/20 **Clinical, Psychological and Behavioural Barriers to HIV Testing amongst MSM (Men who Have Sex with Men) who Use Social and Sociosexual Media: Implications for HIV Prevention Programmes**
Jamie Frankis, United Kingdom
- PE24/1 **Integrated HIV and Gynaecological Services for HIV-positive Women in Warsaw - A Luxury or Standard of Care?**
Justyna Kowalska, Poland
- PE24/2 **Gender Differences in Baseline Epidemiological Profile and Clinical Characteristics and its Evolution in the Spanish AIDS Research Network Cohort (CoRIS)**
Constanza Muñoz, Spain
- PE24/3 **Facts on Contraception Use and Unintended Pregnancies in HIV-infected Women on Antiretroviral Therapy in Switzerland**
Valentina Mercanti, Switzerland
- PE24/4 **Epidemiological Trends of HIV Infection in Women Spanish Cohort Vach**
Dolores Merino Muñoz, Spain

Special Session
12:45 - 13:55

Room Barcelona

EACS Guidelines Session

Chairs:

Jens D. Lundgren, Denmark
Manuel Battegay, Switzerland

- EACS Treatment Guidelines version 8.0: Vision and Mission** 12:45 - 12:50
Lene Ryom, Denmark
- 8.0 Highlights from ART Section** 12:50 - 12:58
José M. Gatell, Spain
- 8.0 Highlights from Co-morbidities Section** 12:58 - 13:06
Georg Behrens, Germany
- 8.0 Highlights from Viral Hepatitis Section** 13:06 - 13:14
Jürgen Rockstroh, Germany
- 8.0 Highlights from Opportunistic Infections Section** 13:14 - 13:22
Hansjakob Furrer, Switzerland
- EACS and WHO Guidelines: Complementarity** 13:22 - 13:32
Marco Vitoria, Switzerland

Scientific Programme

Panel Discussion

Georg Behrens, Germany
 Hansjakob Furrer, Switzerland
 José M. Gatell, Spain
 Jürgen Rockstroh, Germany
 Lene Ryom, Denmark
 Stefano Vella, Italy
 Marco Vitoria, Switzerland

13:32 - 13:55

Parallel Session
 14:00 - 16:00

Room Barcelona

PS10, Antiretroviral Therapy II

Chairs:

Paddy Mallon, Ireland
 Linos Vandekerckhove, Belgium

ML1	Managing Primary HIV Infection Jade Ghosn, France	14:00 - 14:15
PS10/1	Impact of Baseline Viral Load (VL) and Time to Viral Suppression on Subsequent Virologic Rebound (VR) According to First-line Antiretroviral Therapy (cART) Clotilde Allavena, France	14:15 - 14:30
PS10/2	Retention of People Living with HIV in Antiretroviral Therapy Marisol Valenzuela-Lara, Mexico	14:30 - 14:45
PS10/3	Switching from Ritonavir or Cobicistat Boosted Atazanavir (ATV) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-based Single Tablet Regimen (STR): Week 48 Data in Virologically Suppressed Adults Bart Rijnders, Netherlands	14:45 - 15:00
PS10/4	Durability of Dual Therapy (DT) with Lopinavir/Ritonavir (LPV/r) and Lamivudine (3TC) in Comparison to Standard Triple Drug Therapy (TT): 96-week Results of the GARDEL Study Pedro Cahn, Argentina	15:00 - 15:15
PS10/5	Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase IIa Proof-of-Concept Study (AI468002) Carey Hwang, United States	15:15 - 15:30
PS10/6	No Difference between the Effects of Immediate versus Deferred ART on Neuropsychological Test Performance in HIV-positive Adults with CD4+ Cell Counts above 500 cells/μL: The Strategic Timing of Anti Retroviral Treatment (START) Neurology Substudy Richard Price, United States	15:30 - 15:45
LBPS10/1	Measuring Safety and Satisfaction of ABC/DTG/3TC in a Switch Trial: Secondary Endpoints from the STRIVING Study Michael Aboud, United Kingdom	15:45 - 16:00

Scientific Programme

Parallel Session
14:00 - 16:00

Room Cologne

PS11, Co-morbidities II

Chairs:

Nina Friis-Møller, Denmark
Peter Reiss, Netherlands

ML1	The Inflammation and the Microbiome Roger Paredes, Spain	14:00 - 14:15
PS11/1	Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-containing Antiretroviral Treatment Giuseppe Lapadula, Italy	14:15 - 14:30
PS11/2	PCR is a Better Predictor of Renal Disease Progression Than RBP or NGAL in HIV-positive Patients Lisa Hamzah, United Kingdom	14:30 - 14:45
PS11/3	Is HIV Infection Duration Associated with Myocardial Infarctions? Alexandra Lyons, United Kingdom	14:45 - 15:00
PS11/4	Levels of Agreement between Commonly Used Definitions of Cognitive Impairment and the EACS Screening Questions in Older HIV-positive Subjects and Matched Controls Davide De Francesco, United Kingdom	15:00 - 15:15
PS11/5	No Difference in Neurocognitive Function between Patients on PI Monotherapy and cART: Evidence from the PIVOT Trial Alejandro Arenas-Pinto, United Kingdom	15:15 - 15:30
PS11/6	Changes in Cognitive Function over 96 Weeks after Initiating Darunavir/Ritonavir with Either Raltegravir or Tenofovir-Emtricitabine; NEAT 001 / ANRS 143 Randomised Controlled Study Alan Winston, United Kingdom	15:30 - 15:45
ML2	Neurocognitive Disorder - Is It That Frequent in HIV Patients (Pro/Con Debate) Magnus Gisslen, Sweden Juan Tiraboschi, United Kingdom	15:45 - 16:00

Parallel Session
14:00 - 16:00

Room Brussels

PS12, Prospects for HIV Cure and Post Treatment Remission

Chairs:

Bonaventura Clotet, Spain
Christine Katlama, France

ML1	Obstacles to HIV Remission or Eradication Mario Stevenson, United States	14:00 - 14:15
ML2	Overview About Current Strategies for HIV Eradication Lars Østergaard, Denmark	14:15 - 14:30

Scientific Programme

ML3	Allogenic Stem-Cell Transplantation Javier Martínez-Picado, Spain	14:30 - 14:45
ML4	Basic Research to Identify Targets to Purge the HIV Reservoir Daria Hazuda, United States	14:45 - 15:00
ML5	Overview About Current Strategies for HIV Remission Felipe García, Spain	15:00 - 15:15
	Panel Discussion Facilitated by Christian Brander (Spain)	15:15 - 16:00

Industry Sponsored Session
16:30 - 18:00

Room Cologne

Industry Sponsored Session

(For more details, please visit the http://www.eacs-conference2015.com/index.php?article_id=47>EACS Conference website)

Other
16:30 - 18:00

Room Madrid

Living Well when Living Longer - HIV and Rehabilitation (limited seat availability)

Session convened by the Rehabilitation in HIV Association (RHIVA) and the Canada-United Kingdom HIV and Rehabilitation Research Collaborative (CUHRRC) in collaboration with the European AIDS Treatment Group (EATG) and the United Kingdom Community Advisory Board (UK-CAB).

Industry Sponsored Session
18:30 - 20:00

Room Cologne

Industry Sponsored Session

(For more details, please visit the http://www.eacs-conference2015.com/index.php?article_id=47>EACS Conference website)

Scientific Programme

Saturday, 24 October 2015

Plenary Session
08:00 - 08:30

Room Cologne

PL5, Access and Barriers to Treatment in Europe

Chairs:

Daniel Podzamczar, Spain
Anton Pozniak, United Kingdom

Access and Barriers to Treatment in Europe

08:00 - 08:30

Deniz Gökengin, Turkey

Plenary Session
08:30 - 09:00

Room Cologne

PL6, Challenges in Treating HIV

Chairs:

Daniel Podzamczar, Spain
Anton Pozniak, United Kingdom

Challenges in Treating HIV

08:30 - 09:00

José Arribas, Spain

Special Session
09:00 - 10:30

Room Cologne

Clinical Cases

Chairs:

Sanjay Bhagani, United Kingdom
Hansjakob Furrer, Switzerland
Cristiana Oprea, Romania
Lene Ryom, Denmark

End-Stage Liver Disease in HIV

09:00 - 09:15

Ellen Dwyer, United Kingdom

Panel Discussion

09:15 - 09:22

A 'Difficult' Opportunistic Infection - TB, MAI and Crypto

09:22 - 09:37

Irina Ianache, Romania

Panel Discussion

09:37 - 09:44

Complicated Renal Impairment - Exploring Issues Around Cause of Renal Impairment and Appropriate ARVs

09:44 - 09:59

Alvaro Borges, Denmark

Panel Discussion

09:59 - 10:06

Scientific Programme

Multi-Resistant HIV, Poor Adherence - Explore ARV Options and Manage DDIs	10:06 - 10:21
Anna Eichenberger, Switzerland	
Panel Discussion	10:21 - 10:30

Special Session
10:30 - 12:00

Room Cologne

Standard of Care in Europe

Chairs:

Nathan Clumeck, Belgium
Andrzej Horban, Poland

Access to Antiretroviral Therapy in Eastern Europe	10:30 - 10:45
Cristiana Oprea, Romania	
Migrants and Access to Care	10:45 - 11:00
Julia Del Amo, Spain	
Linkage to Care	11:00 - 11:15
Justyna Kowalska, Poland	
Which Model of Care in Europe	11:15 - 11:30
Markus Bickel, Germany	
Panel Discussion	11:30 - 12:00
Markus Bickel, Germany Nikos Dedes, Greece Julia Del Amo, Spain Justyna Kowalska, Poland Cristiana Oprea, Romania	

Ceremony
12:00 - 12:15

Room Cologne

Closing Remarks

Manuel Battegay (Switzerland)
José M. Gatell (Spain)
Antonella d'Arminio Monforte (Italy)
Fiona Mulcahy (Ireland)